<!DOCTYPE html>
<html>
<head>
    
    <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <script src="https://cdn.jsdelivr.net/npm/leaflet@1.9.3/dist/leaflet.js"></script>
    <script src="https://code.jquery.com/jquery-3.7.1.min.js"></script>
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.2.2/dist/js/bootstrap.bundle.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/Leaflet.awesome-markers/2.0.2/leaflet.awesome-markers.js"></script>
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/leaflet@1.9.3/dist/leaflet.css"/>
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@5.2.2/dist/css/bootstrap.min.css"/>
    <link rel="stylesheet" href="https://netdna.bootstrapcdn.com/bootstrap/3.0.0/css/bootstrap-glyphicons.css"/>
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.0/css/all.min.css"/>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/Leaflet.awesome-markers/2.0.2/leaflet.awesome-markers.css"/>
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/python-visualization/folium/folium/templates/leaflet.awesome.rotate.min.css"/>
    
            <meta name="viewport" content="width=device-width,
                initial-scale=1.0, maximum-scale=1.0, user-scalable=no" />
            <style>
                #map_27dca3867907e8cc88ae649e97195903 {
                    position: relative;
                    width: 100.0%;
                    height: 100.0%;
                    left: 0.0%;
                    top: 0.0%;
                }
                .leaflet-container { font-size: 1rem; }
            </style>

            <style>html, body {
                width: 100%;
                height: 100%;
                margin: 0;
                padding: 0;
            }
            </style>

            <style>#map {
                position:absolute;
                top:0;
                bottom:0;
                right:0;
                left:0;
                }
            </style>

            <script>
                L_NO_TOUCH = false;
                L_DISABLE_3D = false;
            </script>

        
    <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet.markercluster/1.1.0/leaflet.markercluster.js"></script>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet.markercluster/1.1.0/MarkerCluster.css"/>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet.markercluster/1.1.0/MarkerCluster.Default.css"/>
</head>
<body>
    
    
    <style>
      #nct-panel {
        position:absolute; top:10px; right:10px; z-index:9999;
        background:white; padding:8px 10px; width:520px; max-height:420px;
        box-shadow:0 2px 8px rgba(0,0,0,0.2); border-radius:8px; font-family:sans-serif; overflow:auto;
      }
      #nct-panel h4 { margin:0 0 6px 0; font-size:14px; }
      .legend-note { font-size:11px; color:#666; margin-bottom:6px; }
      #nct-presets { display:flex; flex-wrap:wrap; gap:8px; margin:6px 0 6px 0; }
      #nct-presets .preset { padding:4px 8px; font-size:12px; }
      #disease-filters { display:flex; flex-wrap:wrap; gap:10px; margin:6px 0 8px 0; }
      #disease-filters label { font-size:12px; user-select:none; }
      .bar-row { display:flex; align-items:center; gap:8px; margin:6px 0; }
      .bar-label { width:160px; font-size:12px; white-space:nowrap; overflow:hidden; text-overflow:ellipsis; }
      .bar-track { position:relative; flex:1; background:#f0f0f0; height:14px; border-radius:7px; overflow:hidden; }
      .bar-global { position:absolute; left:0; top:0; height:14px; opacity:.35; }
      .bar-local { position:absolute; left:0; top:0; height:14px; }
      .bar-count { width:90px; text-align:right; font-size:12px; color:#333; }
    </style>

    <div id="nct-panel" class="leaflet-control">
      <h4>Sites per NCT (cluster vs global)</h4>
      <div class="legend-note">Solid = selected diseases in current area • Faint = total worldwide (selected diseases)</div>

      <div id="nct-presets">
        <button class="preset" data-diseases='["Parkinson Disease"]'>Parkinson’s</button>
        <button class="preset" data-diseases='["Multiple System Atrophy"]'>MSA</button>
        <button class="preset" data-diseases='["Lewy Body Disease"]'>LBD</button>
        <button class="preset" data-diseases="ALL">All</button>
      </div>

      <div id="disease-filters"></div>
      <div id="nct-rows"></div>
      <div id="nct-footer" class="legend-note" style="margin-top:6px; font-size:11px; color:#999; text-align:left;">
        Analysis run: 2025-09-11
      </div>
    </div>

    <script>
    (function(){
      var MAP_NAME = "map_27dca3867907e8cc88ae649e97195903";
      var DATA = [{"lat": 49.9, "lng": 2.3, "nct": "NCT04794634", "color": "#185d4d", "title": "Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Optical coherence tomography (OCT); Optical coherence tomograpohy angiography (OCTA)", "sponsor": "Centre Hospitalier Universitaire, Amiens", "address": "", "url": "https://clinicaltrials.gov/study/NCT04794634", "diseases": ["Lewy Body Disease"]}, {"lat": 41.14149, "lng": -73.3579, "nct": "NCT02795052", "color": "#14033b", "title": "Neurologic Stem Cell Treatment Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Intravenous and Intranasal BMSC", "sponsor": "MD Stem Cells", "address": "", "url": "https://clinicaltrials.gov/study/NCT02795052", "diseases": ["Lewy Body Disease", "Multiple System Atrophy"]}, {"lat": 26.27119, "lng": -80.2706, "nct": "NCT02795052", "color": "#14033b", "title": "Neurologic Stem Cell Treatment Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Intravenous and Intranasal BMSC", "sponsor": "MD Stem Cells", "address": "", "url": "https://clinicaltrials.gov/study/NCT02795052", "diseases": ["Lewy Body Disease", "Multiple System Atrophy"]}, {"lat": 25.07725, "lng": 55.30927, "nct": "NCT02795052", "color": "#14033b", "title": "Neurologic Stem Cell Treatment Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Intravenous and Intranasal BMSC", "sponsor": "MD Stem Cells", "address": "", "url": "https://clinicaltrials.gov/study/NCT02795052", "diseases": ["Lewy Body Disease", "Multiple System Atrophy"]}, {"lat": 56.2428, "lng": 12.86219, "nct": "NCT03174938", "color": "#a6b73c", "title": "The Swedish BioFINDER 2 Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Flutemetamol F18 Injection; [18F]-RO6958948; Elecsys (Roche) Abeta42, Ttau and Ptau; Lumipulse (Fujirebio) Abeta42, Ttau and Ptau", "sponsor": "Skane University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03174938", "diseases": ["Lewy Body Disease", "Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 55.60587, "lng": 13.00073, "nct": "NCT03174938", "color": "#a6b73c", "title": "The Swedish BioFINDER 2 Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Flutemetamol F18 Injection; [18F]-RO6958948; Elecsys (Roche) Abeta42, Ttau and Ptau; Lumipulse (Fujirebio) Abeta42, Ttau and Ptau", "sponsor": "Skane University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03174938", "diseases": ["Lewy Body Disease", "Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 30.29365, "lng": 120.16142, "nct": "NCT05518409", "color": "#070967", "title": "Immunohistochemical Study of Neurodegenerative Diseases", "status": "RECRUITING", "phases": ["NA"], "interventions": "Detection of cytof in peripheral PBMC; Donepezil for patients with AD and DLB", "sponsor": "First Affiliated Hospital of Zhejiang University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05518409", "diseases": ["Lewy Body Disease"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 36.74773, "lng": -119.77237, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 34.26945, "lng": -118.78148, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 27.49893, "lng": -82.57482, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 25.90871, "lng": -80.30866, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 26.97617, "lng": -82.09064, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 29.13832, "lng": -80.99561, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 26.13397, "lng": -80.1131, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 33.77483, "lng": -84.29631, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 45.00969, "lng": -93.34912, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 39.95373, "lng": -74.19792, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 41.70037, "lng": -73.92097, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 35.60095, "lng": -82.55402, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 39.75895, "lng": -84.19161, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 36.15398, "lng": -95.99277, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 29.61968, "lng": -95.63495, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 47.61038, "lng": -122.20068, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT04148391", "color": "#8d106c", "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo Oral Capsule; NYX-458", "sponsor": "Aptinyx", "address": "", "url": "https://clinicaltrials.gov/study/NCT04148391", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 53.55014, "lng": -113.46871, "nct": "NCT04706910", "color": "#f37e39", "title": "18F-DOPA II - PET Imaging Optimization", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "18F-DOPA; Furosemide Injection", "sponsor": "University of Alberta", "address": "", "url": "https://clinicaltrials.gov/study/NCT04706910", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06221202", "color": "#18e436", "title": "Stories in the Moment: Dance Program for People Living With Dementia", "status": "RECRUITING", "phases": ["NA"], "interventions": "Stories in the Moment Dance Program - Online", "sponsor": "DanceStream Projects", "address": "", "url": "https://clinicaltrials.gov/study/NCT06221202", "diseases": ["Lewy Body Disease"]}, {"lat": 42.98339, "lng": -81.23304, "nct": "NCT04405596", "color": "#846716", "title": "Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Ambroxol Hydrochloride; Placebo", "sponsor": "London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's", "address": "", "url": "https://clinicaltrials.gov/study/NCT04405596", "diseases": ["Lewy Body Disease"]}, {"lat": 43.73718, "lng": 7.42145, "nct": "NCT06785948", "color": "#b276a3", "title": "tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "active-tDCS; Sham-tDCS", "sponsor": "Association de Recherche Bibliographique pour les Neurosciences", "address": "", "url": "https://clinicaltrials.gov/study/NCT06785948", "diseases": ["Lewy Body Disease"]}, {"lat": 47.31667, "lng": 5.01667, "nct": "NCT06439355", "color": "#1535d4", "title": "Single-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis", "status": "RECRUITING", "phases": ["NA"], "interventions": "Fasting blood test; Subject interview; Motor assessment; Neurocognitive assessment; Nutritional assessment; Taste tests", "sponsor": "Centre Hospitalier Universitaire Dijon", "address": "", "url": "https://clinicaltrials.gov/study/NCT06439355", "diseases": ["Lewy Body Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT05014971", "color": "#184c72", "title": "Telehealth in Lewy Body Dementia", "status": "RECRUITING", "phases": ["NA"], "interventions": "Tele-neurohub", "sponsor": "University of Florida", "address": "", "url": "https://clinicaltrials.gov/study/NCT05014971", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": 47.60621, "lng": -122.33207, "nct": "NCT05596760", "color": "#5ea085", "title": "Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers", "status": "RECRUITING", "phases": ["NA"], "interventions": "Jumpstart Guide", "sponsor": "University of Washington", "address": "", "url": "https://clinicaltrials.gov/study/NCT05596760", "diseases": ["Lewy Body Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT06389032", "color": "#e0cfde", "title": "PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia", "status": "RECRUITING", "phases": ["NA"], "interventions": "Peer Mentor Support and Caregiver Education; Caregiver Education", "sponsor": "Rush University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06389032", "diseases": ["Lewy Body Disease", "Parkinson Disease"]}, {"lat": -22.90642, "lng": -43.18223, "nct": "NCT06733714", "color": "#926b95", "title": "Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults", "status": "RECRUITING", "phases": ["NA"], "interventions": "Transcranial Alternating Current Stimulation; Digital Cognitive Training", "sponsor": "Universidade Federal do Rio de Janeiro", "address": "", "url": "https://clinicaltrials.gov/study/NCT06733714", "diseases": ["Lewy Body Disease"]}, {"lat": 49.19522, "lng": 16.60796, "nct": "NCT05847985", "color": "#8cee60", "title": "Language and Lewy Body Diseases: Sentence Comprehension Problems and Modifying Noninvasive Brain Stimulation Treatment", "status": "RECRUITING", "phases": ["NA"], "interventions": "transcranial direct current stimulation (tDCS)", "sponsor": "Masaryk University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05847985", "diseases": ["Lewy Body Disease"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT04389437", "color": "#dd451e", "title": "OCT-Angiography and Adaptive Optics in Patients With Memory Impairment", "status": "RECRUITING", "phases": ["NA"], "interventions": "Ophthalmological exam; Blood pressure measurement", "sponsor": "Fondation Ophtalmologique Adolphe de Rothschild", "address": "", "url": "https://clinicaltrials.gov/study/NCT04389437", "diseases": ["Lewy Body Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT04246437", "color": "#475ed9", "title": "[18F]F-DOPA Imaging in Patients with Autonomic Failure", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "[18F]FDOPA; Carbidopa 200mg oral dose; Entacapone 400mg oral dose", "sponsor": "Daniel Claassen", "address": "", "url": "https://clinicaltrials.gov/study/NCT04246437", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06687837", "color": "#8543d1", "title": "Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "autologous dopaminergic cell implantation", "sponsor": "Jeffrey S. Schweitzer, MD, PhD", "address": "", "url": "https://clinicaltrials.gov/study/NCT06687837", "diseases": ["Parkinson Disease"]}, {"lat": 45.64953, "lng": 13.77678, "nct": "NCT06835595", "color": "#b29b85", "title": "TMS-related Measures As Biomarker of Cognitive Impairment in PD", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Transcranial Magnetic Stimulation", "sponsor": "Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento", "address": "", "url": "https://clinicaltrials.gov/study/NCT06835595", "diseases": ["Parkinson Disease"]}, {"lat": 46.89313, "lng": 11.42961, "nct": "NCT06835595", "color": "#b29b85", "title": "TMS-related Measures As Biomarker of Cognitive Impairment in PD", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Transcranial Magnetic Stimulation", "sponsor": "Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento", "address": "", "url": "https://clinicaltrials.gov/study/NCT06835595", "diseases": ["Parkinson Disease"]}, {"lat": 46.06787, "lng": 11.12108, "nct": "NCT06835595", "color": "#b29b85", "title": "TMS-related Measures As Biomarker of Cognitive Impairment in PD", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Transcranial Magnetic Stimulation", "sponsor": "Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento", "address": "", "url": "https://clinicaltrials.gov/study/NCT06835595", "diseases": ["Parkinson Disease"]}, {"lat": 44.99364, "lng": 11.10642, "nct": "NCT05769699", "color": "#f13bbd", "title": "Serum Biomarkers in Parkinson's Disease at Different Stages", "status": "RECRUITING", "phases": ["NA"], "interventions": "blood sample", "sponsor": "Fondazione Policlinico Universitario Agostino Gemelli IRCCS", "address": "", "url": "https://clinicaltrials.gov/study/NCT05769699", "diseases": ["Parkinson Disease"]}, {"lat": 50.87959, "lng": 4.70093, "nct": "NCT04269577", "color": "#29042c", "title": "Motor Learning in Parkinson's Disease: Underlying Effective Connectivity and Influential Factors", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "SSP training", "sponsor": "KU Leuven", "address": "", "url": "https://clinicaltrials.gov/study/NCT04269577", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT03667404", "color": "#57e5dd", "title": "Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Resistant maltodextrin; maltodextrin", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT03667404", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT06388863", "color": "#597f05", "title": "Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Healthy donor-derived FMT capsule; Placebo capsule", "sponsor": "Shanghai Zhongshan Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06388863", "diseases": ["Parkinson Disease"]}, {"lat": 37.42411, "lng": -122.16608, "nct": "NCT05545826", "color": "#44932e", "title": "Vibrotactile Coordinated Reset (VCR): A Treatment for Early Stage Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Vibrotactile coordinated reset", "sponsor": "Stanford University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05545826", "diseases": ["Parkinson Disease"]}, {"lat": 31.86389, "lng": 117.28083, "nct": "NCT06383247", "color": "#89e2fe", "title": "The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "transcranial magnetic stimulation", "sponsor": "Anhui Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06383247", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT05022147", "color": "#6a9a3d", "title": "Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "High-Frequency-Only Stimulation; Low-Frequency-Only Stimulation; Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation; Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation; Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation; Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation; OFF Dopaminergic Medication; ON Dopaminergic Medication", "sponsor": "James Liao", "address": "", "url": "https://clinicaltrials.gov/study/NCT05022147", "diseases": ["Parkinson Disease"]}, {"lat": 33.59754, "lng": -112.27182, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 34.74648, "lng": -92.28959, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 36.74773, "lng": -119.77237, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 33.66946, "lng": -117.82311, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 33.55391, "lng": -117.21392, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 41.30815, "lng": -72.92816, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 33.47097, "lng": -81.97484, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 37.98869, "lng": -84.47772, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 29.95465, "lng": -90.07507, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 45.00969, "lng": -93.34912, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 36.17497, "lng": -115.13722, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 40.80066, "lng": -73.72846, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 43.15478, "lng": -77.61556, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 35.9132, "lng": -79.05584, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 35.7721, "lng": -78.63861, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 36.15398, "lng": -95.99277, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 32.77632, "lng": -79.93275, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 40.76078, "lng": -111.89105, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 38.02931, "lng": -78.47668, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 43.0389, "lng": -87.90647, "nct": "NCT06680830", "color": "#cf0195", "title": "A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "NEU-411; Placebo", "sponsor": "Neuron23 Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06680830", "diseases": ["Parkinson Disease"]}, {"lat": 29.61968, "lng": -95.63495, "nct": "NCT04995081", "color": "#840034", "title": "Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Biological/Vaccine: Allogeneic HB-adMSCs; Placebo", "sponsor": "Hope Biosciences Stem Cell Research Foundation", "address": "", "url": "https://clinicaltrials.gov/study/NCT04995081", "diseases": ["Parkinson Disease"]}, {"lat": 46.516, "lng": 6.63282, "nct": "NCT06295614", "color": "#9897eb", "title": "Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "ARC-IM System implantation", "sponsor": "Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne", "address": "", "url": "https://clinicaltrials.gov/study/NCT06295614", "diseases": ["Parkinson Disease"]}, {"lat": 31.86389, "lng": 117.28083, "nct": "NCT07118956", "color": "#7d6bfb", "title": "Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Active RAVANS; Sham RAVANS", "sponsor": "Anhui Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07118956", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT05489575", "color": "#40bfc3", "title": "CPAP for the Treatment of Supine Hypertension", "status": "RECRUITING", "phases": ["NA"], "interventions": "Active CPAP; Sham CPAP; Sleeping in a head-up tilt (HUT) position", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05489575", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT04946812", "color": "#8ce8e1", "title": "Split-belt Treadmill Training to Rehabilitate Freezing of Gait and Balance in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Split-belt treadmill training", "sponsor": "University of Toronto", "address": "", "url": "https://clinicaltrials.gov/study/NCT04946812", "diseases": ["Parkinson Disease"]}, {"lat": -1.29389, "lng": -47.92639, "nct": "NCT06967493", "color": "#6f5fe0", "title": "Effects of Amazonian Dance on Motor and Non-motor Symptoms of People With Parkinson's: Study Protocol", "status": "RECRUITING", "phases": ["NA"], "interventions": "Amazonian Dance; Nordic Walking", "sponsor": "Federal University of Rio Grande do Sul", "address": "", "url": "https://clinicaltrials.gov/study/NCT06967493", "diseases": ["Parkinson Disease"]}, {"lat": -30.03283, "lng": -51.23019, "nct": "NCT06967493", "color": "#6f5fe0", "title": "Effects of Amazonian Dance on Motor and Non-motor Symptoms of People With Parkinson's: Study Protocol", "status": "RECRUITING", "phases": ["NA"], "interventions": "Amazonian Dance; Nordic Walking", "sponsor": "Federal University of Rio Grande do Sul", "address": "", "url": "https://clinicaltrials.gov/study/NCT06967493", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT06436313", "color": "#d4274a", "title": "DBS Virtual Learning Experience", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Educational Sessions", "sponsor": "University of Toronto", "address": "", "url": "https://clinicaltrials.gov/study/NCT06436313", "diseases": ["Parkinson Disease"]}, {"lat": 32.71571, "lng": -117.16472, "nct": "NCT05400174", "color": "#691a35", "title": "Blood Pressure Effects on Cognition and Brain Blood Flow in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Tilt table (upright position)", "sponsor": "University of California, San Diego", "address": "", "url": "https://clinicaltrials.gov/study/NCT05400174", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT06848205", "color": "#9018ca", "title": "Percept Transitions in FOG and PD", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "OFF Parkinson's Medication(s); OFF Deep Brain Stimulation", "sponsor": "University of Minnesota", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848205", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT05395624", "color": "#6e534d", "title": "Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "18F-OP-801", "sponsor": "Ashvattha Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05395624", "diseases": ["Parkinson Disease"]}, {"lat": 37.42411, "lng": -122.16608, "nct": "NCT05395624", "color": "#6e534d", "title": "Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "18F-OP-801", "sponsor": "Ashvattha Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05395624", "diseases": ["Parkinson Disease"]}, {"lat": 30.33218, "lng": -81.65565, "nct": "NCT05395624", "color": "#6e534d", "title": "Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "18F-OP-801", "sponsor": "Ashvattha Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05395624", "diseases": ["Parkinson Disease"]}, {"lat": 44.39071, "lng": 7.54828, "nct": "NCT06052280", "color": "#5277f8", "title": "Pilot Study: Parkinson's Conventional Physiotherapy vs Home-based Telerehabilitation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation exercise program; Home self-exercise program", "sponsor": "Azienda Sanitaria Locale CN1 Cuneo", "address": "", "url": "https://clinicaltrials.gov/study/NCT06052280", "diseases": ["Parkinson Disease"]}, {"lat": 38.25424, "lng": -85.75941, "nct": "NCT06804642", "color": "#cc42c0", "title": "Spinal Cord Stimulation for Parkinson's Disease Rehabilitation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Spinal cord transcutaneous stimulation (scTS)", "sponsor": "University of Louisville", "address": "", "url": "https://clinicaltrials.gov/study/NCT06804642", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT04897256", "color": "#210769", "title": "Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation", "status": "RECRUITING", "phases": ["NA"], "interventions": "TURN-IT exercise program", "sponsor": "Oregon Health and Science University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04897256", "diseases": ["Parkinson Disease"]}, {"lat": 35.9132, "lng": -79.05584, "nct": "NCT05864157", "color": "#3c6efa", "title": "Targeted Motor Learning to Improve Gait for Individuals With Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Gait training without rhythmic auditory cues; TRAC; dTRAC", "sponsor": "University of North Carolina, Chapel Hill", "address": "", "url": "https://clinicaltrials.gov/study/NCT05864157", "diseases": ["Parkinson Disease"]}, {"lat": 45.19205, "lng": 9.15917, "nct": "NCT04876339", "color": "#0ae23a", "title": "Sonification Techniques for Gait Training", "status": "RECRUITING", "phases": ["NA"], "interventions": "Gait rehabilitation with \"sonification\"; Standard gait rehabilitation (without sonification)", "sponsor": "Istituti Clinici Scientifici Maugeri SpA", "address": "", "url": "https://clinicaltrials.gov/study/NCT04876339", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT05824728", "color": "#68e843", "title": "Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AGB101", "sponsor": "Johns Hopkins University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05824728", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 42.03471, "lng": -93.61994, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 30.44332, "lng": -91.18747, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 38.62727, "lng": -90.19789, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 39.12711, "lng": -84.51439, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 41.15367, "lng": -81.35789, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 40.44062, "lng": -79.99589, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 29.42412, "lng": -98.49363, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 40.76078, "lng": -111.89105, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": 53.55014, "lng": -113.46871, "nct": "NCT04284436", "color": "#47f2ea", "title": "Study in Parkinson Disease of Exercise", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treadmill walking", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04284436", "diseases": ["Parkinson Disease"]}, {"lat": -19.92083, "lng": -43.93778, "nct": "NCT06950255", "color": "#1df3fe", "title": "Effect of Training and Use of Cane on Gait in Individuals With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cane; static stretching and health education", "sponsor": "Federal University of Minas Gerais", "address": "", "url": "https://clinicaltrials.gov/study/NCT06950255", "diseases": ["Parkinson Disease"]}, {"lat": 31.03637, "lng": 31.38069, "nct": "NCT06113640", "color": "#961b87", "title": "Montelukast in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "levodopa-carbidopa; Montelukast", "sponsor": "Mostafa Bahaa", "address": "", "url": "https://clinicaltrials.gov/study/NCT06113640", "diseases": ["Parkinson Disease"]}, {"lat": 45.77969, "lng": 3.08682, "nct": "NCT06582121", "color": "#ffa76a", "title": "Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Polysomnography", "sponsor": "Assistance Publique - H\u00f4pitaux de Paris", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582121", "diseases": ["Parkinson Disease"]}, {"lat": 50.63297, "lng": 3.05858, "nct": "NCT06582121", "color": "#ffa76a", "title": "Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Polysomnography", "sponsor": "Assistance Publique - H\u00f4pitaux de Paris", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582121", "diseases": ["Parkinson Disease"]}, {"lat": 45.74846, "lng": 4.84671, "nct": "NCT06582121", "color": "#ffa76a", "title": "Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Polysomnography", "sponsor": "Assistance Publique - H\u00f4pitaux de Paris", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582121", "diseases": ["Parkinson Disease"]}, {"lat": 47.21725, "lng": -1.55336, "nct": "NCT06582121", "color": "#ffa76a", "title": "Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Polysomnography", "sponsor": "Assistance Publique - H\u00f4pitaux de Paris", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582121", "diseases": ["Parkinson Disease"]}, {"lat": 43.83665, "lng": 4.35788, "nct": "NCT06582121", "color": "#ffa76a", "title": "Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Polysomnography", "sponsor": "Assistance Publique - H\u00f4pitaux de Paris", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582121", "diseases": ["Parkinson Disease"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT06582121", "color": "#ffa76a", "title": "Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Polysomnography", "sponsor": "Assistance Publique - H\u00f4pitaux de Paris", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582121", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT03457493", "color": "#f2a5f7", "title": "The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "DPA-714-PET/MRI; 5-year Follow-up DPA-714-PET/MRI; DPA-714 Metabolite Analysis", "sponsor": "University of Alabama at Birmingham", "address": "", "url": "https://clinicaltrials.gov/study/NCT03457493", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT04922190", "color": "#30accd", "title": "Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "Physical Activity Coaching", "sponsor": "Teachers College, Columbia University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04922190", "diseases": ["Parkinson Disease"]}, {"lat": 51.57515, "lng": 0.18582, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.48095, "lng": -2.23743, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 54.66079, "lng": -5.66802, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 52.62783, "lng": 1.29834, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 55.95206, "lng": -3.19648, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 56.02246, "lng": -3.82872, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.3751, "lng": -2.36172, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 57.14369, "lng": -2.09814, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.55, "lng": -1.48333, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 50.72048, "lng": -1.8795, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.50583, "lng": -3.57722, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.45523, "lng": -2.59665, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.6, "lng": -2.3, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 52.92277, "lng": -1.47663, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 56.46913, "lng": -2.97489, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 54.96209, "lng": -1.60168, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.86568, "lng": -2.2431, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.79648, "lng": -1.54785, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 52.6386, "lng": -1.13169, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.41058, "lng": -2.97794, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 54.57623, "lng": -1.23483, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 54.21804, "lng": -5.88979, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.58774, "lng": -2.99835, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.75222, "lng": -1.25596, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 52.57364, "lng": -0.24777, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 50.37153, "lng": -4.14305, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.76282, "lng": -2.70452, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.45625, "lng": -0.97113, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.48771, "lng": -2.29042, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 54.56848, "lng": -1.3187, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 51.01494, "lng": -3.10293, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.54296, "lng": -2.63706, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 53.04664, "lng": -2.99132, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 50.94159, "lng": -2.63211, "nct": "NCT04226248", "color": "#94dbbe", "title": "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Rivastigmine Transdermal System; Placebo Transdermal System", "sponsor": "University of Bristol", "address": "", "url": "https://clinicaltrials.gov/study/NCT04226248", "diseases": ["Parkinson Disease"]}, {"lat": 24.80361, "lng": 120.96861, "nct": "NCT06536478", "color": "#b08bc7", "title": "The Effect of Exercise Intervention on Posture, Trunk Flexibility and Spine Function in Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "exercise; education", "sponsor": "National Taiwan University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06536478", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT04735458", "color": "#39d8b3", "title": "Investigating Inhibitory Control Networks in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease", "sponsor": "University of Alabama at Birmingham", "address": "", "url": "https://clinicaltrials.gov/study/NCT04735458", "diseases": ["Parkinson Disease"]}, {"lat": 52.58528, "lng": -1.98396, "nct": "NCT05973565", "color": "#09a1c1", "title": "The Effects of a Single Session of Rhythmic Movement Program on Selected Biopsychological Parameters in PD Patients", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Musicokinetic Training", "sponsor": "University of Wolverhampton", "address": "", "url": "https://clinicaltrials.gov/study/NCT05973565", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06540989", "color": "#66314c", "title": "Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "Immediate treatment; Deferred treatment", "sponsor": "Teachers College, Columbia University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06540989", "diseases": ["Parkinson Disease"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 34.74648, "lng": -92.28959, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 34.20112, "lng": -118.53647, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 41.05343, "lng": -73.53873, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 26.14234, "lng": -81.79596, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 42.06538, "lng": -71.24783, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 41.59177, "lng": -70.94115, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 45.00969, "lng": -93.34912, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 40.29039, "lng": -74.01764, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 35.7721, "lng": -78.63861, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 36.15398, "lng": -95.99277, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 32.37896, "lng": -80.69265, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 35.14953, "lng": -90.04898, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 33.15067, "lng": -96.82361, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 43.07305, "lng": -89.40123, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 43.0389, "lng": -87.90647, "nct": "NCT05424276", "color": "#cc0556", "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "IkT-148009; Placebo", "sponsor": "ABLi Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05424276", "diseases": ["Parkinson Disease"]}, {"lat": 40.73583, "lng": 31.60611, "nct": "NCT04941326", "color": "#d9d9b4", "title": "The Effect of Spinal Mobilization on Respiratory Parameters in Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "Diaphragmatic stimulation treatment with PNF techniques; Costal mobilization; Breathing exercises; Spinal mobilization; Sham mobilization", "sponsor": "Abant Izzet Baysal University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04941326", "diseases": ["Parkinson Disease"]}, {"lat": 52.6386, "lng": -1.13169, "nct": "NCT05986643", "color": "#955115", "title": "Brain Training to Improve Balance in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exergame+Neurofeedback; Exergame [alone]", "sponsor": "University of Leicester", "address": "", "url": "https://clinicaltrials.gov/study/NCT05986643", "diseases": ["Parkinson Disease"]}, {"lat": 44.49381, "lng": 11.33875, "nct": "NCT06316232", "color": "#250c74", "title": "DBS and Levodopa for Treating Freezing of Gait in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "STIM ON plus; MED ON plus", "sponsor": "IRCCS Istituto delle Scienze Neurologiche di Bologna", "address": "", "url": "https://clinicaltrials.gov/study/NCT06316232", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT02897063", "color": "#0249fe", "title": "Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Droxidopa; Midodrine; Placebo", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT02897063", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 46.516, "lng": 6.63282, "nct": "NCT06831500", "color": "#ff1f71", "title": "Feasibility Study Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Administration of Carbidopa/levodopa", "sponsor": "Julien Bally", "address": "", "url": "https://clinicaltrials.gov/study/NCT06831500", "diseases": ["Parkinson Disease"]}, {"lat": 38.58157, "lng": -121.4944, "nct": "NCT04650932", "color": "#875bbc", "title": "Dual Frequency Stimulation in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep brain stimulation", "sponsor": "University of California, Davis", "address": "", "url": "https://clinicaltrials.gov/study/NCT04650932", "diseases": ["Parkinson Disease"]}, {"lat": -7.115, "lng": -34.86306, "nct": "NCT06145776", "color": "#4a92ad", "title": "The Role of EEG in Identifying Cognitive Changes in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "tDCS + tredmill training (Standart trehab training); Cognitite-motor Dual Task Training (DT training)", "sponsor": "Federal University of Para\u00edba", "address": "", "url": "https://clinicaltrials.gov/study/NCT06145776", "diseases": ["Parkinson Disease"]}, {"lat": 38.62727, "lng": -90.19789, "nct": "NCT06115382", "color": "#c737e9", "title": "Sing For Your Saunter Part 2 R33", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Self Cueing Training; External Cueing Training", "sponsor": "Washington University School of Medicine", "address": "", "url": "https://clinicaltrials.gov/study/NCT06115382", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT05818189", "color": "#5426e2", "title": "Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing", "status": "RECRUITING", "phases": ["NA"], "interventions": "Personalized tactile cueing; Fixed tactile cueing", "sponsor": "Oregon Health and Science University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05818189", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT05103618", "color": "#6f5d2d", "title": "Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA", "status": "NOT_YET_RECRUITING", "phases": ["PHASE2"], "interventions": "[F-18] Fluorodopa Positron Emission Tomography; OM Meditation", "sponsor": "Andrew Newberg", "address": "", "url": "https://clinicaltrials.gov/study/NCT05103618", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT05720468", "color": "#9a3364", "title": "Exercise for Cognitive Excellence in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exercise; No Exercise", "sponsor": "University of California, San Francisco", "address": "", "url": "https://clinicaltrials.gov/study/NCT05720468", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT06399731", "color": "#52678d", "title": "Non-invasive Brain Stimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "High-frequency (10Hz) rTMS; Anodal tDCS", "sponsor": "Amsterdam UMC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06399731", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06425731", "color": "#70521b", "title": "Dance and Energy Expenditure Among Adults With Parkinson's", "status": "RECRUITING", "phases": ["NA"], "interventions": "Fasting; No Intervention", "sponsor": "Northeastern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06425731", "diseases": ["Parkinson Disease"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT05982730", "color": "#efc480", "title": "SegwayPD: The Effect of Sensory-augmented Postural Training Using Segway on Motor and Cognitive Function in Individuals With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Sensory-Augmented Postural Training", "sponsor": "University of Texas Southwestern Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05982730", "diseases": ["Parkinson Disease"]}, {"lat": 40.44062, "lng": -79.99589, "nct": "NCT07056361", "color": "#8b1f11", "title": "Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control", "status": "RECRUITING", "phases": ["NA"], "interventions": "Direct cortical stimulation and deep brain stimulation of motor thalamus", "sponsor": "University of Pittsburgh", "address": "", "url": "https://clinicaltrials.gov/study/NCT07056361", "diseases": ["Parkinson Disease"]}, {"lat": 43.73718, "lng": 7.42145, "nct": "NCT04731246", "color": "#681f60", "title": "Video-oculography and Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Video-oculography / Neuropsychological evaluations", "sponsor": "Association de Recherche Bibliographique pour les Neurosciences", "address": "", "url": "https://clinicaltrials.gov/study/NCT04731246", "diseases": ["Parkinson Disease"]}, {"lat": 32.22174, "lng": -110.92648, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 38.58157, "lng": -121.4944, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 39.76838, "lng": -86.15804, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 43.64229, "lng": -72.25176, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 30.63269, "lng": -97.67723, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 51.22172, "lng": 6.77616, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 49.98419, "lng": 8.2791, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 41.45004, "lng": 2.24741, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": 55.86515, "lng": -4.25763, "nct": "NCT05269862", "color": "#0bbc55", "title": "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)", "sponsor": "Abbott Medical Devices", "address": "", "url": "https://clinicaltrials.gov/study/NCT05269862", "diseases": ["Parkinson Disease"]}, {"lat": -37.814, "lng": 144.96332, "nct": "NCT06466525", "color": "#626c62", "title": "A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LBT-3627; Placebo", "sponsor": "Longevity Biotech Australia Pty Ltd (subsidiary)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06466525", "diseases": ["Parkinson Disease"]}, {"lat": 45.38193, "lng": 9.1559, "nct": "NCT06814782", "color": "#3884fe", "title": "Effects of Action Observation Training and Motor Imagery Delivered by Telerehabilitation in Patients with Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Action Observation Training; Action Observation and Motor Imagery; Exercise", "sponsor": "Istituto Clinico Humanitas", "address": "", "url": "https://clinicaltrials.gov/study/NCT06814782", "diseases": ["Parkinson Disease"]}, {"lat": 33.41477, "lng": -111.90931, "nct": "NCT06815302", "color": "#9d19cc", "title": "TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Experimental intervention; Active intervention", "sponsor": "Oregon Health and Science University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06815302", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT06815302", "color": "#9d19cc", "title": "TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Experimental intervention; Active intervention", "sponsor": "Oregon Health and Science University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06815302", "diseases": ["Parkinson Disease"]}, {"lat": -22.31472, "lng": -49.06056, "nct": "NCT06815302", "color": "#9d19cc", "title": "TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Experimental intervention; Active intervention", "sponsor": "Oregon Health and Science University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06815302", "diseases": ["Parkinson Disease"]}, {"lat": 46.516, "lng": 6.63282, "nct": "NCT04956770", "color": "#ca9a50", "title": "Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Implantation surgery", "sponsor": "Jocelyne Bloch", "address": "", "url": "https://clinicaltrials.gov/study/NCT04956770", "diseases": ["Parkinson Disease"]}, {"lat": 47.05048, "lng": 8.30635, "nct": "NCT05965661", "color": "#280127", "title": "A New 3D Virtual Reality-based Upper Limb Training to Improve Dexterity in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "virtual reality upper limb hand training; virtual reality control training", "sponsor": "Luzerner Kantonsspital", "address": "", "url": "https://clinicaltrials.gov/study/NCT05965661", "diseases": ["Parkinson Disease"]}, {"lat": 31.86389, "lng": 117.28083, "nct": "NCT06642454", "color": "#472561", "title": "A Comparative Open-Label Crossover Study of Respiratory-Gated Versus Non-Respiratory-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Transcutaneous auricular vagus nerve stimulation", "sponsor": "Anhui Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06642454", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT07154511", "color": "#9d893b", "title": "Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Tributyrin; Placebo", "sponsor": "Prabesh Kanel", "address": "", "url": "https://clinicaltrials.gov/study/NCT07154511", "diseases": ["Parkinson Disease"]}, {"lat": 49.83465, "lng": 18.28204, "nct": "NCT06570421", "color": "#5de6ea", "title": "24-months Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor", "status": "RECRUITING", "phases": ["NA"], "interventions": "Peroneal electrical transcutaneous neuromodulation (peroneal eTNM\u00ae)", "sponsor": "Stimvia s.r.o.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06570421", "diseases": ["Parkinson Disease"]}, {"lat": 42.98339, "lng": -81.23304, "nct": "NCT03343574", "color": "#936ad5", "title": "Cardiovascular Effects of Exercise in Patients With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Abdominal Strengthening Exercise", "sponsor": "Faizan Ahmed", "address": "", "url": "https://clinicaltrials.gov/study/NCT03343574", "diseases": ["Parkinson Disease"]}, {"lat": 41.66113, "lng": -91.53017, "nct": "NCT03217110", "color": "#f54906", "title": "Cerebellar Stimulation and Cognitive Control", "status": "RECRUITING", "phases": ["NA"], "interventions": "Repetitive Transcranial Magnetic Stimulation (rTMS); Sham Repetitive Transcranial Magnetic Stimulation (rTMS)", "sponsor": "Krystal Parker, PhD", "address": "", "url": "https://clinicaltrials.gov/study/NCT03217110", "diseases": ["Parkinson Disease"]}, {"lat": 39.62953, "lng": -79.9559, "nct": "NCT06237868", "color": "#35cb57", "title": "rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "rTMS Active; rTMS Sham", "sponsor": "West Virginia University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06237868", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT03969927", "color": "#0e8a90", "title": "User-friendliness of a Portable Driving Simulator", "status": "RECRUITING", "phases": ["NA"], "interventions": "Low-Fidelity PDS; High Fidelity Fixed-Base Simulator", "sponsor": "University of Kansas Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT03969927", "diseases": ["Parkinson Disease"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT06295458", "color": "#d54aae", "title": "Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait", "status": "RECRUITING", "phases": ["NA"], "interventions": "David Delight Plus Device; Sham Therapy", "sponsor": "Emory University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06295458", "diseases": ["Parkinson Disease"]}, {"lat": 23.7104, "lng": 90.40744, "nct": "NCT07084597", "color": "#4330f6", "title": "Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Parkinson's Disease Patients With Hypovitaminosis D", "status": "RECRUITING", "phases": ["NA"], "interventions": "Vitamin D", "sponsor": "Bangladesh Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07084597", "diseases": ["Parkinson Disease"]}, {"lat": 41.03399, "lng": -73.76291, "nct": "NCT04564495", "color": "#84898b", "title": "Home Based Tele-exercise for People With Chronic Neurological Impairments", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Seated exercise", "sponsor": "Burke Medical Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT04564495", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT05933681", "color": "#2ce865", "title": "Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neural recordings and stimulation", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05933681", "diseases": ["Parkinson Disease"]}, {"lat": 23.7104, "lng": 90.40744, "nct": "NCT07055958", "color": "#489f9b", "title": "Effect of Metformin as Add-on Therapy in Levodopa Treated Parkinson's Disease Patients", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Metformin; placebo", "sponsor": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", "address": "", "url": "https://clinicaltrials.gov/study/NCT07055958", "diseases": ["Parkinson Disease"]}, {"lat": 50.93333, "lng": 6.95, "nct": "NCT06582355", "color": "#39bf87", "title": "FMRI-neurofeedback in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neurofeedback; Kinesthetic imagery", "sponsor": "Maastricht University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582355", "diseases": ["Parkinson Disease"]}, {"lat": 50.84833, "lng": 5.68889, "nct": "NCT06582355", "color": "#39bf87", "title": "FMRI-neurofeedback in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neurofeedback; Kinesthetic imagery", "sponsor": "Maastricht University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582355", "diseases": ["Parkinson Disease"]}, {"lat": 41.51142, "lng": 14.06252, "nct": "NCT06297538", "color": "#5033cc", "title": "Parkinson's Disease and Gamma-transcranial Alternating Current Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "gamma transcranial alternating current stimulation (tACS); sham transcranial alternating current stimulation (tACS)", "sponsor": "Neuromed IRCCS", "address": "", "url": "https://clinicaltrials.gov/study/NCT06297538", "diseases": ["Parkinson Disease"]}, {"lat": 54.32133, "lng": 10.13489, "nct": "NCT07058285", "color": "#c5a999", "title": "Steps Against the Burden of Parkinson's Disease - RCT Kiel", "status": "RECRUITING", "phases": ["NA"], "interventions": "Speed-dependent treadmill training (SDTT); SDTT+ anteroposterior perturbations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT07058285", "diseases": ["Parkinson Disease"]}, {"lat": 47.05048, "lng": 8.30635, "nct": "NCT06062693", "color": "#46df88", "title": "New Interactive Sensor-home-based Hand Training to Improve Dexterity", "status": "RECRUITING", "phases": ["NA"], "interventions": "smart sensor egg training", "sponsor": "Luzerner Kantonsspital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06062693", "diseases": ["Parkinson Disease"]}, {"lat": 30.29365, "lng": 120.16142, "nct": "NCT06596005", "color": "#32b13f", "title": "Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "TJ0113; Placebo", "sponsor": "Second Affiliated Hospital, School of Medicine, Zhejiang University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06596005", "diseases": ["Parkinson Disease"]}, {"lat": 30.00944, "lng": 31.20861, "nct": "NCT06646510", "color": "#189988", "title": "Effect of Sensory Electrical Stimulation on Resting Tremors in Patients with Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "traditional exercises; sensory electrical stimulation", "sponsor": "Cairo University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06646510", "diseases": ["Parkinson Disease"]}, {"lat": 41.01384, "lng": 28.94966, "nct": "NCT07068217", "color": "#527a93", "title": "Effect of Metronome-Based Structured Rhythmic Exercise Program on Freezing and Gait Parameters in Parkinson Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Exercise", "sponsor": "Medipol University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07068217", "diseases": ["Parkinson Disease"]}, {"lat": 23.70944, "lng": 120.54333, "nct": "NCT06197698", "color": "#62e2b0", "title": "A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis", "status": "RECRUITING", "phases": ["NA"], "interventions": "F18-FDG, Tc-99m TRODAT-1", "sponsor": "National Taiwan University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06197698", "diseases": ["Parkinson Disease"]}, {"lat": 52.2, "lng": 0.11667, "nct": "NCT06430151", "color": "#b8d673", "title": "Useability and Acceptability of the CUE1 Device in Older People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "CUE1", "sponsor": "Dr Alistair Mackett", "address": "", "url": "https://clinicaltrials.gov/study/NCT06430151", "diseases": ["Parkinson Disease"]}, {"lat": 47.36667, "lng": 8.55, "nct": "NCT05101161", "color": "#ba9ba4", "title": "Neurofeedback Using Implanted Deep Brain Stimulation Electrodes", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neurofeedback", "sponsor": "ETH Zurich", "address": "", "url": "https://clinicaltrials.gov/study/NCT05101161", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT05166655", "color": "#cd75e3", "title": "DBS Recordings to Characterize Movement Facilitation in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Movement task", "sponsor": "University of California, Los Angeles", "address": "", "url": "https://clinicaltrials.gov/study/NCT05166655", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 27.49893, "lng": -82.57482, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 26.12231, "lng": -80.14338, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 26.62168, "lng": -81.84059, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 28.359, "lng": -80.69, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 28.56917, "lng": -81.54396, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 30.42131, "lng": -87.21691, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 26.23786, "lng": -80.12477, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 28.23973, "lng": -82.32787, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 39.20839, "lng": -84.39911, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 41.37477, "lng": -83.65132, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 41.44894, "lng": -82.70796, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 41.66394, "lng": -83.55521, "nct": "NCT03944447", "color": "#92f4f2", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabis, Medical; RYAH-Medtech Inhaler", "sponsor": "OMNI Medical Services, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT03944447", "diseases": ["Parkinson Disease"]}, {"lat": 9.93388, "lng": -84.08489, "nct": "NCT06141317", "color": "#27451c", "title": "Randomized Clinical Trial in Parkinson's Disease Patients Using Pluripotent Adipose Stem Cells (PASCs)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "PASC transplantation (25 million PASCs/patient); Control", "sponsor": "ClusterXStem-Costa Rica", "address": "", "url": "https://clinicaltrials.gov/study/NCT06141317", "diseases": ["Parkinson Disease"]}, {"lat": 43.07305, "lng": -89.40123, "nct": "NCT06616948", "color": "#aedc5f", "title": "In-home Cycling for Individuals With PD: Effectiveness", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Social Cycling Group; coaching calls; No coaching calls", "sponsor": "University of Wisconsin, Madison", "address": "", "url": "https://clinicaltrials.gov/study/NCT06616948", "diseases": ["Parkinson Disease"]}, {"lat": 37.566, "lng": 126.9784, "nct": "NCT05995782", "color": "#f3aa20", "title": "A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "FB418", "sponsor": "1ST Biotherapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05995782", "diseases": ["Parkinson Disease"]}, {"lat": 37.98376, "lng": 23.72784, "nct": "NCT06220084", "color": "#9b543e", "title": "The UPbeating GReek Application of DancE in Parkinson's Disease Clinical Trial", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Dance for PD\u00ae", "sponsor": "University of West Attica", "address": "", "url": "https://clinicaltrials.gov/study/NCT06220084", "diseases": ["Parkinson Disease"]}, {"lat": 33.80307, "lng": -118.07256, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 28.62778, "lng": -81.36312, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 26.14234, "lng": -81.79596, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 28.93408, "lng": -81.95994, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 33.77483, "lng": -84.29631, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 30.26715, "lng": -97.74306, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 33.1956, "lng": 131.37829, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 35.65583, "lng": 139.32389, "nct": "NCT06809400", "color": "#3d658d", "title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "LY4006896; Placebo", "sponsor": "Eli Lilly and Company", "address": "", "url": "https://clinicaltrials.gov/study/NCT06809400", "diseases": ["Parkinson Disease"]}, {"lat": 56.15674, "lng": 10.21076, "nct": "NCT05981261", "color": "#7422ae", "title": "Experimental Pain in Parkinsons", "status": "RECRUITING", "phases": ["NA"], "interventions": "inducement of experimental pain", "sponsor": "University of Aarhus", "address": "", "url": "https://clinicaltrials.gov/study/NCT05981261", "diseases": ["Parkinson Disease"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT06489483", "color": "#99f29c", "title": "Action Regulation Behavioral", "status": "RECRUITING", "phases": ["NA"], "interventions": "Action Regulation Movement Task", "sponsor": "University of Texas Southwestern Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06489483", "diseases": ["Parkinson Disease"]}, {"lat": 48.09115, "lng": 14.26352, "nct": "NCT06690931", "color": "#0b1b22", "title": "Neurofeedback Rehabilitation With FES and VR for PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Brain-Computer Interface with FES and VR; Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback", "sponsor": "g.tec medical engineering GmbH", "address": "", "url": "https://clinicaltrials.gov/study/NCT06690931", "diseases": ["Parkinson Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT06911229", "color": "#62d878", "title": "Neurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation (DBS)", "sponsor": "University of Florida", "address": "", "url": "https://clinicaltrials.gov/study/NCT06911229", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT05459753", "color": "#55b086", "title": "Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET; Dihydrotetrabenazine (DTBZ) PET", "sponsor": "University of Michigan", "address": "", "url": "https://clinicaltrials.gov/study/NCT05459753", "diseases": ["Parkinson Disease"]}, {"lat": -8.05389, "lng": -34.88111, "nct": "NCT06856941", "color": "#d9683e", "title": "CsDCS on Functional Mobility in Parkinsons Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "cerebello-spinal direct current stimulation; sham cerebello-spinal direct current stimulation", "sponsor": "Universidade Federal de Pernambuco", "address": "", "url": "https://clinicaltrials.gov/study/NCT06856941", "diseases": ["Parkinson Disease"]}, {"lat": 47.60621, "lng": -122.33207, "nct": "NCT02696603", "color": "#9d6e8d", "title": "Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Participant self-assessment surveys; Phonation; Gait and balance; Memory; Dexterity; Participant open-response writing; Parkinson mPower mobile application", "sponsor": "Sage Bionetworks", "address": "", "url": "https://clinicaltrials.gov/study/NCT02696603", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT06416345", "color": "#816b85", "title": "Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Cue2Walk; Usual Care", "sponsor": "Amsterdam UMC, location VUmc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06416345", "diseases": ["Parkinson Disease"]}, {"lat": 54.32133, "lng": 10.13489, "nct": "NCT06463769", "color": "#cb0070", "title": "Impact of Diet on the Microbiome-Immune-Brain Axis in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "8 week predominantly plant-based New Nordic LPF-diet program; maintenance of the predominantly plant-based New Nordic LPF-diet", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06463769", "diseases": ["Parkinson Disease"]}, {"lat": 30.78847, "lng": 31.00192, "nct": "NCT07001150", "color": "#3262a5", "title": "Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "levodopa-carbidopa; Silymarin", "sponsor": "Tanta University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07001150", "diseases": ["Parkinson Disease"]}, {"lat": 41.71982, "lng": -72.83204, "nct": "NCT06954662", "color": "#0ca507", "title": "A Targeted Amino Acid Supplement for People With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "Amino acid supplement; Whey Protein Supplement; Isonitrogenous Placebo Supplement", "sponsor": "UConn Health", "address": "", "url": "https://clinicaltrials.gov/study/NCT06954662", "diseases": ["Parkinson Disease"]}, {"lat": 59.32938, "lng": 18.06871, "nct": "NCT05510739", "color": "#a7441f", "title": "Support for Physical Activity in Everyday Life With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Motor-cognitive home exercise supported by eHealth technology; Individualized home exercise program", "sponsor": "Stiftelsen Stockholms Sjukhem", "address": "", "url": "https://clinicaltrials.gov/study/NCT05510739", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT04768101", "color": "#b4fa03", "title": "Quantitative Imaging of Brain Glymphatic Function in Humans", "status": "ACTIVE_NOT_RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "[11C]-PIB", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT04768101", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT04459052", "color": "#4a1285", "title": "FDOPA PET and Nutritional Support in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "N acetyl cysteine; [F-18] Fluorodopa Positron Emission Tomography", "sponsor": "Thomas Jefferson University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04459052", "diseases": ["Parkinson Disease"]}, {"lat": 52.2, "lng": 0.11667, "nct": "NCT07157735", "color": "#6d32d4", "title": "A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["PHASE2"], "interventions": "dapansutrile; placebo", "sponsor": "Cambridge University Hospitals NHS Foundation Trust", "address": "", "url": "https://clinicaltrials.gov/study/NCT07157735", "diseases": ["Parkinson Disease"]}, {"lat": 38.72509, "lng": -9.1498, "nct": "NCT06094309", "color": "#25b1f8", "title": "Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Botulinum toxin type A injection", "sponsor": "Centro Hospitalar de Lisboa Central", "address": "", "url": "https://clinicaltrials.gov/study/NCT06094309", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT04620382", "color": "#9852e4", "title": "Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "Midodrine; Placebo pill; Abdominal compression; sham compression", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT04620382", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 30.78847, "lng": 31.00192, "nct": "NCT06785298", "color": "#ada722", "title": "Fexofenadine As Adjuvant Therapy in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "Levodopa/carbidopa; Fexofenadine", "sponsor": "Tanta University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06785298", "diseases": ["Parkinson Disease"]}, {"lat": 38.62727, "lng": -90.19789, "nct": "NCT04922411", "color": "#661aad", "title": "Cortical Network Modulation by Subthalamic Nucleus DBS", "status": "RECRUITING", "phases": ["NA"], "interventions": "STN DBS", "sponsor": "Washington University School of Medicine", "address": "", "url": "https://clinicaltrials.gov/study/NCT04922411", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT06710574", "color": "#7ddcc7", "title": "Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "PD-RBD; iRBD", "sponsor": "Beijing Friendship Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06710574", "diseases": ["Parkinson Disease"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT06259708", "color": "#2d913c", "title": "Using Low Intensity Focused Ultrasound to Modulate Deep Brain Areas for Tremor Control in Parkinson's Disease Patients.", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Low intensity focused ultrasound", "sponsor": "University of British Columbia", "address": "", "url": "https://clinicaltrials.gov/study/NCT06259708", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT03526991", "color": "#4b835b", "title": "Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.", "status": "RECRUITING", "phases": ["NA"], "interventions": "Spinal Cord Stimulator (SCS)", "sponsor": "Nora Vanegas", "address": "", "url": "https://clinicaltrials.gov/study/NCT03526991", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT03526991", "color": "#4b835b", "title": "Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.", "status": "RECRUITING", "phases": ["NA"], "interventions": "Spinal Cord Stimulator (SCS)", "sponsor": "Nora Vanegas", "address": "", "url": "https://clinicaltrials.gov/study/NCT03526991", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 33.59754, "lng": -112.27182, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 34.74648, "lng": -92.28959, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 32.84727, "lng": -117.2742, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 33.78779, "lng": -117.85311, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 34.09751, "lng": -117.64839, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 41.71982, "lng": -72.83204, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 41.30815, "lng": -72.92816, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 41.39093, "lng": -72.85954, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 41.05343, "lng": -73.53873, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 26.5909, "lng": -80.10088, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 30.33218, "lng": -81.65565, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 28.62778, "lng": -81.36312, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 26.10037, "lng": -80.39977, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 42.50482, "lng": -71.19561, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 42.06538, "lng": -71.24783, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 45.00969, "lng": -93.34912, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 44.94441, "lng": -93.09327, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 38.66311, "lng": -90.57707, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 36.17497, "lng": -115.13722, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 43.64229, "lng": -72.25176, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 40.30428, "lng": -73.99236, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 40.48622, "lng": -74.45182, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 35.08449, "lng": -106.65114, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 42.65258, "lng": -73.75623, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 40.84288, "lng": -73.29289, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 43.15478, "lng": -77.61556, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 40.79895, "lng": -81.37845, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 36.15398, "lng": -95.99277, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 32.77632, "lng": -79.93275, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 35.14953, "lng": -90.04898, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 29.42412, "lng": -98.49363, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 40.76078, "lng": -111.89105, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 44.47588, "lng": -73.21207, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 38.02931, "lng": -78.47668, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 36.59264, "lng": -78.61611, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 36.98038, "lng": -76.42975, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 47.61038, "lng": -122.20068, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 47.60621, "lng": -122.33207, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 43.0389, "lng": -87.90647, "nct": "NCT06976268", "color": "#dcd030", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "BHV-8000; Placebo", "sponsor": "Biohaven Therapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06976268", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.12589, "nct": "NCT06602544", "color": "#011a3e", "title": "Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Robotic Apparel", "sponsor": "Harvard Medical School (HMS and HSDM)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602544", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06602544", "color": "#011a3e", "title": "Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Robotic Apparel", "sponsor": "Harvard Medical School (HMS and HSDM)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602544", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT07102342", "color": "#bf956e", "title": "This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1"], "interventions": "Human Dopaminergic Progenitor Cells", "sponsor": "iRegene Therapeutics Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07102342", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT06193252", "color": "#2ad21a", "title": "Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands", "status": "RECRUITING", "phases": ["NA"], "interventions": "Increase of physical activity volume and intensity with the use of a motivational smartphone application", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06193252", "diseases": ["Parkinson Disease"]}, {"lat": -27.46794, "lng": 153.02809, "nct": "NCT04643327", "color": "#1613b2", "title": "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Levetiracetam; Placebo", "sponsor": "The University of Queensland", "address": "", "url": "https://clinicaltrials.gov/study/NCT04643327", "diseases": ["Parkinson Disease"]}, {"lat": 41.48581, "lng": 13.82835, "nct": "NCT06906679", "color": "#ef5e94", "title": "Upper Limb Rehabilitation in People With Parkinson's Disease:", "status": "RECRUITING", "phases": ["NA"], "interventions": "Experimental Group; control group", "sponsor": "IRCCS San Raffaele Roma", "address": "", "url": "https://clinicaltrials.gov/study/NCT06906679", "diseases": ["Parkinson Disease"]}, {"lat": 41.89193, "lng": 12.51133, "nct": "NCT06906679", "color": "#ef5e94", "title": "Upper Limb Rehabilitation in People With Parkinson's Disease:", "status": "RECRUITING", "phases": ["NA"], "interventions": "Experimental Group; control group", "sponsor": "IRCCS San Raffaele Roma", "address": "", "url": "https://clinicaltrials.gov/study/NCT06906679", "diseases": ["Parkinson Disease"]}, {"lat": 52.15833, "lng": 4.49306, "nct": "NCT05814614", "color": "#70f8e5", "title": "Bladder Complaints in Parkinson's Disease Effectiveness of Pelvic Floor Muscle Exercises and Electrical Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "pelvic physical therapy", "sponsor": "Leiden University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05814614", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT05551377", "color": "#5f4870", "title": "Head-up Tilt Sleeping to Alleviate Orthostatic Hypotension, Supine Hypertension and Nocturia in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Head-up tilt sleeping", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05551377", "diseases": ["Parkinson Disease"]}, {"lat": 52.15833, "lng": 4.49306, "nct": "NCT05551377", "color": "#5f4870", "title": "Head-up Tilt Sleeping to Alleviate Orthostatic Hypotension, Supine Hypertension and Nocturia in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Head-up tilt sleeping", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05551377", "diseases": ["Parkinson Disease"]}, {"lat": 31.558, "lng": 74.35071, "nct": "NCT07129304", "color": "#3abb68", "title": "Design And Analysis of The Effectiveness of CVRE VS Non-Immersive VR in the Rehabilitation of Parkinson", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Collaborative Virtual Reality with Routine Physical Therapy; Non-Immersive Virtual Reality with Routine Physical Therapy", "sponsor": "Superior University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07129304", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT06455293", "color": "#2621d8", "title": "Psilocybin Therapy for Depression in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Psilocybin", "sponsor": "Joshua Woolley, MD, PhD", "address": "", "url": "https://clinicaltrials.gov/study/NCT06455293", "diseases": ["Parkinson Disease"]}, {"lat": 45.53329, "lng": 9.22585, "nct": "NCT05273957", "color": "#64c0cc", "title": "A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Case Manager; Standard-of-care", "sponsor": "Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta", "address": "", "url": "https://clinicaltrials.gov/study/NCT05273957", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT05273957", "color": "#64c0cc", "title": "A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Case Manager; Standard-of-care", "sponsor": "Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta", "address": "", "url": "https://clinicaltrials.gov/study/NCT05273957", "diseases": ["Parkinson Disease"]}, {"lat": 42.78235, "lng": 12.59836, "nct": "NCT05871359", "color": "#b36c15", "title": "Transcranial Direct Current Stimulation and Dual Tasks", "status": "RECRUITING", "phases": ["NA"], "interventions": "Transcranial Direct Current Stimulation; Dual task", "sponsor": "Casa di Cura Privata del Policlinico SpA", "address": "", "url": "https://clinicaltrials.gov/study/NCT05871359", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT04635436", "color": "#db1c30", "title": "Efficacy of Split Gait in the Treatment of Dynamic Asymmetries in Subjects With Pathologic Claudication", "status": "RECRUITING", "phases": ["NA"], "interventions": "Split-belt treadmill walking.", "sponsor": "Istituto Auxologico Italiano", "address": "", "url": "https://clinicaltrials.gov/study/NCT04635436", "diseases": ["Parkinson Disease"]}, {"lat": 31.76904, "lng": 35.21633, "nct": "NCT06193421", "color": "#af3a7a", "title": "High-Dose Ambroxol in GBA1-Related Parkinson", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Ambroxol Hydrochloride", "sponsor": "Agyany Pharma LTD", "address": "", "url": "https://clinicaltrials.gov/study/NCT06193421", "diseases": ["Parkinson Disease"]}, {"lat": 50.87959, "lng": 4.70093, "nct": "NCT04269590", "color": "#f3c8ad", "title": "Triggering Motor Memory Consolidation in PD: Complex Practice of Fine Motor Tasks and Brain Activity During Learning", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Dual Task (DT) training; Single Task (ST) training", "sponsor": "KU Leuven", "address": "", "url": "https://clinicaltrials.gov/study/NCT04269590", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT06893055", "color": "#b8b7f7", "title": "Strength-Endurance Circuit Training in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Strength-Endurance Training; Endurance Training", "sponsor": "General University Hospital, Prague", "address": "", "url": "https://clinicaltrials.gov/study/NCT06893055", "diseases": ["Parkinson Disease"]}, {"lat": 31.86389, "lng": 117.28083, "nct": "NCT06542991", "color": "#fcb059", "title": "An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "transcranial magnetic stimulation", "sponsor": "Anhui Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06542991", "diseases": ["Parkinson Disease"]}, {"lat": 37.42411, "lng": -122.16608, "nct": "NCT05558189", "color": "#062cb1", "title": "Vibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Vibrotactile Coordinated Reset (vCR)", "sponsor": "Stanford University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05558189", "diseases": ["Parkinson Disease"]}, {"lat": 35.7721, "lng": -78.63861, "nct": "NCT05308368", "color": "#88807b", "title": "Analysis and Suppression of Tremor During Grasp Using Ultrasound Imaging and Electrical Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Ultrasound Imaging; Electromyography; Inertial Measurement Units (IMU); Functional Electrical Stimulation (FES)", "sponsor": "North Carolina State University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05308368", "diseases": ["Parkinson Disease"]}, {"lat": 45.4105, "lng": 12.36649, "nct": "NCT05826548", "color": "#6c4d9a", "title": "Financial Abilities in Neurological Diseases. Development of a Telerehabilitation Program: FINAGE", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation group; Conventioanl treatment group", "sponsor": "IRCCS San Camillo, Venezia, Italy", "address": "", "url": "https://clinicaltrials.gov/study/NCT05826548", "diseases": ["Parkinson Disease"]}, {"lat": 38.19394, "lng": 15.55256, "nct": "NCT06793735", "color": "#d17913", "title": "Effectiveness of TeleVR App in Cognitive Decline and MCI Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation with Virtual Reality; Traditional Cognitive Rehabilitation", "sponsor": "IRCCS Centro Neurolesi Bonino Pulejo", "address": "", "url": "https://clinicaltrials.gov/study/NCT06793735", "diseases": ["Parkinson Disease"]}, {"lat": 42.04114, "lng": -87.69006, "nct": "NCT04664634", "color": "#027512", "title": "A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Aria Sensor", "sponsor": "Northwestern University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04664634", "diseases": ["Parkinson Disease"]}, {"lat": 48.90982, "lng": 2.45012, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 45.77969, "lng": 3.08682, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 48.79266, "lng": 2.46569, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 47.31667, "lng": 5.01667, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 50.63297, "lng": 3.05858, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 45.74846, "lng": 4.84671, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 43.29695, "lng": 5.38107, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 48.68439, "lng": 6.18496, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 47.21725, "lng": -1.55336, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 43.83665, "lng": 4.35788, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 48.11198, "lng": -1.67429, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 48.58392, "lng": 7.74553, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 47.39484, "lng": 0.70398, "nct": "NCT04265209", "color": "#be880d", "title": "[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "SPECT; PET", "sponsor": "Zionexa", "address": "", "url": "https://clinicaltrials.gov/study/NCT04265209", "diseases": ["Parkinson Disease"]}, {"lat": 49.01096, "lng": 1.0873, "nct": "NCT06695455", "color": "#b61b4c", "title": "The Effect of an Auditory Rhythmic Cue on the Frequency of Rolling in Patients with Dysphagia and Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Swallowing rehabilitation by rhythmic auditory cue", "sponsor": "Hopital La Musse", "address": "", "url": "https://clinicaltrials.gov/study/NCT06695455", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06804668", "color": "#a35ca9", "title": "Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "tDCS", "sponsor": "Brigham and Women's Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06804668", "diseases": ["Parkinson Disease"]}, {"lat": 38.58157, "lng": -121.4944, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 32.71571, "lng": -117.16472, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 42.73698, "lng": -84.48387, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 40.80066, "lng": -73.72846, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT03741920", "color": "#f98be2", "title": "Evaluation of the Personal KinetiGraph\u2122 (PKG\u2122) to Improve Insight Into Parkinson's Disease Status", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Personal KinetiGraph\u2122 (PKG\u2122)", "sponsor": "Global Kinetics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03741920", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT06306768", "color": "#a40371", "title": "Remote Therapeutic Monitoring Exercise Tracking", "status": "RECRUITING", "phases": ["NA"], "interventions": "Activity Monitoring", "sponsor": "Shirley Ryan AbilityLab", "address": "", "url": "https://clinicaltrials.gov/study/NCT06306768", "diseases": ["Parkinson Disease"]}, {"lat": 49.84889, "lng": 3.28757, "nct": "NCT06500182", "color": "#77cfcd", "title": "The Benefits of Hippotherapy for Patients With Parkinson's Disease of 75 Years", "status": "RECRUITING", "phases": ["NA"], "interventions": "hippotherapy sessions", "sponsor": "Central Hospital Saint Quentin", "address": "", "url": "https://clinicaltrials.gov/study/NCT06500182", "diseases": ["Parkinson Disease"]}, {"lat": 37.42411, "lng": -122.16608, "nct": "NCT04043403", "color": "#3c99a2", "title": "Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Open Loop DBS; Adaptive (Closed Loop) DBS; Intermittent Open Loop DBS", "sponsor": "Stanford University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04043403", "diseases": ["Parkinson Disease"]}, {"lat": 46.87719, "lng": -96.7898, "nct": "NCT03191916", "color": "#aac4b9", "title": "Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson's Patients", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "transcranial direct current stimulation; Sham (for transcranial direct current stimulation)", "sponsor": "Sanford Health", "address": "", "url": "https://clinicaltrials.gov/study/NCT03191916", "diseases": ["Parkinson Disease"]}, {"lat": 46.94809, "lng": 7.44744, "nct": "NCT06629207", "color": "#aff225", "title": "Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder", "status": "RECRUITING", "phases": ["NA"], "interventions": "PET/CT with 18-FDG; SPECT : 123 I-FP-CIT (DATSCAN); MRI", "sponsor": "Insel Gruppe AG, University Hospital Bern", "address": "", "url": "https://clinicaltrials.gov/study/NCT06629207", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT06506058", "color": "#20b955", "title": "Vestibular and Cortical Contributions to Transitions in Freezing of Gait in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "EVS and EEG", "sponsor": "University of Minnesota", "address": "", "url": "https://clinicaltrials.gov/study/NCT06506058", "diseases": ["Parkinson Disease"]}, {"lat": 31.86389, "lng": 117.28083, "nct": "NCT06978920", "color": "#313b70", "title": "A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Allogeneic dopaminergic neural precursor cell(NCR201)", "sponsor": "Nuwacell Biotechnologies Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06978920", "diseases": ["Parkinson Disease"]}, {"lat": -19.92083, "lng": -43.93778, "nct": "NCT06646523", "color": "#e39c6c", "title": "Effects of Home-based High-speed Bodyweight Resistance Training in Individual with Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "High-speed bodyweight resistance training; Control group (Bodyweight intervention, usual speed)", "sponsor": "Federal University of Minas Gerais", "address": "", "url": "https://clinicaltrials.gov/study/NCT06646523", "diseases": ["Parkinson Disease"]}, {"lat": 38.19394, "lng": 15.55256, "nct": "NCT04045080", "color": "#1446ca", "title": "Hand Rehab Using AMADEO in PD Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "AMADEO; Training; OT Training", "sponsor": "IRCCS Centro Neurolesi Bonino Pulejo", "address": "", "url": "https://clinicaltrials.gov/study/NCT04045080", "diseases": ["Parkinson Disease"]}, {"lat": 49.40768, "lng": 8.69079, "nct": "NCT06580977", "color": "#e4f724", "title": "Exploring the Effects of Exercise on Memory and Cognition in Parkinson\u00b4s Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "cardiovascular training; stretching", "sponsor": "Heidelberg University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06580977", "diseases": ["Parkinson Disease"]}, {"lat": 43.64229, "lng": -72.25176, "nct": "NCT06260228", "color": "#1ea6ff", "title": "HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's)", "status": "RECRUITING", "phases": ["NA"], "interventions": "HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)", "sponsor": "Dartmouth-Hitchcock Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06260228", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 51.05089, "lng": 13.73832, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 53.86893, "lng": 10.68729, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 43.31283, "lng": -1.97499, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 43.46472, "lng": -3.80444, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT06602193", "color": "#2d991b", "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122 225 mg; BIIB122-Matching Placebo", "sponsor": "Denali Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06602193", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT04715984", "color": "#96bc4a", "title": "Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neurophysiology recordings; Neural stimulation", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT04715984", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT03049033", "color": "#2e6a2f", "title": "NMT for Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neurologic Music Therapy; Occupational Therapy; Music Supported Therapy", "sponsor": "University of Colorado, Denver", "address": "", "url": "https://clinicaltrials.gov/study/NCT03049033", "diseases": ["Parkinson Disease"]}, {"lat": 43.15478, "lng": -77.61556, "nct": "NCT05222386", "color": "#c0473a", "title": "Community Outreach for Palliative Engagement -- Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Parkinson Disease Standard Care; Online Community-Supported Palliative Care", "sponsor": "University of Rochester", "address": "", "url": "https://clinicaltrials.gov/study/NCT05222386", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT03683225", "color": "#6b690a", "title": "A Study to Evaluate in Patients With Parkinsonian Type Disorders", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "CTC-413", "sponsor": "Chase Therapeutics Corporation", "address": "", "url": "https://clinicaltrials.gov/study/NCT03683225", "diseases": ["Parkinson Disease"]}, {"lat": 37.3925, "lng": 126.92694, "nct": "NCT06329141", "color": "#d2c10f", "title": "A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Vutiglabridin; Placebo", "sponsor": "Glaceum", "address": "", "url": "https://clinicaltrials.gov/study/NCT06329141", "diseases": ["Parkinson Disease"]}, {"lat": 37.7415, "lng": 127.0474, "nct": "NCT06329141", "color": "#d2c10f", "title": "A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Vutiglabridin; Placebo", "sponsor": "Glaceum", "address": "", "url": "https://clinicaltrials.gov/study/NCT06329141", "diseases": ["Parkinson Disease"]}, {"lat": 35.10168, "lng": 129.03004, "nct": "NCT06329141", "color": "#d2c10f", "title": "A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Vutiglabridin; Placebo", "sponsor": "Glaceum", "address": "", "url": "https://clinicaltrials.gov/study/NCT06329141", "diseases": ["Parkinson Disease"]}, {"lat": 37.566, "lng": 126.9784, "nct": "NCT06329141", "color": "#d2c10f", "title": "A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Vutiglabridin; Placebo", "sponsor": "Glaceum", "address": "", "url": "https://clinicaltrials.gov/study/NCT06329141", "diseases": ["Parkinson Disease"]}, {"lat": 43.5283, "lng": 5.44973, "nct": "NCT06155942", "color": "#17e7d1", "title": "Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "7 Tesla MRI", "sponsor": "Assistance Publique Hopitaux De Marseille", "address": "", "url": "https://clinicaltrials.gov/study/NCT06155942", "diseases": ["Parkinson Disease"]}, {"lat": 43.29276, "lng": 5.57067, "nct": "NCT06155942", "color": "#17e7d1", "title": "Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "7 Tesla MRI", "sponsor": "Assistance Publique Hopitaux De Marseille", "address": "", "url": "https://clinicaltrials.gov/study/NCT06155942", "diseases": ["Parkinson Disease"]}, {"lat": 43.94834, "lng": 4.80892, "nct": "NCT06155942", "color": "#17e7d1", "title": "Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "7 Tesla MRI", "sponsor": "Assistance Publique Hopitaux De Marseille", "address": "", "url": "https://clinicaltrials.gov/study/NCT06155942", "diseases": ["Parkinson Disease"]}, {"lat": 43.70313, "lng": 7.26608, "nct": "NCT06155942", "color": "#17e7d1", "title": "Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "7 Tesla MRI", "sponsor": "Assistance Publique Hopitaux De Marseille", "address": "", "url": "https://clinicaltrials.gov/study/NCT06155942", "diseases": ["Parkinson Disease"]}, {"lat": 43.83665, "lng": 4.35788, "nct": "NCT06155942", "color": "#17e7d1", "title": "Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "7 Tesla MRI", "sponsor": "Assistance Publique Hopitaux De Marseille", "address": "", "url": "https://clinicaltrials.gov/study/NCT06155942", "diseases": ["Parkinson Disease"]}, {"lat": 43.12442, "lng": 5.92836, "nct": "NCT06155942", "color": "#17e7d1", "title": "Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "7 Tesla MRI", "sponsor": "Assistance Publique Hopitaux De Marseille", "address": "", "url": "https://clinicaltrials.gov/study/NCT06155942", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT06679374", "color": "#14adf3", "title": "Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; Varenicline", "sponsor": "Vikas Kotagal", "address": "", "url": "https://clinicaltrials.gov/study/NCT06679374", "diseases": ["Parkinson Disease"]}, {"lat": 21.30694, "lng": -157.85833, "nct": "NCT06543810", "color": "#d34254", "title": "Parkinson's Improvement Activated by Hula Understanding", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Hula for Parkinson's", "sponsor": "University of Hawaii", "address": "", "url": "https://clinicaltrials.gov/study/NCT06543810", "diseases": ["Parkinson Disease"]}, {"lat": 49.86988, "lng": 2.2434, "nct": "NCT06799923", "color": "#511a12", "title": "Possibilities of Use MRI-Guided Laser Interstitial Thermal Therapy in Medically Intractable Tremor", "status": "RECRUITING", "phases": ["NA"], "interventions": "laser electrode", "sponsor": "Centre Hospitalier Universitaire, Amiens", "address": "", "url": "https://clinicaltrials.gov/study/NCT06799923", "diseases": ["Parkinson Disease"]}, {"lat": 37.42411, "lng": -122.16608, "nct": "NCT06029686", "color": "#511036", "title": "Vibrotactile Coordinated Reset for Parkinson's Patients of a More Variable Population", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Stanford Glove", "sponsor": "Stanford University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06029686", "diseases": ["Parkinson Disease"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT06438419", "color": "#e69180", "title": "Parkinsonism-Related Oscillations in the Cortico-Basal Ganglia-Thalamic Network During Movement: Beyond the Frequency Range", "status": "RECRUITING", "phases": ["NA"], "interventions": "Electrophysiological recordings", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT06438419", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT06013956", "color": "#a79cf5", "title": "Personalized Real-Time DBS and PD Mechanisms", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "Neurostimulation; Carbidopa 25/Levodopa 100Mg Tab", "sponsor": "David Escobar", "address": "", "url": "https://clinicaltrials.gov/study/NCT06013956", "diseases": ["Parkinson Disease"]}, {"lat": -23.5475, "lng": -46.63611, "nct": "NCT05008289", "color": "#75834c", "title": "Effects of Magnetic Stimulation of the Dorsal Spinal Cord on Gait in Patients With Parkinson\u00b4s Disease and Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Magnetic transcutaneous spinal cord stimulation; Transcutaneous electrical nerve stimulation", "sponsor": "University of Sao Paulo General Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT05008289", "diseases": ["Parkinson Disease"]}, {"lat": 37.42411, "lng": -122.16608, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 26.52535, "lng": -80.06643, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 38.02931, "lng": -78.47668, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 47.60621, "lng": -122.33207, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 32.81303, "lng": 34.99928, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 45.43854, "lng": 10.9938, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 37.566, "lng": 126.9784, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 40.32234, "lng": -3.86496, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 42.81687, "lng": -1.64323, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 24.0692, "lng": 120.5512, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT03319485", "color": "#2fcfe0", "title": "ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "ExAblate Pallidotomy; Sham ExAblate Pallidotomy", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT03319485", "diseases": ["Parkinson Disease"]}, {"lat": 42.3751, "lng": -71.10561, "nct": "NCT05268887", "color": "#9b13ff", "title": "High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "GENUS device (Active Settings); GENUS device (Sham settings)", "sponsor": "Massachusetts Institute of Technology", "address": "", "url": "https://clinicaltrials.gov/study/NCT05268887", "diseases": ["Parkinson Disease"]}, {"lat": 38.02931, "lng": -78.47668, "nct": "NCT06903910", "color": "#0aa436", "title": "Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Donepezil (Aricept)", "sponsor": "University of Virginia", "address": "", "url": "https://clinicaltrials.gov/study/NCT06903910", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT04286308", "color": "#843e8c", "title": "Cortical-Basal Ganglia Speech Networks", "status": "RECRUITING", "phases": ["NA"], "interventions": "electrophysiological data collection", "sponsor": "Massachusetts General Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT04286308", "diseases": ["Parkinson Disease"]}, {"lat": 25.05306, "lng": 121.52639, "nct": "NCT05800470", "color": "#849c5c", "title": "The Effects of fNIRS-based Neurofeedback Training on Balance and Gait in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "fNIRS-based neurofeedback with motor imagery; Kinesthetic motor imagery; Motor training", "sponsor": "National Yang Ming Chiao Tung University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05800470", "diseases": ["Parkinson Disease"]}, {"lat": 47.3264, "lng": 8.79779, "nct": "NCT06631742", "color": "#f9a788", "title": "Exergaming Revolution in Dementia", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exergaming on Dividat Senso; Usual Care", "sponsor": "Eastern Switzerland University of Applied Sciences", "address": "", "url": "https://clinicaltrials.gov/study/NCT06631742", "diseases": ["Parkinson Disease"]}, {"lat": 33.44838, "lng": -112.07404, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 33.66946, "lng": -117.82311, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 34.04835, "lng": -117.26115, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 28.66111, "lng": -81.36562, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 26.27119, "lng": -80.2706, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 25.9812, "lng": -80.14838, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 28.62778, "lng": -81.36312, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 29.1872, "lng": -82.14009, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 29.13832, "lng": -80.99561, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 33.47097, "lng": -81.97484, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 33.77483, "lng": -84.29631, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 45.00969, "lng": -93.34912, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 42.65258, "lng": -73.75623, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 34.92487, "lng": -81.02508, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 35.14953, "lng": -90.04898, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 30.26715, "lng": -97.74306, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 30.63269, "lng": -97.67723, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 38.88233, "lng": -77.17109, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 36.59264, "lng": -78.61611, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 43.0389, "lng": -87.90647, "nct": "NCT05766813", "color": "#6adfaf", "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Lenrispodun; Placebo", "sponsor": "Intra-Cellular Therapies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05766813", "diseases": ["Parkinson Disease"]}, {"lat": 22.27832, "lng": 114.17469, "nct": "NCT06078046", "color": "#ef3e2c", "title": "MOVIN' CARE for PD (Mind-body Interventions)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Mind-body interventions", "sponsor": "The University of Hong Kong", "address": "", "url": "https://clinicaltrials.gov/study/NCT06078046", "diseases": ["Parkinson Disease"]}, {"lat": 35.69439, "lng": 51.42151, "nct": "NCT06530290", "color": "#58c3a1", "title": "Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Mirtazapine 15 MG; Placebo", "sponsor": "Leila Dargahi. PharmD PhD", "address": "", "url": "https://clinicaltrials.gov/study/NCT06530290", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT04386317", "color": "#d01bc7", "title": "Terazosin Effect on Cardiac Changes in Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Terazosin", "sponsor": "Cedars-Sinai Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT04386317", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT06196242", "color": "#d2ff04", "title": "Deep Brain Stimulation Lead Localization After Implantation", "status": "RECRUITING", "phases": ["NA"], "interventions": "MRI and CT scan", "sponsor": "Tsinghua University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06196242", "diseases": ["Parkinson Disease"]}, {"lat": 42.96395, "lng": -78.73781, "nct": "NCT06339034", "color": "#e62df2", "title": "Repurposing Lithium for Parkinson's Disease: a RCT", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Lithium; Placebo", "sponsor": "State University of New York at Buffalo", "address": "", "url": "https://clinicaltrials.gov/study/NCT06339034", "diseases": ["Parkinson Disease"]}, {"lat": 51.05, "lng": 3.71667, "nct": "NCT06120049", "color": "#2bcba0", "title": "[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "[18F]-MFBG PET CT; [18F]-FE-PE2I PET CT or PET MRI; [123I]-MIBG SPECT CT; [18F]-MFBG PET dosimetry scans", "sponsor": "prof. dr. Koen Van Laere", "address": "", "url": "https://clinicaltrials.gov/study/NCT06120049", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 50.87959, "lng": 4.70093, "nct": "NCT06120049", "color": "#2bcba0", "title": "[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD", "status": "RECRUITING", "phases": ["PHASE2", "PHASE3"], "interventions": "[18F]-MFBG PET CT; [18F]-FE-PE2I PET CT or PET MRI; [123I]-MIBG SPECT CT; [18F]-MFBG PET dosimetry scans", "sponsor": "prof. dr. Koen Van Laere", "address": "", "url": "https://clinicaltrials.gov/study/NCT06120049", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT02800460", "color": "#c47948", "title": "New Approaches in MRI at 3T Dedicated to Targeting Subthalamic Nucleus on Parkinsonian Patients", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "fMRI-3T", "sponsor": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", "address": "", "url": "https://clinicaltrials.gov/study/NCT02800460", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT06481540", "color": "#6a37aa", "title": "SpiroGym App-Aided Cough Rehabilitation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Expiratory muscle strength training + SpiroGym application; Expiratory muscle strength training", "sponsor": "General University Hospital, Prague", "address": "", "url": "https://clinicaltrials.gov/study/NCT06481540", "diseases": ["Parkinson Disease"]}, {"lat": 51.75222, "lng": -1.25596, "nct": "NCT06485986", "color": "#29bb96", "title": "Frontosubthalamic Networks in Parkinson's Disease.", "status": "RECRUITING", "phases": ["NA"], "interventions": "DBS on/off", "sponsor": "University of Oxford", "address": "", "url": "https://clinicaltrials.gov/study/NCT06485986", "diseases": ["Parkinson Disease"]}, {"lat": 41.01384, "lng": 28.94966, "nct": "NCT06416722", "color": "#95c491", "title": "Telerehabilitation Dual-Task Training for Parkinson's: A Multidimensional Evaluation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cognitive-Motor Dual Task Activities; Motor-Motor Dual Task Activities; Cognitive-Motor & Motor-Motor Dual Task Activities", "sponsor": "Fenerbahce University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06416722", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT03815656", "color": "#89f137", "title": "Closed Loop DBS Implanted RC+S Study", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "STN alone; GPi alone; STN + GPi; Closed-loop stimulation", "sponsor": "Dennis Turner, M.D.", "address": "", "url": "https://clinicaltrials.gov/study/NCT03815656", "diseases": ["Parkinson Disease"]}, {"lat": 43.4668, "lng": -80.51639, "nct": "NCT05971459", "color": "#036eac", "title": "A Study of the Efficacy of IAMT as an Assessment Tool for Prediction of Progression of Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Improvised Active Music Therapy", "sponsor": "Wilfrid Laurier University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05971459", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT06998303", "color": "#ff5ee4", "title": "Imaging Core Aim 2, and Udall Project 2 Aim 2", "status": "RECRUITING", "phases": ["NA"], "interventions": "Bipolar DBS stimulation", "sponsor": "University of Minnesota", "address": "", "url": "https://clinicaltrials.gov/study/NCT06998303", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT05307055", "color": "#52fccb", "title": "Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "STN DBS - Theta Burst; STN DBS - Gamma", "sponsor": "University of Southern California", "address": "", "url": "https://clinicaltrials.gov/study/NCT05307055", "diseases": ["Parkinson Disease"]}, {"lat": 34.25833, "lng": 108.92861, "nct": "NCT06914427", "color": "#fddfa2", "title": "PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "PET/CT", "sponsor": "Xijing Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06914427", "diseases": ["Parkinson Disease"]}, {"lat": 46.87909, "lng": 7.62013, "nct": "NCT04976127", "color": "#831f92", "title": "Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "Talineuren", "sponsor": "InnoMedica Schweiz AG", "address": "", "url": "https://clinicaltrials.gov/study/NCT04976127", "diseases": ["Parkinson Disease"]}, {"lat": 39.68372, "lng": -75.74966, "nct": "NCT04616508", "color": "#2ffd06", "title": "Online Motor Control in People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "motor control assessment", "sponsor": "University of Delaware", "address": "", "url": "https://clinicaltrials.gov/study/NCT04616508", "diseases": ["Parkinson Disease"]}, {"lat": 43.60717, "lng": 13.5103, "nct": "NCT05005208", "color": "#427e5f", "title": "SocIal ROBOTics for Active and Healthy Ageing", "status": "RECRUITING", "phases": ["NA"], "interventions": "rehabilitation program with the support of the technological platform SI-ROBOTICS", "sponsor": "Istituto Nazionale di Ricovero e Cura per Anziani", "address": "", "url": "https://clinicaltrials.gov/study/NCT05005208", "diseases": ["Parkinson Disease"]}, {"lat": 50.63297, "lng": 3.05858, "nct": "NCT04691661", "color": "#508d12", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Radotinib HCl 50 mg; Placebo", "sponsor": "Il-Yang Pharm. Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04691661", "diseases": ["Parkinson Disease"]}, {"lat": 45.83362, "lng": 1.24759, "nct": "NCT04691661", "color": "#508d12", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Radotinib HCl 50 mg; Placebo", "sponsor": "Il-Yang Pharm. Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04691661", "diseases": ["Parkinson Disease"]}, {"lat": 45.74846, "lng": 4.84671, "nct": "NCT04691661", "color": "#508d12", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Radotinib HCl 50 mg; Placebo", "sponsor": "Il-Yang Pharm. Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04691661", "diseases": ["Parkinson Disease"]}, {"lat": 47.21725, "lng": -1.55336, "nct": "NCT04691661", "color": "#508d12", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Radotinib HCl 50 mg; Placebo", "sponsor": "Il-Yang Pharm. Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04691661", "diseases": ["Parkinson Disease"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT04691661", "color": "#508d12", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Radotinib HCl 50 mg; Placebo", "sponsor": "Il-Yang Pharm. Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04691661", "diseases": ["Parkinson Disease"]}, {"lat": 46.58261, "lng": 0.34348, "nct": "NCT04691661", "color": "#508d12", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Radotinib HCl 50 mg; Placebo", "sponsor": "Il-Yang Pharm. Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04691661", "diseases": ["Parkinson Disease"]}, {"lat": 49.44313, "lng": 1.09932, "nct": "NCT04691661", "color": "#508d12", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Radotinib HCl 50 mg; Placebo", "sponsor": "Il-Yang Pharm. Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04691661", "diseases": ["Parkinson Disease"]}, {"lat": 51.48165, "lng": 7.21648, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 51.31667, "lng": 9.5, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 54.32133, "lng": 10.13489, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 43.31283, "lng": -1.97499, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 40.47353, "lng": -3.87182, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 40.43293, "lng": -3.81338, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": 53.48771, "lng": -2.29042, "nct": "NCT06015841", "color": "#bf1988", "title": "A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06015841", "diseases": ["Parkinson Disease"]}, {"lat": -30.03283, "lng": -51.23019, "nct": "NCT06921122", "color": "#922768", "title": "Use Of A Tongue Strength Training Device And Its Relationship With Speech In Patients With Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "IOWA ORAL PERFORMANCE INSTRUMENT; Placebo Group - Without Treatment", "sponsor": "Hospital de Clinicas de Porto Alegre", "address": "", "url": "https://clinicaltrials.gov/study/NCT06921122", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT06997484", "color": "#e4d84f", "title": "First-in-Human Single and Multiple Dose of HL-400", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "HL-400; Placebo", "sponsor": "Highlightll Pharmaceutical (USA) LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06997484", "diseases": ["Parkinson Disease"]}, {"lat": 33.44838, "lng": -112.07404, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 33.59754, "lng": -112.27182, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 34.14778, "lng": -118.14452, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 41.30815, "lng": -72.92816, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 21.30694, "lng": -157.85833, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 32.77632, "lng": -79.93275, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 35.15565, "lng": -89.7762, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 37.55376, "lng": -77.46026, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 47.26266, "lng": 11.39454, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 48.20849, "lng": 16.37208, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 51.05011, "lng": -114.08529, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 44.64269, "lng": -63.57688, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 45.50884, "lng": -73.58781, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 30.66667, "lng": 104.06667, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.29695, "lng": 5.38107, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.61093, "lng": 3.87635, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 48.11198, "lng": -1.67429, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 45.77969, "lng": 3.08682, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 45.73865, "lng": 4.91303, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 48.39841, "lng": 9.99155, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 48.13743, "lng": 11.57549, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 49.79391, "lng": 9.95121, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 51.31667, "lng": 9.5, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 50.80904, "lng": 8.77069, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 52.37052, "lng": 9.73322, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 51.48165, "lng": 7.21648, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 51.22172, "lng": 6.77616, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 51.05089, "lng": 13.73832, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 53.86893, "lng": 10.68729, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 32.08707, "lng": 34.88747, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 32.08227, "lng": 34.81065, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 32.08088, "lng": 34.78057, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 44.49381, "lng": 11.33875, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 45.53558, "lng": 10.21472, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 37.49223, "lng": 15.07041, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 42.34827, "lng": 14.16494, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 42.78235, "lng": 12.59836, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 40.87618, "lng": 14.5195, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.70853, "lng": 10.4036, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 44.99364, "lng": 11.10642, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 34.69379, "lng": 135.50107, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 38.26667, "lng": 140.86667, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 35.6895, "lng": 139.69171, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 52.5125, "lng": 6.09444, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 50.03437, "lng": 19.21037, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 52.22977, "lng": 21.01178, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 53.1235, "lng": 18.00762, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 50.25841, "lng": 19.02754, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 41.47063, "lng": 2.08611, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 42.81687, "lng": -1.64323, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.37135, "lng": -8.396, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.29639, "lng": -2.98813, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 43.31283, "lng": -1.97499, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 50.37153, "lng": -4.14305, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 53.48771, "lng": -2.29042, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 55.78924, "lng": -3.99187, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 54.97328, "lng": -1.61396, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 52.48142, "lng": -1.89983, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 56.46913, "lng": -2.97489, "nct": "NCT05348785", "color": "#a69e06", "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "BIIB122; BIIB122-Matching Placebo", "sponsor": "Biogen", "address": "", "url": "https://clinicaltrials.gov/study/NCT05348785", "diseases": ["Parkinson Disease"]}, {"lat": 37.42411, "lng": -122.16608, "nct": "NCT06028477", "color": "#33ff19", "title": "Vibrotactile Coordinated Reset in Parkinson's Disease - Proof of Concept Study", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Stanford Glove", "sponsor": "Stanford University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06028477", "diseases": ["Parkinson Disease"]}, {"lat": 35.9132, "lng": -79.05584, "nct": "NCT06087926", "color": "#7f738a", "title": "Apathy in Parkinson Disease TMS Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Transcranial Magnetic Stimulation (TMS)", "sponsor": "University of North Carolina, Chapel Hill", "address": "", "url": "https://clinicaltrials.gov/study/NCT06087926", "diseases": ["Parkinson Disease"]}, {"lat": 55.70584, "lng": 13.19321, "nct": "NCT05635409", "color": "#ddcaf1", "title": "A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "STEM-PD", "sponsor": "Region Skane", "address": "", "url": "https://clinicaltrials.gov/study/NCT05635409", "diseases": ["Parkinson Disease"]}, {"lat": 52.2, "lng": 0.11667, "nct": "NCT05635409", "color": "#ddcaf1", "title": "A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "STEM-PD", "sponsor": "Region Skane", "address": "", "url": "https://clinicaltrials.gov/study/NCT05635409", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT06603012", "color": "#8114db", "title": "Behavioral Intervention for Lifestyle Physical Activity in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "GET Up PD; Stretching and Flexibility", "sponsor": "University of Illinois at Chicago", "address": "", "url": "https://clinicaltrials.gov/study/NCT06603012", "diseases": ["Parkinson Disease"]}, {"lat": 32.08088, "lng": 34.78057, "nct": "NCT07105787", "color": "#b0fb15", "title": "Steps Against the Burden of Parkinson's Disease - TelAviv/Bologna", "status": "RECRUITING", "phases": ["NA"], "interventions": "SDTT + VR triggered adaptations; Speed-dependent treadmill training (SDTT)", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT07105787", "diseases": ["Parkinson Disease"]}, {"lat": 44.49381, "lng": 11.33875, "nct": "NCT07105787", "color": "#b0fb15", "title": "Steps Against the Burden of Parkinson's Disease - TelAviv/Bologna", "status": "RECRUITING", "phases": ["NA"], "interventions": "SDTT + VR triggered adaptations; Speed-dependent treadmill training (SDTT)", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT07105787", "diseases": ["Parkinson Disease"]}, {"lat": 39.47391, "lng": -0.37966, "nct": "NCT06879821", "color": "#e05acf", "title": "High-intensity Functional Training on Functional and Cognitive Performance in People with Parkinson's Disease.", "status": "RECRUITING", "phases": ["NA"], "interventions": "high intensity functional training", "sponsor": "Fundacion Para La Investigacion Hospital La Fe", "address": "", "url": "https://clinicaltrials.gov/study/NCT06879821", "diseases": ["Parkinson Disease"]}, {"lat": -30.03283, "lng": -51.23019, "nct": "NCT04863118", "color": "#6ac5d8", "title": "Acute Effects of Strength Training and High Intensity Training on Functional and Biochemical Measurements of Individuals With Parkinson's Disease in Different Environments and Depths", "status": "RECRUITING", "phases": ["NA"], "interventions": "Strength training in shallow water and dry land; High-intensity training in shallow and deep water", "sponsor": "Federal University of Health Science of Porto Alegre", "address": "", "url": "https://clinicaltrials.gov/study/NCT04863118", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT04062526", "color": "#eb332c", "title": "Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT", "status": "ACTIVE_NOT_RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "[18F]NOS", "sponsor": "University of Pennsylvania", "address": "", "url": "https://clinicaltrials.gov/study/NCT04062526", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT04796506", "color": "#2a817a", "title": "Slow Wave Sleep As a Biomarker of Rehabilitation-induced Cognitive Improvement in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Progressive Resistance Training (PRT); Delayed Exercise Training (DE); Endurance Training (ET)", "sponsor": "University of Colorado, Denver", "address": "", "url": "https://clinicaltrials.gov/study/NCT04796506", "diseases": ["Parkinson Disease"]}, {"lat": 30.00944, "lng": 31.20861, "nct": "NCT05198076", "color": "#cbdbd9", "title": "6 Month Follow up Study on the Changes of Postural Stability in Parkinsonian Patients in Response to High Frequency TMS.", "status": "RECRUITING", "phases": ["NA"], "interventions": "High Frequency Repetitive Transcranial Magnetic Stimulation", "sponsor": "Cairo University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05198076", "diseases": ["Parkinson Disease"]}, {"lat": 47.06667, "lng": 15.45, "nct": "NCT06403280", "color": "#a90147", "title": "The Effect of Alcohol on Common Tremor Syndromes", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Alcoholic drink; Placebo drink", "sponsor": "Medical University of Graz", "address": "", "url": "https://clinicaltrials.gov/study/NCT06403280", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT05773612", "color": "#f672b6", "title": "Rock Steady Boxing: A Community Based In Person Class", "status": "RECRUITING", "phases": ["NA"], "interventions": "Rock Steady Boxing Class", "sponsor": "University of St. Augustine for Health Sciences", "address": "", "url": "https://clinicaltrials.gov/study/NCT05773612", "diseases": ["Parkinson Disease"]}, {"lat": 38.62727, "lng": -90.19789, "nct": "NCT06859528", "color": "#6669af", "title": "Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Community Walking Program", "sponsor": "St. Louis University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06859528", "diseases": ["Parkinson Disease"]}, {"lat": 40.42587, "lng": -86.90807, "nct": "NCT05700825", "color": "#59370b", "title": "Rehabilitation of Airway Protection in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Expiratory Muscle Strength Training + Cough Skill Training", "sponsor": "Teachers College, Columbia University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05700825", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT05700825", "color": "#59370b", "title": "Rehabilitation of Airway Protection in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Expiratory Muscle Strength Training + Cough Skill Training", "sponsor": "Teachers College, Columbia University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05700825", "diseases": ["Parkinson Disease"]}, {"lat": 36.90812, "lng": 30.69556, "nct": "NCT05919485", "color": "#1a56bb", "title": "The Effects of Specific tDCS on Cognition in MCI", "status": "RECRUITING", "phases": ["NA"], "interventions": "tDCS", "sponsor": "Istanbul Medipol University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT05919485", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT06232629", "color": "#2663e0", "title": "Towards Noninvasive DBS of the Basal Ganglia in Parkinson's Disease Using TUS", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "TUS Active; TUS Sham", "sponsor": "University Health Network, Toronto", "address": "", "url": "https://clinicaltrials.gov/study/NCT06232629", "diseases": ["Parkinson Disease"]}, {"lat": 47.36667, "lng": 8.55, "nct": "NCT06608875", "color": "#7681e5", "title": "Precision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops", "status": "RECRUITING", "phases": ["NA"], "interventions": "Hyper-personalized feedback (HPF intervention); Targeted auditory stimulation during sleep (TASS verum intervention); Control targeted auditory stimulation during sleep (TASS sham intervention)", "sponsor": "University of Zurich", "address": "", "url": "https://clinicaltrials.gov/study/NCT06608875", "diseases": ["Parkinson Disease"]}, {"lat": 58.97005, "lng": 5.73332, "nct": "NCT06487975", "color": "#0e4bdd", "title": "Bacillus Subtilis in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Bacillus Subtilis; Placebo", "sponsor": "University of Edinburgh", "address": "", "url": "https://clinicaltrials.gov/study/NCT06487975", "diseases": ["Parkinson Disease"]}, {"lat": 55.95206, "lng": -3.19648, "nct": "NCT06487975", "color": "#0e4bdd", "title": "Bacillus Subtilis in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Bacillus Subtilis; Placebo", "sponsor": "University of Edinburgh", "address": "", "url": "https://clinicaltrials.gov/study/NCT06487975", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT06573866", "color": "#ac736e", "title": "Enhancement of Quality of Work And Life", "status": "RECRUITING", "phases": ["NA"], "interventions": "Preventive Participatory workplace intervention", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06573866", "diseases": ["Parkinson Disease"]}, {"lat": 45.17869, "lng": 5.71479, "nct": "NCT06582212", "color": "#fdbb81", "title": "Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms", "status": "RECRUITING", "phases": ["NA"], "interventions": "Mymovesmatter mobile application", "sponsor": "University Hospital, Grenoble", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582212", "diseases": ["Parkinson Disease"]}, {"lat": 47.21725, "lng": -1.55336, "nct": "NCT06582212", "color": "#fdbb81", "title": "Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms", "status": "RECRUITING", "phases": ["NA"], "interventions": "Mymovesmatter mobile application", "sponsor": "University Hospital, Grenoble", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582212", "diseases": ["Parkinson Disease"]}, {"lat": 48.11198, "lng": -1.67429, "nct": "NCT06582212", "color": "#fdbb81", "title": "Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms", "status": "RECRUITING", "phases": ["NA"], "interventions": "Mymovesmatter mobile application", "sponsor": "University Hospital, Grenoble", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582212", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT06582212", "color": "#fdbb81", "title": "Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms", "status": "RECRUITING", "phases": ["NA"], "interventions": "Mymovesmatter mobile application", "sponsor": "University Hospital, Grenoble", "address": "", "url": "https://clinicaltrials.gov/study/NCT06582212", "diseases": ["Parkinson Disease"]}, {"lat": 46.96658, "lng": 9.47705, "nct": "NCT04108741", "color": "#1029ac", "title": "Augmented Reality Treadmill Training in Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "C-Mill augmented reality treadmill training", "sponsor": "Klinik Valens", "address": "", "url": "https://clinicaltrials.gov/study/NCT04108741", "diseases": ["Parkinson Disease"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT07074119", "color": "#0359f9", "title": "Sensor-Based Optimization of Therapy for Parkinson's Disease Patients With Motor Fluctuations", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "wearable-based adjustment therapy", "sponsor": "Assistance Publique - H\u00f4pitaux de Paris", "address": "", "url": "https://clinicaltrials.gov/study/NCT07074119", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT03305588", "color": "#5e845f", "title": "RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Unframed Virtual Cone", "sponsor": "University of Alabama at Birmingham", "address": "", "url": "https://clinicaltrials.gov/study/NCT03305588", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT05446194", "color": "#b45169", "title": "Vestibulopathy, Imbalance, and Gait Disturbances in Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Non invasive neuromodulation device pattern 1; Non invasive neuromodulation device pattern 2", "sponsor": "University of Michigan", "address": "", "url": "https://clinicaltrials.gov/study/NCT05446194", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT06309147", "color": "#91893f", "title": "A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "BMS-9894923", "sponsor": "Allyx Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT06309147", "diseases": ["Parkinson Disease"]}, {"lat": 28.4853, "lng": -16.32014, "nct": "NCT06853262", "color": "#84da5a", "title": "Manual Therapy in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Manual Therapy Protocol; Sham Manual Protocol", "sponsor": "University of La Laguna", "address": "", "url": "https://clinicaltrials.gov/study/NCT06853262", "diseases": ["Parkinson Disease"]}, {"lat": 30.78847, "lng": 31.00192, "nct": "NCT05781711", "color": "#9182a7", "title": "Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "levodopa-carbidopa; Metformin", "sponsor": "Tanta University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05781711", "diseases": ["Parkinson Disease"]}, {"lat": 40.73583, "lng": 31.60611, "nct": "NCT06147726", "color": "#9981e6", "title": "Upper Extremity Rehabilitation With Virtual Reality in Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "Upper extremity position matching exercises in virtual reality; Conventional physiotherapy", "sponsor": "Ramazan KURUL", "address": "", "url": "https://clinicaltrials.gov/study/NCT06147726", "diseases": ["Parkinson Disease"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 33.55391, "lng": -117.21392, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 28.62778, "lng": -81.36312, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 31.76904, "lng": 35.21633, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 32.08227, "lng": 34.81065, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 32.08088, "lng": 34.78057, "nct": "NCT04127578", "color": "#9e7bac", "title": "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "LY3884961; Methylprednisolone; Sirolimus", "sponsor": "Prevail Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT04127578", "diseases": ["Parkinson Disease"]}, {"lat": 30.29365, "lng": 120.16142, "nct": "NCT06356662", "color": "#20afa1", "title": "Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Tenofovir Disoproxil Fumarate", "sponsor": "The Fourth Affiliated Hospital of Zhejiang University School of Medicine", "address": "", "url": "https://clinicaltrials.gov/study/NCT06356662", "diseases": ["Parkinson Disease"]}, {"lat": -7.115, "lng": -34.86306, "nct": "NCT04581590", "color": "#bd63b6", "title": "The Impact TDCS-linked Motor and Cognitive Training Gains in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Cognitive training", "sponsor": "Federal University of Para\u00edba", "address": "", "url": "https://clinicaltrials.gov/study/NCT04581590", "diseases": ["Parkinson Disease"]}, {"lat": 58.46151, "lng": 8.77253, "nct": "NCT03568968", "color": "#bacbae", "title": "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03568968", "diseases": ["Parkinson Disease"]}, {"lat": 60.39299, "lng": 5.32415, "nct": "NCT03568968", "color": "#bacbae", "title": "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03568968", "diseases": ["Parkinson Disease"]}, {"lat": 59.91273, "lng": 10.74609, "nct": "NCT03568968", "color": "#bacbae", "title": "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03568968", "diseases": ["Parkinson Disease"]}, {"lat": 59.74389, "lng": 10.20449, "nct": "NCT03568968", "color": "#bacbae", "title": "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03568968", "diseases": ["Parkinson Disease"]}, {"lat": 61.45217, "lng": 5.85717, "nct": "NCT03568968", "color": "#bacbae", "title": "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03568968", "diseases": ["Parkinson Disease"]}, {"lat": 59.41378, "lng": 5.268, "nct": "NCT03568968", "color": "#bacbae", "title": "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03568968", "diseases": ["Parkinson Disease"]}, {"lat": 62.73752, "lng": 7.15912, "nct": "NCT03568968", "color": "#bacbae", "title": "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03568968", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT05699694", "color": "#f2311c", "title": "Clinical Study on the Efficacy of Natural Stem Cell Mobilizers on Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "StemRegen product", "sponsor": "Sociedad Espa\u00f1ola de Medicina Regenerativa y Terapia Celular", "address": "", "url": "https://clinicaltrials.gov/study/NCT05699694", "diseases": ["Parkinson Disease"]}, {"lat": 55.6666, "lng": 12.40377, "nct": "NCT06284629", "color": "#92134d", "title": "Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes.", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Neptune; Standard clinical care", "sponsor": "Rigshospitalet, Denmark", "address": "", "url": "https://clinicaltrials.gov/study/NCT06284629", "diseases": ["Parkinson Disease"]}, {"lat": 55.39594, "lng": 10.38831, "nct": "NCT06284629", "color": "#92134d", "title": "Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes.", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Neptune; Standard clinical care", "sponsor": "Rigshospitalet, Denmark", "address": "", "url": "https://clinicaltrials.gov/study/NCT06284629", "diseases": ["Parkinson Disease"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT06005584", "color": "#cdf13b", "title": "Spinal Cord Stimulation for Gait Dysfunction in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Spinal Cord Stimulation - High Frequency SCS; Spinal Cord Stimulation - Burst SCS; Spinal Cord Stimulation - Sham SCS", "sponsor": "Imperial College London", "address": "", "url": "https://clinicaltrials.gov/study/NCT06005584", "diseases": ["Parkinson Disease"]}, {"lat": 41.61674, "lng": 0.62218, "nct": "NCT06444685", "color": "#8962fe", "title": "Effects of Table Tennis for People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exercise and cognitive training interventino", "sponsor": "Universitat de Lleida", "address": "", "url": "https://clinicaltrials.gov/study/NCT06444685", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT05357638", "color": "#545ddc", "title": "Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body", "status": "RECRUITING", "phases": ["NA"], "interventions": "High Intensity Interval Training (HIIT); Continuous Aerobic Training (CAT); Movement Advice", "sponsor": "Amsterdam UMC, location VUmc", "address": "", "url": "https://clinicaltrials.gov/study/NCT05357638", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT06932692", "color": "#a2c79e", "title": "The BRAINMAP-DBS Study: BRain Network AnalysIs usiNg 7-Tesla MRI and MAgnetoencephalograPhy for Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "magnetoencephalography", "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06932692", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT05109364", "color": "#eda021", "title": "Terazosin and Parkinson's Disease Extension Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Terazosin therapy", "sponsor": "Cedars-Sinai Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05109364", "diseases": ["Parkinson Disease"]}, {"lat": 23.11667, "lng": 113.25, "nct": "NCT06112392", "color": "#b47d30", "title": "Clinical Study of Stellate Ganglion Block in Treatment of Patients With Advanced Primary Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Treatment \uff08Stellate ganglion block\uff1bOral standard anti-Parkinson's drugs\uff09; Treatment \uff08Oral standard anti-Parkinson's drugs\uff09", "sponsor": "Zhujiang Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06112392", "diseases": ["Parkinson Disease"]}, {"lat": 17.12096, "lng": -61.84329, "nct": "NCT05152394", "color": "#9e3153", "title": "Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "AlloEx", "sponsor": "The Foundation for Orthopaedics and Regenerative Medicine", "address": "", "url": "https://clinicaltrials.gov/study/NCT05152394", "diseases": ["Parkinson Disease"]}, {"lat": -23.5475, "lng": -46.63611, "nct": "NCT06957405", "color": "#c4bc4d", "title": "Remote Mental Practice for Freezing of Gait in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "MPPG (Mental and Physical Practice Group); PPG (Physical Practice Group)", "sponsor": "University of Sao Paulo General Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06957405", "diseases": ["Parkinson Disease"]}, {"lat": 55.67594, "lng": 12.56553, "nct": "NCT04229056", "color": "#b43646", "title": "COMPuter-assisted Self-training to Improve EXecutive Function", "status": "RECRUITING", "phases": ["NA"], "interventions": "Computer-based cognitive rehabilitation (CBCR); General computer-based cognitive stimulation", "sponsor": "Bispebjerg Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT04229056", "diseases": ["Parkinson Disease"]}, {"lat": 22.61626, "lng": 120.31333, "nct": "NCT06548256", "color": "#247b7c", "title": "The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Miyarisan-BM (Clostridium Butyricum Miyairi)", "sponsor": "Kaohsiung Medical University Chung-Ho Memorial Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06548256", "diseases": ["Parkinson Disease"]}, {"lat": 36.17497, "lng": -115.13722, "nct": "NCT05854524", "color": "#fc3bd9", "title": "Exercise Neuroprotection in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Aerobic exercise", "sponsor": "University of Nevada, Las Vegas", "address": "", "url": "https://clinicaltrials.gov/study/NCT05854524", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT03775096", "color": "#c8597c", "title": "Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Carvedilol", "sponsor": "Michele Tagliati, MD", "address": "", "url": "https://clinicaltrials.gov/study/NCT03775096", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT05179187", "color": "#77fca5", "title": "Non-invasive Brain Mapping of Movement Facilitation in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Movement task", "sponsor": "University of California, Los Angeles", "address": "", "url": "https://clinicaltrials.gov/study/NCT05179187", "diseases": ["Parkinson Disease"]}, {"lat": 23.7104, "lng": 90.40744, "nct": "NCT07096336", "color": "#6259bb", "title": "Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "vitamin D3 capsule", "sponsor": "Bangladesh Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07096336", "diseases": ["Parkinson Disease"]}, {"lat": 46.87909, "lng": 7.62013, "nct": "NCT06431971", "color": "#be368e", "title": "Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease", "status": "NOT_YET_RECRUITING", "phases": ["PHASE2"], "interventions": "Talineuren; Placebo", "sponsor": "InnoMedica Schweiz AG", "address": "", "url": "https://clinicaltrials.gov/study/NCT06431971", "diseases": ["Parkinson Disease"]}, {"lat": 25.28545, "lng": 51.53096, "nct": "NCT06962930", "color": "#1b00df", "title": "An Online Physical Activity Coaching Intervention for People With PD in Qatar", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "8-week personalized self-management program tailored to their individual needs using Engage-Qatar PD. participants will be invited to one face-to-face coaching session and 7 online sessions", "sponsor": "Qatar University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06962930", "diseases": ["Parkinson Disease"]}, {"lat": 42.98339, "lng": -81.23304, "nct": "NCT07066163", "color": "#d94c5c", "title": "SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Kinesia U; Standard of care treatment", "sponsor": "Western University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07066163", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT06669455", "color": "#a793dc", "title": "An Integrated and Personalized Lifestyle Approach for People with Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Personalized and combined lifestyle approach", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06669455", "diseases": ["Parkinson Disease"]}, {"lat": 53.79648, "lng": -1.54785, "nct": "NCT05794542", "color": "#bb5910", "title": "Cue X as a Treatment for People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cue X", "sponsor": "University of Leeds", "address": "", "url": "https://clinicaltrials.gov/study/NCT05794542", "diseases": ["Parkinson Disease"]}, {"lat": 50.93333, "lng": 6.95, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 51.05089, "lng": 13.73832, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 51.22172, "lng": 6.77616, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 53.55073, "lng": 9.99302, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 54.32133, "lng": 10.13489, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 50.80904, "lng": 8.77069, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 52.52003, "lng": 13.40489, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 49.79391, "lng": 9.95121, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 46.94809, "lng": 7.44744, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 47.36667, "lng": 8.55, "nct": "NCT06498349", "color": "#d3d0e2", "title": "Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations", "sponsor": "University of Kiel", "address": "", "url": "https://clinicaltrials.gov/study/NCT06498349", "diseases": ["Parkinson Disease"]}, {"lat": 48.11198, "lng": -1.67429, "nct": "NCT06080659", "color": "#290d6b", "title": "Network-based BiOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity", "status": "RECRUITING", "phases": ["NA"], "interventions": "fMRI; CONFMEM", "sponsor": "Rennes University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06080659", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT06778135", "color": "#017676", "title": "Neocortical Microarchitecture of Executive Function", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Temporary implatation of large-scale intracranial electrode.; brain electrode", "sponsor": "University of Colorado, Denver", "address": "", "url": "https://clinicaltrials.gov/study/NCT06778135", "diseases": ["Parkinson Disease"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT06207136", "color": "#c549e1", "title": "Microbiome and Diet in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Mediterranean-style diet", "sponsor": "University of British Columbia", "address": "", "url": "https://clinicaltrials.gov/study/NCT06207136", "diseases": ["Parkinson Disease"]}, {"lat": 39.14583, "lng": 34.16389, "nct": "NCT07165106", "color": "#444899", "title": "Effects of Resistance and Aerobic Exercises on Walking and Sarcopenic Parameters in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Aerobic Exercise; Resistance Exercise; Conventional Rehabilitation", "sponsor": "Ahi Evran University Education and Research Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT07165106", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT06169852", "color": "#1b7eea", "title": "Stimulus-Evoked Directional Field Potentials to Guide Subthalamic and Pallidal DBS for PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Unilateral dual-target (STN/GPi) DBS", "sponsor": "University of Alabama at Birmingham", "address": "", "url": "https://clinicaltrials.gov/study/NCT06169852", "diseases": ["Parkinson Disease"]}, {"lat": 40.07706, "lng": -75.12684, "nct": "NCT06225830", "color": "#d99974", "title": "Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton", "status": "RECRUITING", "phases": ["NA"], "interventions": "Eksobionics Eksoskeleton NR", "sponsor": "Albert Einstein Healthcare Network", "address": "", "url": "https://clinicaltrials.gov/study/NCT06225830", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT06885541", "color": "#af86b1", "title": "Detection of Internal Tremors by Oscillometry in Parkinson's Patient", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Detection of objective internal tremors", "sponsor": "University Hospital, Toulouse", "address": "", "url": "https://clinicaltrials.gov/study/NCT06885541", "diseases": ["Parkinson Disease"]}, {"lat": 45.56995, "lng": -73.692, "nct": "NCT04558879", "color": "#a4872a", "title": "Exercise and Sleep in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "CT; RT", "sponsor": "McGill University", "address": "", "url": "https://clinicaltrials.gov/study/NCT04558879", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT06446505", "color": "#58c232", "title": "Evaluation of a Decision Aid for Deep Brain Stimulation Surgery for Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation Decision Aid", "sponsor": "University of Colorado, Denver", "address": "", "url": "https://clinicaltrials.gov/study/NCT06446505", "diseases": ["Parkinson Disease"]}, {"lat": 25.05306, "lng": 121.52639, "nct": "NCT05960331", "color": "#1db19d", "title": "Influence of Autonomy on Motor Learning in People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Autonomy supported learning; Practice with predetermined feedback", "sponsor": "National Taiwan University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT05960331", "diseases": ["Parkinson Disease"]}, {"lat": 34.14251, "lng": -118.25508, "nct": "NCT05670782", "color": "#9e226e", "title": "A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "KM-819; Placebo", "sponsor": "FAScinate Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05670782", "diseases": ["Parkinson Disease"]}, {"lat": 32.71571, "lng": -117.16472, "nct": "NCT05670782", "color": "#9e226e", "title": "A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "KM-819; Placebo", "sponsor": "FAScinate Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05670782", "diseases": ["Parkinson Disease"]}, {"lat": 42.48948, "lng": -83.14465, "nct": "NCT05670782", "color": "#9e226e", "title": "A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "KM-819; Placebo", "sponsor": "FAScinate Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05670782", "diseases": ["Parkinson Disease"]}, {"lat": 37.48522, "lng": -122.23635, "nct": "NCT05292794", "color": "#3edcb2", "title": "Use of CereGate Therapy for Freezing of Gait in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "CereGate Software; BSN cDBS Programmer; BSN Burst Programmer", "sponsor": "CereGate Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05292794", "diseases": ["Parkinson Disease"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT05292794", "color": "#3edcb2", "title": "Use of CereGate Therapy for Freezing of Gait in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "CereGate Software; BSN cDBS Programmer; BSN Burst Programmer", "sponsor": "CereGate Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05292794", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT05292794", "color": "#3edcb2", "title": "Use of CereGate Therapy for Freezing of Gait in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "CereGate Software; BSN cDBS Programmer; BSN Burst Programmer", "sponsor": "CereGate Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05292794", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT05292794", "color": "#3edcb2", "title": "Use of CereGate Therapy for Freezing of Gait in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "CereGate Software; BSN cDBS Programmer; BSN Burst Programmer", "sponsor": "CereGate Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05292794", "diseases": ["Parkinson Disease"]}, {"lat": 36.09986, "lng": -80.24422, "nct": "NCT05292794", "color": "#3edcb2", "title": "Use of CereGate Therapy for Freezing of Gait in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "CereGate Software; BSN cDBS Programmer; BSN Burst Programmer", "sponsor": "CereGate Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05292794", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT05292794", "color": "#3edcb2", "title": "Use of CereGate Therapy for Freezing of Gait in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "CereGate Software; BSN cDBS Programmer; BSN Burst Programmer", "sponsor": "CereGate Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05292794", "diseases": ["Parkinson Disease"]}, {"lat": 47.60621, "lng": -122.33207, "nct": "NCT05292794", "color": "#3edcb2", "title": "Use of CereGate Therapy for Freezing of Gait in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "CereGate Software; BSN cDBS Programmer; BSN Burst Programmer", "sponsor": "CereGate Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05292794", "diseases": ["Parkinson Disease"]}, {"lat": 41.89193, "lng": 12.51133, "nct": "NCT05741151", "color": "#7c3a61", "title": "Superior Cervical Ganglion in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "PET-Neck Parkinsonian patients", "sponsor": "Fondazione Policlinico Universitario Agostino Gemelli IRCCS", "address": "", "url": "https://clinicaltrials.gov/study/NCT05741151", "diseases": ["Parkinson Disease"]}, {"lat": 43.60717, "lng": 13.5103, "nct": "NCT06984393", "color": "#563b04", "title": "Tele-Rehabilitation Intervention in Community-Based Healthcare for Patients With Parkinson's Disease (DHEAL-COM-PD)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "home tele-rehabilitation; Usual care", "sponsor": "Istituto Nazionale di Ricovero e Cura per Anziani", "address": "", "url": "https://clinicaltrials.gov/study/NCT06984393", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT04497168", "color": "#1760d3", "title": "Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Citalopram 20mg; Placebo", "sponsor": "University of Michigan", "address": "", "url": "https://clinicaltrials.gov/study/NCT04497168", "diseases": ["Parkinson Disease"]}, {"lat": 39.14583, "lng": 34.16389, "nct": "NCT06272838", "color": "#a40be3", "title": "Biodex Balance System in Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Biodex balance system; The conventional balance exercise program", "sponsor": "Kirsehir Ahi Evran Universitesi", "address": "", "url": "https://clinicaltrials.gov/study/NCT06272838", "diseases": ["Parkinson Disease"]}, {"lat": 43.61093, "lng": 3.87635, "nct": "NCT05626608", "color": "#65d2a6", "title": "Continuous Electrical Neuromodulation of the Globus Pallidus Intern in Parkinson's Disease by the Directional Electrode CARTESIA\u2122", "status": "RECRUITING", "phases": ["NA"], "interventions": "Classical ring stimulation; Stimulation in directional mode", "sponsor": "University Hospital, Montpellier", "address": "", "url": "https://clinicaltrials.gov/study/NCT05626608", "diseases": ["Parkinson Disease"]}, {"lat": 30.29365, "lng": 120.16142, "nct": "NCT06852352", "color": "#fa2b19", "title": "An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Modified deep cervical Lymphatic-Venous Anastomosis", "sponsor": "Zhejiang Provincial People's Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06852352", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT03582891", "color": "#0474f9", "title": "The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Summit RC+S for Motor; 8-week pilot trial of Closed-loop vs. Open-loop Stimulation; Summit RC+S for Sleep", "sponsor": "University of California, San Francisco", "address": "", "url": "https://clinicaltrials.gov/study/NCT03582891", "diseases": ["Parkinson Disease"]}, {"lat": 33.80307, "lng": -118.07256, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 38.89511, "lng": -77.03637, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 25.9812, "lng": -80.14838, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 26.97617, "lng": -82.09064, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 21.30694, "lng": -157.85833, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 41.25626, "lng": -95.94043, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 49.18585, "lng": -0.35912, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 53.55073, "lng": 9.99302, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 53.20139, "lng": 5.80859, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT04291859", "color": "#0d7201", "title": "Lu AF28996 in Participants With Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Lu AF28996", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT04291859", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT07011771", "color": "#341431", "title": "A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "gene therapy", "sponsor": "Capsida Biotherapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07011771", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT07011771", "color": "#341431", "title": "A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "gene therapy", "sponsor": "Capsida Biotherapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07011771", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT07011771", "color": "#341431", "title": "A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "gene therapy", "sponsor": "Capsida Biotherapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07011771", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT07011771", "color": "#341431", "title": "A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "gene therapy", "sponsor": "Capsida Biotherapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07011771", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT07011771", "color": "#341431", "title": "A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "gene therapy", "sponsor": "Capsida Biotherapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07011771", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT07011771", "color": "#341431", "title": "A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "gene therapy", "sponsor": "Capsida Biotherapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07011771", "diseases": ["Parkinson Disease"]}, {"lat": 46.01008, "lng": 8.96004, "nct": "NCT07097298", "color": "#b14639", "title": "Empathy and (Self-)Compassion in Parkinson's Disease Patients and Caregivers", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "empathy and compassion training", "sponsor": "Alain Kaelin", "address": "", "url": "https://clinicaltrials.gov/study/NCT07097298", "diseases": ["Parkinson Disease"]}, {"lat": 33.44838, "lng": -112.07404, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 34.74648, "lng": -92.28959, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 33.56504, "lng": -117.72712, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 25.95648, "lng": -80.13921, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 41.8617, "lng": -88.1609, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 36.17497, "lng": -115.13722, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 40.84288, "lng": -73.29289, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 36.09986, "lng": -80.24422, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 40.79895, "lng": -81.37845, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 39.12711, "lng": -84.51439, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 36.15398, "lng": -95.99277, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 30.63269, "lng": -97.67723, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 38.84622, "lng": -77.30637, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 36.59264, "lng": -78.61611, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 38.93428, "lng": -77.17748, "nct": "NCT06765668", "color": "#faf841", "title": "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "Impax Laboratories, LLC", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765668", "diseases": ["Parkinson Disease"]}, {"lat": 31.558, "lng": 74.35071, "nct": "NCT06111924", "color": "#b705ec", "title": "Effects of Telerehabilitation Versus Clinic-based Task-oriented Circuit Training in Parkinson's Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "Task oriented circuit training based telerehabilitation; Clinic based Task oriented circuit training", "sponsor": "Riphah International University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06111924", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT05862649", "color": "#c82231", "title": "Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "NeuraLight", "sponsor": "NeuraLight", "address": "", "url": "https://clinicaltrials.gov/study/NCT05862649", "diseases": ["Parkinson Disease"]}, {"lat": 40.20564, "lng": -8.41955, "nct": "NCT05862649", "color": "#c82231", "title": "Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "NeuraLight", "sponsor": "NeuraLight", "address": "", "url": "https://clinicaltrials.gov/study/NCT05862649", "diseases": ["Parkinson Disease"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT05862649", "color": "#c82231", "title": "Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "NeuraLight", "sponsor": "NeuraLight", "address": "", "url": "https://clinicaltrials.gov/study/NCT05862649", "diseases": ["Parkinson Disease"]}, {"lat": 47.36667, "lng": 8.55, "nct": "NCT05862649", "color": "#c82231", "title": "Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "NeuraLight", "sponsor": "NeuraLight", "address": "", "url": "https://clinicaltrials.gov/study/NCT05862649", "diseases": ["Parkinson Disease"]}, {"lat": 51.75222, "lng": -1.25596, "nct": "NCT05862649", "color": "#c82231", "title": "Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "NeuraLight", "sponsor": "NeuraLight", "address": "", "url": "https://clinicaltrials.gov/study/NCT05862649", "diseases": ["Parkinson Disease"]}, {"lat": 25.05306, "lng": 121.52639, "nct": "NCT06476912", "color": "#c43119", "title": "Balance Exercise and Vagus Nerve Stimulation on Weight-shifting Control and Ambulation in Parkinson Disease and Anxiety", "status": "RECRUITING", "phases": ["NA"], "interventions": "weight-shifting exercise", "sponsor": "National Taiwan University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06476912", "diseases": ["Parkinson Disease"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT05433441", "color": "#f17e6c", "title": "Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention", "status": "RECRUITING", "phases": ["NA"], "interventions": "ESPark Intervention", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT05433441", "diseases": ["Parkinson Disease"]}, {"lat": 50.63297, "lng": 3.05858, "nct": "NCT05433441", "color": "#f17e6c", "title": "Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention", "status": "RECRUITING", "phases": ["NA"], "interventions": "ESPark Intervention", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT05433441", "diseases": ["Parkinson Disease"]}, {"lat": 45.83362, "lng": 1.24759, "nct": "NCT05433441", "color": "#f17e6c", "title": "Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention", "status": "RECRUITING", "phases": ["NA"], "interventions": "ESPark Intervention", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT05433441", "diseases": ["Parkinson Disease"]}, {"lat": 46.58261, "lng": 0.34348, "nct": "NCT05433441", "color": "#f17e6c", "title": "Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention", "status": "RECRUITING", "phases": ["NA"], "interventions": "ESPark Intervention", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT05433441", "diseases": ["Parkinson Disease"]}, {"lat": 32.84727, "lng": -117.2742, "nct": "NCT03616145", "color": "#8d74d4", "title": "Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Osteopathic Manipulative Treatment (OMT); Light Touch", "sponsor": "University of California, San Diego", "address": "", "url": "https://clinicaltrials.gov/study/NCT03616145", "diseases": ["Parkinson Disease"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT04957095", "color": "#8960a0", "title": "Motor Network Physiology", "status": "RECRUITING", "phases": ["NA"], "interventions": "Apomorphine Injectable Solution; Subcortical Stimulation", "sponsor": "University of Texas Southwestern Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT04957095", "diseases": ["Parkinson Disease"]}, {"lat": 41.25626, "lng": -95.94043, "nct": "NCT04620551", "color": "#16cd34", "title": "Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Sub-clinical stimulation", "sponsor": "University of Nebraska", "address": "", "url": "https://clinicaltrials.gov/study/NCT04620551", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT06388551", "color": "#d0c6a5", "title": "A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1"], "interventions": "LY03017; LY03017-Placebo", "sponsor": "Luye Pharma Group Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06388551", "diseases": ["Parkinson Disease"]}, {"lat": 30.33218, "lng": -81.65565, "nct": "NCT06263673", "color": "#6e7d77", "title": "Anti-Diabetic Medications to Fight PD and LBD", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Sitagliptin; Dapagliflozin; Placebo", "sponsor": "Mayo Clinic", "address": "", "url": "https://clinicaltrials.gov/study/NCT06263673", "diseases": ["Parkinson Disease"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT04426786", "color": "#dc1b64", "title": "Exercise & Brain Energetics in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Active exercise; Passive exercise", "sponsor": "Pacific Parkinson's Research Centre", "address": "", "url": "https://clinicaltrials.gov/study/NCT04426786", "diseases": ["Parkinson Disease"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT06234995", "color": "#928f5c", "title": "Cortical Electrophysiology of Response Inhibition in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "Levodopa; Clinical DBS Setting; Sham DBS; DBS Setting Maximizing Prefrontal Activation; DBS Setting Minimizing Prefrontal Activation", "sponsor": "Emory University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06234995", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT07085195", "color": "#0e138a", "title": "A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "gene therapy; clozapine", "sponsor": "Ruijin Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT07085195", "diseases": ["Parkinson Disease"]}, {"lat": 50.87959, "lng": 4.70093, "nct": "NCT06875765", "color": "#364abe", "title": "Long-term Longitudinal Imaging of Presynaptic Terminals in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "11C-UCB-J PET-CT; 18F-PE2I PET-CT; MRI brain", "sponsor": "Universitaire Ziekenhuizen KU Leuven", "address": "", "url": "https://clinicaltrials.gov/study/NCT06875765", "diseases": ["Parkinson Disease"]}, {"lat": 43.60717, "lng": 13.5103, "nct": "NCT04087031", "color": "#08b905", "title": "Innovative Models in the Rehabilitation of the Elderly With Parkinson's Disease Through Technological Innovation", "status": "RECRUITING", "phases": ["NA"], "interventions": "control arm; virtual reality games; robotic treadmill", "sponsor": "Istituto Nazionale di Ricovero e Cura per Anziani", "address": "", "url": "https://clinicaltrials.gov/study/NCT04087031", "diseases": ["Parkinson Disease"]}, {"lat": 43.16296, "lng": 13.72274, "nct": "NCT04087031", "color": "#08b905", "title": "Innovative Models in the Rehabilitation of the Elderly With Parkinson's Disease Through Technological Innovation", "status": "RECRUITING", "phases": ["NA"], "interventions": "control arm; virtual reality games; robotic treadmill", "sponsor": "Istituto Nazionale di Ricovero e Cura per Anziani", "address": "", "url": "https://clinicaltrials.gov/study/NCT04087031", "diseases": ["Parkinson Disease"]}, {"lat": 51.05089, "lng": 13.73832, "nct": "NCT04329676", "color": "#6e0a6d", "title": "directSTIM Deep Brain Stimulation System Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation", "sponsor": "Aleva Neurotherapeutics SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT04329676", "diseases": ["Parkinson Disease"]}, {"lat": 47.9959, "lng": 7.85222, "nct": "NCT04329676", "color": "#6e0a6d", "title": "directSTIM Deep Brain Stimulation System Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation", "sponsor": "Aleva Neurotherapeutics SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT04329676", "diseases": ["Parkinson Disease"]}, {"lat": 53.55073, "lng": 9.99302, "nct": "NCT04329676", "color": "#6e0a6d", "title": "directSTIM Deep Brain Stimulation System Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation", "sponsor": "Aleva Neurotherapeutics SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT04329676", "diseases": ["Parkinson Disease"]}, {"lat": 52.37052, "lng": 9.73322, "nct": "NCT04329676", "color": "#6e0a6d", "title": "directSTIM Deep Brain Stimulation System Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation", "sponsor": "Aleva Neurotherapeutics SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT04329676", "diseases": ["Parkinson Disease"]}, {"lat": 54.32133, "lng": 10.13489, "nct": "NCT04329676", "color": "#6e0a6d", "title": "directSTIM Deep Brain Stimulation System Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation", "sponsor": "Aleva Neurotherapeutics SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT04329676", "diseases": ["Parkinson Disease"]}, {"lat": 51.96236, "lng": 7.62571, "nct": "NCT04329676", "color": "#6e0a6d", "title": "directSTIM Deep Brain Stimulation System Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation", "sponsor": "Aleva Neurotherapeutics SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT04329676", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT06442033", "color": "#9df4b4", "title": "Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial", "status": "RECRUITING", "phases": ["NA"], "interventions": "High intensity stationary cycling", "sponsor": "Jay Alberts", "address": "", "url": "https://clinicaltrials.gov/study/NCT06442033", "diseases": ["Parkinson Disease"]}, {"lat": 1.28967, "lng": 103.85007, "nct": "NCT04491383", "color": "#99a32a", "title": "Tocotrienols in Parkinson's Disease (PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Tocovid Suprabio (HOV-12020); Placebo", "sponsor": "National Neuroscience Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT04491383", "diseases": ["Parkinson Disease"]}, {"lat": 47.36667, "lng": 8.55, "nct": "NCT07082595", "color": "#a9462d", "title": "Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "TASS Intervention (Sham); TASS Intervention (Verum)", "sponsor": "University of Zurich", "address": "", "url": "https://clinicaltrials.gov/study/NCT07082595", "diseases": ["Parkinson Disease"]}, {"lat": 33.77483, "lng": -84.29631, "nct": "NCT06088355", "color": "#5463d4", "title": "Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "HV-PDAE: High Volume Partnered Dance Aerobic Exercise; MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise; MV-WALK: Moderate Volume Walking", "sponsor": "VA Office of Research and Development", "address": "", "url": "https://clinicaltrials.gov/study/NCT06088355", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT06817200", "color": "#3cb71b", "title": "The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial", "status": "NOT_YET_RECRUITING", "phases": ["PHASE2"], "interventions": "Amantadine (100mg) as add on therapy.; Placebo", "sponsor": "University Hospital, Toulouse", "address": "", "url": "https://clinicaltrials.gov/study/NCT06817200", "diseases": ["Parkinson Disease"]}, {"lat": 25.05306, "lng": 121.52639, "nct": "NCT06588439", "color": "#c786db", "title": "Cognitive-motor Training in Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cognitive-motor training; Conventional physiotherapy", "sponsor": "National Yang Ming Chiao Tung University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06588439", "diseases": ["Parkinson Disease"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT04784494", "color": "#479043", "title": "MST for Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Magnetic Seizure Theapy (MagPro XP MST)", "sponsor": "University of British Columbia", "address": "", "url": "https://clinicaltrials.gov/study/NCT04784494", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT06467461", "color": "#832ab9", "title": "Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder", "status": "RECRUITING", "phases": ["NA"], "interventions": "Skin biopsy; Speech testing; Ultra high field 7T MRI", "sponsor": "University of Minnesota", "address": "", "url": "https://clinicaltrials.gov/study/NCT06467461", "diseases": ["Parkinson Disease"]}, {"lat": 43.61093, "lng": 3.87635, "nct": "NCT07083089", "color": "#deeb27", "title": "Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Thorough Hearing assessment", "sponsor": "Cilcare SAS", "address": "", "url": "https://clinicaltrials.gov/study/NCT07083089", "diseases": ["Parkinson Disease"]}, {"lat": 43.70313, "lng": 7.26608, "nct": "NCT07083089", "color": "#deeb27", "title": "Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Thorough Hearing assessment", "sponsor": "Cilcare SAS", "address": "", "url": "https://clinicaltrials.gov/study/NCT07083089", "diseases": ["Parkinson Disease"]}, {"lat": 43.83665, "lng": 4.35788, "nct": "NCT07083089", "color": "#deeb27", "title": "Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Thorough Hearing assessment", "sponsor": "Cilcare SAS", "address": "", "url": "https://clinicaltrials.gov/study/NCT07083089", "diseases": ["Parkinson Disease"]}, {"lat": 45.76601, "lng": 4.8795, "nct": "NCT07083089", "color": "#deeb27", "title": "Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Thorough Hearing assessment", "sponsor": "Cilcare SAS", "address": "", "url": "https://clinicaltrials.gov/study/NCT07083089", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT07157345", "color": "#e95b92", "title": "Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "PDR001", "sponsor": "Ruijin Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT07157345", "diseases": ["Parkinson Disease"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT05505019", "color": "#c98800", "title": "Targeting Apathy With Music in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Music listening; Podcast listening", "sponsor": "University of British Columbia", "address": "", "url": "https://clinicaltrials.gov/study/NCT05505019", "diseases": ["Parkinson Disease"]}, {"lat": 23.7104, "lng": 90.40744, "nct": "NCT05959044", "color": "#857b4c", "title": "Effect of Folic Acid in Levodopa Treated Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Folic Acid Tablet; Placebo", "sponsor": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", "address": "", "url": "https://clinicaltrials.gov/study/NCT05959044", "diseases": ["Parkinson Disease"]}, {"lat": 45.77969, "lng": 3.08682, "nct": "NCT04375280", "color": "#11eea5", "title": "Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort", "status": "RECRUITING", "phases": ["NA"], "interventions": "Development of a screening algorithm designed to determine a \"dysmobility\" profile in patients with chronic illness.", "sponsor": "University Hospital, Clermont-Ferrand", "address": "", "url": "https://clinicaltrials.gov/study/NCT04375280", "diseases": ["Parkinson Disease"]}, {"lat": -22.88333, "lng": -43.10361, "nct": "NCT06912997", "color": "#451aae", "title": "Effects of Inspiratory Muscle Training on Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exercise; Sham Comparator", "sponsor": "Universidade Federal Fluminense", "address": "", "url": "https://clinicaltrials.gov/study/NCT06912997", "diseases": ["Parkinson Disease"]}, {"lat": 47.47156, "lng": -0.55202, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 46.20574, "lng": 5.2258, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 49.18585, "lng": -0.35912, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 48.80299, "lng": 2.26692, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 45.04366, "lng": 3.88523, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 43.61093, "lng": 3.87635, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 43.70313, "lng": 7.26608, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 48.30073, "lng": 4.08524, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 50.35909, "lng": 3.52506, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 45.76601, "lng": 4.8795, "nct": "NCT06401395", "color": "#5930f5", "title": "Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "DIGIPARK MONITOR", "sponsor": "DIAMPARK", "address": "", "url": "https://clinicaltrials.gov/study/NCT06401395", "diseases": ["Parkinson Disease"]}, {"lat": 24.9896, "lng": 121.3187, "nct": "NCT06363071", "color": "#1c7e11", "title": "APA and PAS Training for Gait Initiation in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Weight shift training and APA feedback; Paired associative stimulation", "sponsor": "Chang Gung University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06363071", "diseases": ["Parkinson Disease"]}, {"lat": 46.60207, "lng": -120.5059, "nct": "NCT06576817", "color": "#775188", "title": "High-intensity Interval Circuit Training in People With Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "High intensity circuit exercise class - Lower and upper extremity; High intensity circuit exercise class - Lower extremity alone", "sponsor": "Pacific Northwest University of Health Sciences", "address": "", "url": "https://clinicaltrials.gov/study/NCT06576817", "diseases": ["Parkinson Disease"]}, {"lat": 46.60207, "lng": -120.5059, "nct": "NCT06908135", "color": "#43f684", "title": "Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Independent walking program using walking poles; Independent walking program without walking poles", "sponsor": "Pacific Northwest University of Health Sciences", "address": "", "url": "https://clinicaltrials.gov/study/NCT06908135", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT05763732", "color": "#ce6809", "title": "Effects of RAS on Gait in PD Patients With DBS", "status": "RECRUITING", "phases": ["NA"], "interventions": "Rhythmic Auditory Stimulation (RAS)", "sponsor": "Johns Hopkins University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05763732", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT06142448", "color": "#7fb660", "title": "The Effect of Compensation Strategies on Gait Impairment in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cueing app", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06142448", "diseases": ["Parkinson Disease"]}, {"lat": 41.01384, "lng": 28.94966, "nct": "NCT06615115", "color": "#534ab2", "title": "The Effect of Different Types of Focus Instructions in Parkinson's Rehabilitation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exercise", "sponsor": "Bah\u00e7e\u015fehir University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06615115", "diseases": ["Parkinson Disease"]}, {"lat": 49.02012, "lng": -0.63238, "nct": "NCT07063810", "color": "#a21a58", "title": "NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Mixed Reality Rehabilitation", "sponsor": "Slb Pharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT07063810", "diseases": ["Parkinson Disease"]}, {"lat": 49.21088, "lng": -0.30653, "nct": "NCT07063810", "color": "#a21a58", "title": "NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Mixed Reality Rehabilitation", "sponsor": "Slb Pharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT07063810", "diseases": ["Parkinson Disease"]}, {"lat": 49.01096, "lng": 1.0873, "nct": "NCT07063810", "color": "#a21a58", "title": "NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Mixed Reality Rehabilitation", "sponsor": "Slb Pharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT07063810", "diseases": ["Parkinson Disease"]}, {"lat": 46.94809, "lng": 7.44744, "nct": "NCT06386497", "color": "#61cec7", "title": "Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Nocturnal translational vestibular stimulation", "sponsor": "Insel Gruppe AG, University Hospital Bern", "address": "", "url": "https://clinicaltrials.gov/study/NCT06386497", "diseases": ["Parkinson Disease"]}, {"lat": 47.36667, "lng": 8.55, "nct": "NCT06386497", "color": "#61cec7", "title": "Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Nocturnal translational vestibular stimulation", "sponsor": "Insel Gruppe AG, University Hospital Bern", "address": "", "url": "https://clinicaltrials.gov/study/NCT06386497", "diseases": ["Parkinson Disease"]}, {"lat": 42.37787, "lng": -71.062, "nct": "NCT03981055", "color": "#810d7c", "title": "Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Active Comparator: Active tDCS and Active TUS; Sham Comparator: Sham TDCS and Sham TUS; Physical Therapy", "sponsor": "Spaulding Rehabilitation Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03981055", "diseases": ["Parkinson Disease"]}, {"lat": 31.3141, "lng": 34.62025, "nct": "NCT06730074", "color": "#5ad50b", "title": "A Novel Robotic System for Motor-cognitive Exercise for Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)", "sponsor": "Adi Negev-Nahalat Eran", "address": "", "url": "https://clinicaltrials.gov/study/NCT06730074", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT04675398", "color": "#213ffc", "title": "Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Summit RC+S", "sponsor": "Doris Wang, MD, PhD", "address": "", "url": "https://clinicaltrials.gov/study/NCT04675398", "diseases": ["Parkinson Disease"]}, {"lat": 30.29365, "lng": 120.16142, "nct": "NCT06821529", "color": "#66edc3", "title": "Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1"], "interventions": "ICA07 therapy", "sponsor": "iCamuno Biotherapeutics Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06821529", "diseases": ["Parkinson Disease"]}, {"lat": 42.12753, "lng": -87.82895, "nct": "NCT07127120", "color": "#5155a3", "title": "Open Label Single Arm Prebiotic Pilot Trial SR001", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Prebiotic fiber blend", "sponsor": "Sorridi Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT07127120", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT06868160", "color": "#cba622", "title": "Comparison of Different Non-invasive Electrical Stimulation Protocols to Facilitate Rehabilitation in Parkinson's Disease Subjects With Postural Instability and Gait Disorders", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Rehabilitation; SHAM tDCS; tDCS; tsDCS (first cycle); tsDCS (second cycle); SHAM tsDCS (first cycle); SHAM tsDCS (second cycle); SHAM tsDCS", "sponsor": "IRCCS San Raffaele", "address": "", "url": "https://clinicaltrials.gov/study/NCT06868160", "diseases": ["Parkinson Disease"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT05469997", "color": "#e71323", "title": "Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Mediterranean-Ketogenic Diet; Mediterranean diet supplemented with medium-chain triglyceride oil", "sponsor": "University of British Columbia", "address": "", "url": "https://clinicaltrials.gov/study/NCT05469997", "diseases": ["Parkinson Disease"]}, {"lat": 39.68372, "lng": -75.74966, "nct": "NCT06916260", "color": "#f6da85", "title": "Light Therapy Intervention in Individuals With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Red Light (PDT); Placebo", "sponsor": "University of Delaware", "address": "", "url": "https://clinicaltrials.gov/study/NCT06916260", "diseases": ["Parkinson Disease"]}, {"lat": 45.73865, "lng": 4.91303, "nct": "NCT07127146", "color": "#4e5891", "title": "Opioidergic and Noradrenergic Systems in Central Parkisonian Pain", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "PET-MRI exam with administration of [11C]Carfentanil; PET-MRI exam with administration of [11C]Yohimbine", "sponsor": "Hospices Civils de Lyon", "address": "", "url": "https://clinicaltrials.gov/study/NCT07127146", "diseases": ["Parkinson Disease"]}, {"lat": 45.77969, "lng": 3.08682, "nct": "NCT07127146", "color": "#4e5891", "title": "Opioidergic and Noradrenergic Systems in Central Parkisonian Pain", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "PET-MRI exam with administration of [11C]Carfentanil; PET-MRI exam with administration of [11C]Yohimbine", "sponsor": "Hospices Civils de Lyon", "address": "", "url": "https://clinicaltrials.gov/study/NCT07127146", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT07127146", "color": "#4e5891", "title": "Opioidergic and Noradrenergic Systems in Central Parkisonian Pain", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "PET-MRI exam with administration of [11C]Carfentanil; PET-MRI exam with administration of [11C]Yohimbine", "sponsor": "Hospices Civils de Lyon", "address": "", "url": "https://clinicaltrials.gov/study/NCT07127146", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT05317390", "color": "#051487", "title": "Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia", "status": "RECRUITING", "phases": ["NA"], "interventions": "DystoniaNet-based diagnosis of isolated dystonia", "sponsor": "Massachusetts Eye and Ear Infirmary", "address": "", "url": "https://clinicaltrials.gov/study/NCT05317390", "diseases": ["Parkinson Disease"]}, {"lat": 32.06167, "lng": 118.77778, "nct": "NCT06665113", "color": "#199c85", "title": "Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "taVNS real stimulation; taVNS sham stimulation", "sponsor": "Kezhong Zhang", "address": "", "url": "https://clinicaltrials.gov/study/NCT06665113", "diseases": ["Parkinson Disease"]}, {"lat": 51.89797, "lng": -8.47061, "nct": "NCT06192628", "color": "#39e23c", "title": "Behavioural Change Techniques for Physical Activity and Exercise Adherence Among People With Parkinson's", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Parkinson's Exercise and Education Programme; Parkinson's Exercise and Education Programme and Behavioural Change", "sponsor": "University College Cork", "address": "", "url": "https://clinicaltrials.gov/study/NCT06192628", "diseases": ["Parkinson Disease"]}, {"lat": 55.64297, "lng": 12.47708, "nct": "NCT06570824", "color": "#68c5ab", "title": "rTMS as an Intervention for Levodopa-induced Dyskinesia", "status": "RECRUITING", "phases": ["NA"], "interventions": "active TMS; sham TMS", "sponsor": "Danish Research Centre for Magnetic Resonance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06570824", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT06490861", "color": "#1362be", "title": "Performance of the Paragit Sleeve to Measure and Monitor Motor Symptoms in Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Paragit", "sponsor": "Paragit ApS", "address": "", "url": "https://clinicaltrials.gov/study/NCT06490861", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT05893186", "color": "#3d89b8", "title": "Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "Deep Brain Stimulation, STN; GP Deep Brain Stimulation", "sponsor": "University of Minnesota", "address": "", "url": "https://clinicaltrials.gov/study/NCT05893186", "diseases": ["Parkinson Disease"]}, {"lat": 23.11667, "lng": 113.25, "nct": "NCT07156773", "color": "#ffde6b", "title": "The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "XJN010 Nasal Spray; Placebo", "sponsor": "Guangzhou Novaken Pharm Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07156773", "diseases": ["Parkinson Disease"]}, {"lat": 44.97997, "lng": -93.26384, "nct": "NCT06692920", "color": "#e5eb88", "title": "Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.", "status": "RECRUITING", "phases": ["NA"], "interventions": "DBS stimulation", "sponsor": "University of Minnesota", "address": "", "url": "https://clinicaltrials.gov/study/NCT06692920", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT05509842", "color": "#750aec", "title": "Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "rTMS", "sponsor": "University of Michigan", "address": "", "url": "https://clinicaltrials.gov/study/NCT05509842", "diseases": ["Parkinson Disease"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT06241924", "color": "#327b51", "title": "Oscillatory Activity in Basal Ganglia Circuits During Normal and Pathological Movement", "status": "RECRUITING", "phases": ["NA"], "interventions": "High Resolution Electroencephalogram (EEG-HR); Stereo-electro-encephalography (SEEG)", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT06241924", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT05765110", "color": "#7c4be9", "title": "SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Dopaminergic OFF drug state; DBS OFF state; Dopaminergic ON drug state; DBS ON state", "sponsor": "Insel Gruppe AG, University Hospital Bern", "address": "", "url": "https://clinicaltrials.gov/study/NCT05765110", "diseases": ["Parkinson Disease"]}, {"lat": 46.94809, "lng": 7.44744, "nct": "NCT05765110", "color": "#7c4be9", "title": "SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Dopaminergic OFF drug state; DBS OFF state; Dopaminergic ON drug state; DBS ON state", "sponsor": "Insel Gruppe AG, University Hospital Bern", "address": "", "url": "https://clinicaltrials.gov/study/NCT05765110", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT06607900", "color": "#42aeef", "title": "hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1"], "interventions": "hUC-MSC-sEV-001 nasal drops", "sponsor": "Xuanwu Hospital, Beijing", "address": "", "url": "https://clinicaltrials.gov/study/NCT06607900", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 44.33352, "lng": 10.83544, "nct": "NCT07010328", "color": "#dd2ce8", "title": "Integrating AI in Postural Rehabilitation for Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neurorehabilitation; AI-based home rehabilitation for postural disorders", "sponsor": "IRCCS National Neurological Institute \"C. Mondino\" Foundation", "address": "", "url": "https://clinicaltrials.gov/study/NCT07010328", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT05799690", "color": "#2d116c", "title": "Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders", "status": "RECRUITING", "phases": ["NA"], "interventions": "Gait and balance training with dual-task + action observation and motor imagery (six weeks); Gait and balance training with dual-task (six weeks); Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6); Gait and balance training with dual-task (twelve weeks: 6 +6)", "sponsor": "Prof. Massimo Filippi", "address": "", "url": "https://clinicaltrials.gov/study/NCT05799690", "diseases": ["Parkinson Disease"]}, {"lat": 45.43854, "lng": 10.9938, "nct": "NCT05799690", "color": "#2d116c", "title": "Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders", "status": "RECRUITING", "phases": ["NA"], "interventions": "Gait and balance training with dual-task + action observation and motor imagery (six weeks); Gait and balance training with dual-task (six weeks); Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6); Gait and balance training with dual-task (twelve weeks: 6 +6)", "sponsor": "Prof. Massimo Filippi", "address": "", "url": "https://clinicaltrials.gov/study/NCT05799690", "diseases": ["Parkinson Disease"]}, {"lat": 38.19394, "lng": 15.55256, "nct": "NCT06838975", "color": "#6e31c1", "title": "Virtual Reality Rehabilitation for Cognitive, Emotional, and Motor Recovery in Neurological Disorders", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "VR Training; traditional cognitive and motor rehabilitation following standard clinical practices", "sponsor": "IRCCS Centro Neurolesi Bonino Pulejo", "address": "", "url": "https://clinicaltrials.gov/study/NCT06838975", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT05076565", "color": "#9c8860", "title": "Wearable Airbag Technology to Mitigate Falls in Individuals With High Fall Risk", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Airbag Belt Fall Protection System", "sponsor": "Shirley Ryan AbilityLab", "address": "", "url": "https://clinicaltrials.gov/study/NCT05076565", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT06012461", "color": "#23ee3a", "title": "Closed-loop DBS in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Closed-loop DBS stimulation for 24 hours; Open-loop DBS stimulation for 24 hours; Closed-loop DBS stimulation for 72 hours; Open-loop DBS stimulation for 72 hours", "sponsor": "Tsinghua University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06012461", "diseases": ["Parkinson Disease"]}, {"lat": 52.155, "lng": 5.3875, "nct": "NCT05164783", "color": "#c0c5ab", "title": "Multicenter Implementation of E-monitoring in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Sanacoach Parkinson (SCP)", "sponsor": "Zuyderland Medisch Centrum", "address": "", "url": "https://clinicaltrials.gov/study/NCT05164783", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT05164783", "color": "#c0c5ab", "title": "Multicenter Implementation of E-monitoring in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Sanacoach Parkinson (SCP)", "sponsor": "Zuyderland Medisch Centrum", "address": "", "url": "https://clinicaltrials.gov/study/NCT05164783", "diseases": ["Parkinson Disease"]}, {"lat": 52.48333, "lng": 4.65694, "nct": "NCT05164783", "color": "#c0c5ab", "title": "Multicenter Implementation of E-monitoring in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Sanacoach Parkinson (SCP)", "sponsor": "Zuyderland Medisch Centrum", "address": "", "url": "https://clinicaltrials.gov/study/NCT05164783", "diseases": ["Parkinson Disease"]}, {"lat": 50.97417, "lng": 5.82917, "nct": "NCT05164783", "color": "#c0c5ab", "title": "Multicenter Implementation of E-monitoring in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Sanacoach Parkinson (SCP)", "sponsor": "Zuyderland Medisch Centrum", "address": "", "url": "https://clinicaltrials.gov/study/NCT05164783", "diseases": ["Parkinson Disease"]}, {"lat": 50.88365, "lng": 5.98154, "nct": "NCT05164783", "color": "#c0c5ab", "title": "Multicenter Implementation of E-monitoring in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Sanacoach Parkinson (SCP)", "sponsor": "Zuyderland Medisch Centrum", "address": "", "url": "https://clinicaltrials.gov/study/NCT05164783", "diseases": ["Parkinson Disease"]}, {"lat": 51.48167, "lng": 5.66111, "nct": "NCT05164783", "color": "#c0c5ab", "title": "Multicenter Implementation of E-monitoring in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Sanacoach Parkinson (SCP)", "sponsor": "Zuyderland Medisch Centrum", "address": "", "url": "https://clinicaltrials.gov/study/NCT05164783", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT05881460", "color": "#bdbf7b", "title": "Vibrotactile Coordinated Reset: a Non-invasive Treatment for Parkinson's Disease 2", "status": "RECRUITING", "phases": ["NA"], "interventions": "Active vibrotactile coordinated reset; Sham vibrotactile coordinated reset", "sponsor": "Synergic Medical Technologies, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05881460", "diseases": ["Parkinson Disease"]}, {"lat": 38.19394, "lng": 15.55256, "nct": "NCT07066137", "color": "#3b1190", "title": "Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "CAREN; Control group", "sponsor": "IRCCS Centro Neurolesi Bonino Pulejo", "address": "", "url": "https://clinicaltrials.gov/study/NCT07066137", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT06793995", "color": "#240751", "title": "Effect of Food and Age on the Pharmacokinetics of LY03017", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1"], "interventions": "LY03017", "sponsor": "Luye Pharma Group Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06793995", "diseases": ["Parkinson Disease"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT07026734", "color": "#964c48", "title": "The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep brain stimulation surgery - GPi; Deep Brain Stimulation Surgery - STN", "sponsor": "University of Florida", "address": "", "url": "https://clinicaltrials.gov/study/NCT07026734", "diseases": ["Parkinson Disease"]}, {"lat": 51.22172, "lng": 6.77616, "nct": "NCT06617884", "color": "#602e74", "title": "Home-based Gait and Balance Training in Patients With Movement Disorders", "status": "RECRUITING", "phases": ["NA"], "interventions": "Gait and balance training", "sponsor": "Forschungszentrum Juelich", "address": "", "url": "https://clinicaltrials.gov/study/NCT06617884", "diseases": ["Parkinson Disease"]}, {"lat": 49.8844, "lng": -97.14704, "nct": "NCT03025334", "color": "#3865aa", "title": "tDCS on Parkinson's Disease Cognition", "status": "RECRUITING", "phases": ["NA"], "interventions": "High-definition transcranial direct current stimulation", "sponsor": "University of Manitoba", "address": "", "url": "https://clinicaltrials.gov/study/NCT03025334", "diseases": ["Parkinson Disease"]}, {"lat": 43.15478, "lng": -77.61556, "nct": "NCT06993142", "color": "#e22742", "title": "Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Increase of physical activity volume and intensity with the use of a motivational smartphone application", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06993142", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT06993142", "color": "#e22742", "title": "Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Increase of physical activity volume and intensity with the use of a motivational smartphone application", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT06993142", "diseases": ["Parkinson Disease"]}, {"lat": 35.17284, "lng": 33.35397, "nct": "NCT06459154", "color": "#07ed11", "title": "The Effectiveness of Mixed Reality as Interventional Tool for the Improvement on Quality of Life for People With Parkinson\u00b4s Disease.", "status": "RECRUITING", "phases": ["NA"], "interventions": "Mixed Reality; Traditional Physiotherapy", "sponsor": "University of Nicosia", "address": "", "url": "https://clinicaltrials.gov/study/NCT06459154", "diseases": ["Parkinson Disease"]}, {"lat": 49.19522, "lng": 16.60796, "nct": "NCT06416553", "color": "#1f2240", "title": "Effect of Speech Therapy in Combination With Non-invasive Brain Stimulation on Speech of Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Home-based transcranial direct current stimulation- real tDCS; Home-based transcranial direct current stimulation- sham tDCS; Lee-Silverman voice treatment", "sponsor": "Masaryk University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06416553", "diseases": ["Parkinson Disease"]}, {"lat": 14.61341, "lng": -60.99964, "nct": "NCT04492345", "color": "#7f2cd2", "title": "Assessment of a Special Modality of Back Muscles Strengthening for Postural Deformations in Parkinsonian Patient", "status": "RECRUITING", "phases": ["NA"], "interventions": "Isokinetic reeducation; Conventional reeducation", "sponsor": "University Hospital Center of Martinique", "address": "", "url": "https://clinicaltrials.gov/study/NCT04492345", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT04953637", "color": "#8d0c93", "title": "Physiotherapy and Deep Brain Stimulation in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Physiotherapy", "sponsor": "University of Toronto", "address": "", "url": "https://clinicaltrials.gov/study/NCT04953637", "diseases": ["Parkinson Disease"]}, {"lat": 39.76838, "lng": -86.15804, "nct": "NCT05218187", "color": "#6b65fa", "title": "Robotic Gait Rehabilitation in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "G-EO End-Effector Gait Trainer; Conventional Physical Therapy Treatment", "sponsor": "Indiana University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05218187", "diseases": ["Parkinson Disease"]}, {"lat": -33.45694, "lng": -70.64827, "nct": "NCT06584383", "color": "#1ac126", "title": "A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exablate MRgFUS subthalamotomy; Best Medical Treatment", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT06584383", "diseases": ["Parkinson Disease"]}, {"lat": 54.32133, "lng": 10.13489, "nct": "NCT06584383", "color": "#1ac126", "title": "A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exablate MRgFUS subthalamotomy; Best Medical Treatment", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT06584383", "diseases": ["Parkinson Disease"]}, {"lat": 40.32234, "lng": -3.86496, "nct": "NCT06584383", "color": "#1ac126", "title": "A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exablate MRgFUS subthalamotomy; Best Medical Treatment", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT06584383", "diseases": ["Parkinson Disease"]}, {"lat": 42.81687, "lng": -1.64323, "nct": "NCT06584383", "color": "#1ac126", "title": "A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exablate MRgFUS subthalamotomy; Best Medical Treatment", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT06584383", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT05238545", "color": "#1f2c72", "title": "The Effect of Gluten-free Diet on Parkinsonism", "status": "RECRUITING", "phases": ["NA"], "interventions": "gluten-free diet", "sponsor": "General University Hospital, Prague", "address": "", "url": "https://clinicaltrials.gov/study/NCT05238545", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 33.44838, "lng": -112.07404, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 34.74648, "lng": -92.28959, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 33.70918, "lng": -117.95367, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 36.74773, "lng": -119.77237, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 34.14778, "lng": -118.14452, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 34.20112, "lng": -118.53647, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 25.96537, "lng": -80.14282, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 26.27119, "lng": -80.2706, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 28.62778, "lng": -81.36312, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 26.14234, "lng": -81.79596, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 29.1872, "lng": -82.14009, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 26.97617, "lng": -82.09064, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 29.13832, "lng": -80.99561, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 28.6, "lng": -81.33924, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 33.47097, "lng": -81.97484, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.8617, "lng": -88.1609, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 37.98869, "lng": -84.47772, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.57814, "lng": -70.32172, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.70704, "lng": -71.16311, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.73698, "lng": -84.48387, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.56891, "lng": -83.38356, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 36.17497, "lng": -115.13722, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.92595, "lng": -75.11962, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.65258, "lng": -73.75623, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.04812, "lng": -76.14742, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 35.60095, "lng": -82.55402, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.12711, "lng": -84.51439, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.75895, "lng": -84.19161, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.66394, "lng": -83.55521, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 35.14953, "lng": -90.04898, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 30.63269, "lng": -97.67723, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 33.57786, "lng": -101.85517, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 44.47588, "lng": -73.21207, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 37.55376, "lng": -77.46026, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 36.85293, "lng": -75.97799, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": -33.43218, "lng": 151.38972, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": -33.9681, "lng": 151.13564, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": -33.86785, "lng": 151.20732, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": -27.48855, "lng": 153.03655, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": -37.91667, "lng": 145.11667, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": -37.78333, "lng": 144.95, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.41667, "lng": 24.61667, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.69751, "lng": 23.32415, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 45.41117, "lng": -75.69812, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.00161, "lng": 16.22303, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.16284, "lng": 16.27488, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 45.73865, "lng": 4.91303, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 48.79266, "lng": 2.46569, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 48.68439, "lng": 6.18496, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 45.17869, "lng": 5.71479, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.83665, "lng": 4.35788, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 48.58392, "lng": 7.74553, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.22683, "lng": 8.61816, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.88029, "lng": 12.08187, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 48.16196, "lng": 12.17942, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 51.60698, "lng": 13.31243, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 51.96236, "lng": 7.62571, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 52.52437, "lng": 13.41053, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 51.48165, "lng": 7.21648, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 48.13743, "lng": 11.57549, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.85684, "lng": 11.72677, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 47.49835, "lng": 19.04045, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 46.0725, "lng": 18.23083, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 47.58494, "lng": 18.39325, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 32.08227, "lng": 34.81065, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 32.81303, "lng": 34.99928, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 32.08707, "lng": 34.88747, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 31.99866, "lng": 34.94559, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 32.08088, "lng": 34.78057, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.78235, "lng": 12.59836, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.89193, "lng": 12.51133, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 44.88856, "lng": 11.99138, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 45.40797, "lng": 11.88586, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.60717, "lng": 13.5103, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.48581, "lng": 13.82835, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.70853, "lng": 10.4036, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.06143, "lng": 19.93658, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.25841, "lng": 19.02754, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 51.25, "lng": 22.56667, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 52.22977, "lng": 21.01178, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 50.32738, "lng": 19.02901, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 53.1235, "lng": 18.00762, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 44.80401, "lng": 20.46513, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 38.26218, "lng": -0.70107, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 43.31283, "lng": -1.97499, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 42.81687, "lng": -1.64323, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 41.56667, "lng": 2.01667, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 39.47391, "lng": -0.37966, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 48.46664, "lng": 35.04066, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 49.83826, "lng": 24.02324, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 49.84639, "lng": 37.71861, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 47.85167, "lng": 35.11714, "nct": "NCT04760769", "color": "#d3e26a", "title": "Open-label Trial in Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Tavapadon", "sponsor": "AbbVie", "address": "", "url": "https://clinicaltrials.gov/study/NCT04760769", "diseases": ["Parkinson Disease"]}, {"lat": 48.41675, "lng": -71.06573, "nct": "NCT06175871", "color": "#820d0b", "title": "New Clinical Rehabilitation Approach for the Management of Falls Risks", "status": "RECRUITING", "phases": ["NA"], "interventions": "OTAGO exercises; Conventional therapy", "sponsor": "Universit\u00e9 du Qu\u00e9bec \u00e0 Chicoutimi", "address": "", "url": "https://clinicaltrials.gov/study/NCT06175871", "diseases": ["Parkinson Disease"]}, {"lat": 36.17497, "lng": -115.13722, "nct": "NCT06605183", "color": "#9657ea", "title": "10,000 Step Club: Community Walking Program for People with Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Community walking program using Nordic walking poles", "sponsor": "University of Nevada, Las Vegas", "address": "", "url": "https://clinicaltrials.gov/study/NCT06605183", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT04607174", "color": "#8b5650", "title": "Voluntary Activation During Isokinetic Contractions in Subjects with Neuromotor Disorders", "status": "RECRUITING", "phases": ["NA"], "interventions": "Pathologic group", "sponsor": "Istituto Auxologico Italiano", "address": "", "url": "https://clinicaltrials.gov/study/NCT04607174", "diseases": ["Parkinson Disease"]}, {"lat": 52.48142, "lng": -1.89983, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 51.45523, "lng": -2.59665, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 52.2, "lng": 0.11667, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 55.95206, "lng": -3.19648, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 54.21804, "lng": -5.88979, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 54.97328, "lng": -1.61396, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 51.75222, "lng": -1.25596, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 50.37153, "lng": -4.14305, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 53.48771, "lng": -2.29042, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 50.90395, "lng": -1.40428, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 53.34061, "lng": -1.28162, "nct": "NCT05778617", "color": "#ec3cfd", "title": "Ambroxol to Slow Progression in Parkinson Disease", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Ambroxol Hydrochloride (420mg); Placebo", "sponsor": "University College, London", "address": "", "url": "https://clinicaltrials.gov/study/NCT05778617", "diseases": ["Parkinson Disease"]}, {"lat": 47.52065, "lng": 9.25736, "nct": "NCT04459559", "color": "#547622", "title": "Usability of a Novel Cueing Device for Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Tactile Cueing Device", "sponsor": "Swiss Federal Institute of Technology", "address": "", "url": "https://clinicaltrials.gov/study/NCT04459559", "diseases": ["Parkinson Disease"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 36.06258, "lng": -94.15743, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 34.74648, "lng": -92.28959, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 37.87159, "lng": -122.27275, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 33.70918, "lng": -117.95367, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 33.66946, "lng": -117.82311, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 34.04835, "lng": -117.26115, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 37.22661, "lng": -121.97468, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 33.95335, "lng": -117.39616, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 38.58157, "lng": -121.4944, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 39.72943, "lng": -104.83192, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 39.06387, "lng": -108.55065, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.71982, "lng": -72.83204, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.76371, "lng": -72.68509, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 30.33218, "lng": -81.65565, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 33.47097, "lng": -81.97484, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 21.30694, "lng": -157.85833, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.85364, "lng": -87.8395, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 37.98869, "lng": -84.47772, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 29.95465, "lng": -90.07507, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 42.73698, "lng": -84.48387, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 43.64229, "lng": -72.25176, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 42.65258, "lng": -73.75623, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.94149, "lng": -73.10594, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.86232, "lng": -73.63374, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.80066, "lng": -73.72846, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.79788, "lng": -73.69957, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 43.15478, "lng": -77.61556, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.92565, "lng": -73.14094, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 36.09986, "lng": -80.24422, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 39.12711, "lng": -84.51439, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.44062, "lng": -79.99589, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.00289, "lng": -75.27074, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 32.77632, "lng": -79.93275, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 35.14953, "lng": -90.04898, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 29.42412, "lng": -98.49363, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.66689, "lng": -111.88799, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.76078, "lng": -111.89105, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 44.47588, "lng": -73.21207, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 43.07305, "lng": -89.40123, "nct": "NCT03924414", "color": "#a36837", "title": "Trial of Parkinson's And Zoledronic Acid", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE4"], "interventions": "Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo", "sponsor": "California Pacific Medical Center Research Institute", "address": "", "url": "https://clinicaltrials.gov/study/NCT03924414", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 43.15478, "lng": -77.61556, "nct": "NCT04453033", "color": "#63438e", "title": "DB RCT for Specialized Phototherapy in Parkinson's Disease.", "status": "RECRUITING", "phases": ["NA"], "interventions": "Celeste Specialized Phototherapy Device", "sponsor": "PhotoPharmics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04453033", "diseases": ["Parkinson Disease"]}, {"lat": 41.15367, "lng": -81.35789, "nct": "NCT05361200", "color": "#e3ad0d", "title": "Speed Manipulated Adaptive Rehabilitation Therapy Bike for Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Dynamic high-cadence cycling", "sponsor": "Kent State University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05361200", "diseases": ["Parkinson Disease"]}, {"lat": 30.00944, "lng": 31.20861, "nct": "NCT06104072", "color": "#749778", "title": "Effect of Adding Computerized Cognitive Training on Balance, Locomotion and Cognition in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "REHACOM Software; A Designed Physical Therapy Program", "sponsor": "Engy Badreldin Saleh Moustafa, PhD", "address": "", "url": "https://clinicaltrials.gov/study/NCT06104072", "diseases": ["Parkinson Disease"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT05779839", "color": "#2ce3c5", "title": "A Study of Caregiver Connections Via Technology in Dementia", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Algorithm; Random Match", "sponsor": "Mayo Clinic", "address": "", "url": "https://clinicaltrials.gov/study/NCT05779839", "diseases": ["Parkinson Disease"]}, {"lat": 45.56995, "lng": -73.692, "nct": "NCT05644327", "color": "#6d40b4", "title": "Exercise to Improve Sleep in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cardiovascular training (CT); Resistance training (RT); Multimodal training (MT)", "sponsor": "McGill University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05644327", "diseases": ["Parkinson Disease"]}, {"lat": 45.50884, "lng": -73.58781, "nct": "NCT05644327", "color": "#6d40b4", "title": "Exercise to Improve Sleep in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cardiovascular training (CT); Resistance training (RT); Multimodal training (MT)", "sponsor": "McGill University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05644327", "diseases": ["Parkinson Disease"]}, {"lat": 50.93333, "lng": 6.95, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 51.05089, "lng": 13.73832, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 51.22172, "lng": 6.77616, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 53.55073, "lng": 9.99302, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 54.32133, "lng": 10.13489, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 50.80904, "lng": 8.77069, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 52.52003, "lng": 13.40489, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 49.79391, "lng": 9.95121, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 46.94809, "lng": 7.44744, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 47.36667, "lng": 8.55, "nct": "NCT06561919", "color": "#0c0674", "title": "STIMPulseControl Ancillary Speech Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\u00b4s disease according to widely accepted expert consensus paper", "sponsor": "Steffen Paschen", "address": "", "url": "https://clinicaltrials.gov/study/NCT06561919", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT06919822", "color": "#638a20", "title": "SCAN Electrical Stimulation for Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Personalized SCAN Electrical Stimulation", "sponsor": "Changping Laboratory", "address": "", "url": "https://clinicaltrials.gov/study/NCT06919822", "diseases": ["Parkinson Disease"]}, {"lat": 42.4584, "lng": 14.20283, "nct": "NCT07013214", "color": "#82893a", "title": "Rehabilitation With Dual-task Exercises to Improve Balance in Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Dual-Task Exercise; Standard Rehabilitation", "sponsor": "G. d'Annunzio University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07013214", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT05382858", "color": "#17f64e", "title": "PSA Versus STN DBS for TD-PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep brain stimulation", "sponsor": "Ruijin Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT05382858", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT05972759", "color": "#f5fc01", "title": "Identifying the Neural Signature of Exercise to Advance Treatment of PD Cognitive Declines", "status": "RECRUITING", "phases": ["NA"], "interventions": "Forced and voluntary exercise", "sponsor": "The Cleveland Clinic", "address": "", "url": "https://clinicaltrials.gov/study/NCT05972759", "diseases": ["Parkinson Disease"]}, {"lat": 49.32637, "lng": 7.33867, "nct": "NCT06479083", "color": "#95feb8", "title": "Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson's Network", "status": "RECRUITING", "phases": ["NA"], "interventions": "New Intervention form including; Standard treatment", "sponsor": "Johannes Gutenberg University Mainz", "address": "", "url": "https://clinicaltrials.gov/study/NCT06479083", "diseases": ["Parkinson Disease"]}, {"lat": 49.98419, "lng": 8.2791, "nct": "NCT06479083", "color": "#95feb8", "title": "Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson's Network", "status": "RECRUITING", "phases": ["NA"], "interventions": "New Intervention form including; Standard treatment", "sponsor": "Johannes Gutenberg University Mainz", "address": "", "url": "https://clinicaltrials.gov/study/NCT06479083", "diseases": ["Parkinson Disease"]}, {"lat": 56.16558, "lng": 10.21231, "nct": "NCT06707402", "color": "#87087e", "title": "The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "WALK; ACTIVE; CON", "sponsor": "University of Aarhus", "address": "", "url": "https://clinicaltrials.gov/study/NCT06707402", "diseases": ["Parkinson Disease"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 26.46146, "lng": -80.07282, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 39.29038, "lng": -76.61219, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 42.81687, "lng": -1.64323, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 24.05533, "lng": 120.4335, "nct": "NCT04728295", "color": "#b4f42b", "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Exablate 4000", "sponsor": "InSightec", "address": "", "url": "https://clinicaltrials.gov/study/NCT04728295", "diseases": ["Parkinson Disease"]}, {"lat": 41.12066, "lng": 16.86982, "nct": "NCT06685744", "color": "#964666", "title": "TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA", "sponsor": "Fondazione Don Carlo Gnocchi Onlus", "address": "", "url": "https://clinicaltrials.gov/study/NCT06685744", "diseases": ["Parkinson Disease"]}, {"lat": 45.21604, "lng": 11.87211, "nct": "NCT06685744", "color": "#964666", "title": "TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA", "sponsor": "Fondazione Don Carlo Gnocchi Onlus", "address": "", "url": "https://clinicaltrials.gov/study/NCT06685744", "diseases": ["Parkinson Disease"]}, {"lat": 45.85589, "lng": 9.39704, "nct": "NCT06685744", "color": "#964666", "title": "TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA", "sponsor": "Fondazione Don Carlo Gnocchi Onlus", "address": "", "url": "https://clinicaltrials.gov/study/NCT06685744", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT06685744", "color": "#964666", "title": "TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA", "sponsor": "Fondazione Don Carlo Gnocchi Onlus", "address": "", "url": "https://clinicaltrials.gov/study/NCT06685744", "diseases": ["Parkinson Disease"]}, {"lat": 44.64783, "lng": 10.92539, "nct": "NCT06685744", "color": "#964666", "title": "TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA", "sponsor": "Fondazione Don Carlo Gnocchi Onlus", "address": "", "url": "https://clinicaltrials.gov/study/NCT06685744", "diseases": ["Parkinson Disease"]}, {"lat": 45.19205, "lng": 9.15917, "nct": "NCT06685744", "color": "#964666", "title": "TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA", "sponsor": "Fondazione Don Carlo Gnocchi Onlus", "address": "", "url": "https://clinicaltrials.gov/study/NCT06685744", "diseases": ["Parkinson Disease"]}, {"lat": 53.1235, "lng": 18.00762, "nct": "NCT06671938", "color": "#e01f7a", "title": "Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "exidavnemab; Placebo Comparator", "sponsor": "BioArctic AB", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671938", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 50.06143, "lng": 19.93658, "nct": "NCT06671938", "color": "#e01f7a", "title": "Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "exidavnemab; Placebo Comparator", "sponsor": "BioArctic AB", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671938", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT06671938", "color": "#e01f7a", "title": "Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "exidavnemab; Placebo Comparator", "sponsor": "BioArctic AB", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671938", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT06671938", "color": "#e01f7a", "title": "Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "exidavnemab; Placebo Comparator", "sponsor": "BioArctic AB", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671938", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.47063, "lng": 2.08611, "nct": "NCT06671938", "color": "#e01f7a", "title": "Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "exidavnemab; Placebo Comparator", "sponsor": "BioArctic AB", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671938", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT06671938", "color": "#e01f7a", "title": "Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "exidavnemab; Placebo Comparator", "sponsor": "BioArctic AB", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671938", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 43.56667, "lng": -5.9, "nct": "NCT06671938", "color": "#e01f7a", "title": "Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "exidavnemab; Placebo Comparator", "sponsor": "BioArctic AB", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671938", "diseases": ["Parkinson Disease", "Multiple System Atrophy"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT07105384", "color": "#1386bc", "title": "Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Radiotracer", "sponsor": "Fundacion Clinic per a la Recerca Biom\u00e9dica", "address": "", "url": "https://clinicaltrials.gov/study/NCT07105384", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT03797378", "color": "#a1f437", "title": "Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "eM2M", "sponsor": "University of Alabama at Birmingham", "address": "", "url": "https://clinicaltrials.gov/study/NCT03797378", "diseases": ["Parkinson Disease"]}, {"lat": 47.21725, "lng": -1.55336, "nct": "NCT03230526", "color": "#f82107", "title": "Identification of a Biomarker Predictive of Evolution of Parkinson Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "[18F]DPA-714 PET scan", "sponsor": "Nantes University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03230526", "diseases": ["Parkinson Disease"]}, {"lat": 48.11198, "lng": -1.67429, "nct": "NCT03230526", "color": "#f82107", "title": "Identification of a Biomarker Predictive of Evolution of Parkinson Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "[18F]DPA-714 PET scan", "sponsor": "Nantes University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03230526", "diseases": ["Parkinson Disease"]}, {"lat": 47.39484, "lng": 0.70398, "nct": "NCT03230526", "color": "#f82107", "title": "Identification of a Biomarker Predictive of Evolution of Parkinson Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "[18F]DPA-714 PET scan", "sponsor": "Nantes University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT03230526", "diseases": ["Parkinson Disease"]}, {"lat": 30.29365, "lng": 120.16142, "nct": "NCT05882487", "color": "#abd3a3", "title": "Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD", "status": "NOT_YET_RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "KL002 injection solution", "sponsor": "Second Affiliated Hospital, School of Medicine, Zhejiang University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05882487", "diseases": ["Parkinson Disease"]}, {"lat": 38.62727, "lng": -90.19789, "nct": "NCT04474379", "color": "#87f8f1", "title": "Everyday Memory Impairment in PD-related Cognitive Decline", "status": "RECRUITING", "phases": ["NA"], "interventions": "Strategy Training (Time- and Event- Based)", "sponsor": "Washington University School of Medicine", "address": "", "url": "https://clinicaltrials.gov/study/NCT04474379", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT07044973", "color": "#350d5e", "title": "VIM+PTT MRgFUS for PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Transcranial focused ultrasound thalamotomy", "sponsor": "Chinese PLA General Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT07044973", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT06963918", "color": "#2208d0", "title": "Expiratory Muscle Training and Trunk Flexion in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Expiratory muscle strength training", "sponsor": "General University Hospital, Prague", "address": "", "url": "https://clinicaltrials.gov/study/NCT06963918", "diseases": ["Parkinson Disease"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT06518824", "color": "#a92f46", "title": "Theta Deep Brain Stimulation for Cognitive Enhancement in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "DBS On; DBS Off", "sponsor": "University of British Columbia", "address": "", "url": "https://clinicaltrials.gov/study/NCT06518824", "diseases": ["Parkinson Disease"]}, {"lat": 43.75115, "lng": 11.32252, "nct": "NCT06907589", "color": "#fcb887", "title": "A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson's Disease Promoting Continuity of Care", "status": "RECRUITING", "phases": ["NA"], "interventions": "Motor Data Analysis", "sponsor": "Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna", "address": "", "url": "https://clinicaltrials.gov/study/NCT06907589", "diseases": ["Parkinson Disease"]}, {"lat": 43.77925, "lng": 11.24626, "nct": "NCT06907589", "color": "#fcb887", "title": "A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson's Disease Promoting Continuity of Care", "status": "RECRUITING", "phases": ["NA"], "interventions": "Motor Data Analysis", "sponsor": "Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna", "address": "", "url": "https://clinicaltrials.gov/study/NCT06907589", "diseases": ["Parkinson Disease"]}, {"lat": 44.03541, "lng": 10.13927, "nct": "NCT06907589", "color": "#fcb887", "title": "A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson's Disease Promoting Continuity of Care", "status": "RECRUITING", "phases": ["NA"], "interventions": "Motor Data Analysis", "sponsor": "Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna", "address": "", "url": "https://clinicaltrials.gov/study/NCT06907589", "diseases": ["Parkinson Disease"]}, {"lat": 42.78235, "lng": 12.59836, "nct": "NCT06907589", "color": "#fcb887", "title": "A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson's Disease Promoting Continuity of Care", "status": "RECRUITING", "phases": ["NA"], "interventions": "Motor Data Analysis", "sponsor": "Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna", "address": "", "url": "https://clinicaltrials.gov/study/NCT06907589", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT06980207", "color": "#bd54d2", "title": "A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1"], "interventions": "LY03017; LY03017-Placebo", "sponsor": "Luye Pharma Group Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06980207", "diseases": ["Parkinson Disease"]}, {"lat": -33.91439, "lng": 151.24895, "nct": "NCT07057219", "color": "#807321", "title": "Steps Against the Burden of Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Exercise", "sponsor": "The University of New South Wales", "address": "", "url": "https://clinicaltrials.gov/study/NCT07057219", "diseases": ["Parkinson Disease"]}, {"lat": 32.77632, "lng": -79.93275, "nct": "NCT06994728", "color": "#3a5b18", "title": "Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait", "status": "RECRUITING", "phases": ["NA"], "interventions": "Left STN-DBS on, right STN-DBS off first; Right STN-DBS on, left STN-DBS off first", "sponsor": "Medical University of South Carolina", "address": "", "url": "https://clinicaltrials.gov/study/NCT06994728", "diseases": ["Parkinson Disease"]}, {"lat": 40.48622, "lng": -74.45182, "nct": "NCT04976959", "color": "#533535", "title": "High Fiber in Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "High Fiber supplement", "sponsor": "Rutgers, The State University of New Jersey", "address": "", "url": "https://clinicaltrials.gov/study/NCT04976959", "diseases": ["Parkinson Disease"]}, {"lat": -33.87939, "lng": 151.21925, "nct": "NCT06732180", "color": "#8b18ef", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "GT-02287", "sponsor": "Gain Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06732180", "diseases": ["Parkinson Disease"]}, {"lat": -33.9681, "lng": 151.13564, "nct": "NCT06732180", "color": "#8b18ef", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "GT-02287", "sponsor": "Gain Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06732180", "diseases": ["Parkinson Disease"]}, {"lat": -33.80383, "lng": 150.98768, "nct": "NCT06732180", "color": "#8b18ef", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "GT-02287", "sponsor": "Gain Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06732180", "diseases": ["Parkinson Disease"]}, {"lat": -27.48855, "lng": 153.03655, "nct": "NCT06732180", "color": "#8b18ef", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "GT-02287", "sponsor": "Gain Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06732180", "diseases": ["Parkinson Disease"]}, {"lat": -34.92866, "lng": 138.59863, "nct": "NCT06732180", "color": "#8b18ef", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "GT-02287", "sponsor": "Gain Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06732180", "diseases": ["Parkinson Disease"]}, {"lat": -37.814, "lng": 144.96332, "nct": "NCT06732180", "color": "#8b18ef", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "GT-02287", "sponsor": "Gain Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06732180", "diseases": ["Parkinson Disease"]}, {"lat": -37.78333, "lng": 144.95, "nct": "NCT06732180", "color": "#8b18ef", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "GT-02287", "sponsor": "Gain Therapeutics, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06732180", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT07028632", "color": "#a90763", "title": "The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["PHASE2"], "interventions": "Human Dopaminergic Progenitor Cells", "sponsor": "iRegene Therapeutics Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT07028632", "diseases": ["Parkinson Disease"]}, {"lat": 49.88307, "lng": -119.48568, "nct": "NCT06915987", "color": "#025973", "title": "Parkinson Disease and Exercise Snacks", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Exercise Intervention", "sponsor": "University of British Columbia", "address": "", "url": "https://clinicaltrials.gov/study/NCT06915987", "diseases": ["Parkinson Disease"]}, {"lat": 19.07283, "lng": 72.88261, "nct": "NCT06205043", "color": "#3e5228", "title": "Algorithm Guided DBS Programming in Parkinson's Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "StimSearch programming algorithm software; Clinician based programming", "sponsor": "Jaslok Hospital and Research Centre", "address": "", "url": "https://clinicaltrials.gov/study/NCT06205043", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT06377033", "color": "#8193f5", "title": "Using the EHR to Advance Genomic Medicine Across a Diverse Health System", "status": "RECRUITING", "phases": ["NA"], "interventions": "Behavioral nudge", "sponsor": "University of Pennsylvania", "address": "", "url": "https://clinicaltrials.gov/study/NCT06377033", "diseases": ["Parkinson Disease"]}, {"lat": 45.53558, "lng": 10.21472, "nct": "NCT06657274", "color": "#bc7983", "title": "EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069", "status": "RECRUITING", "phases": ["NA"], "interventions": "RICORDO-DTx; Home-based unstructured cognitive stimulation", "sponsor": "IRCCS Centro San Giovanni di Dio Fatebenefratelli", "address": "", "url": "https://clinicaltrials.gov/study/NCT06657274", "diseases": ["Parkinson Disease"]}, {"lat": 38.19394, "lng": 15.55256, "nct": "NCT06657274", "color": "#bc7983", "title": "EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069", "status": "RECRUITING", "phases": ["NA"], "interventions": "RICORDO-DTx; Home-based unstructured cognitive stimulation", "sponsor": "IRCCS Centro San Giovanni di Dio Fatebenefratelli", "address": "", "url": "https://clinicaltrials.gov/study/NCT06657274", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT06657274", "color": "#bc7983", "title": "EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069", "status": "RECRUITING", "phases": ["NA"], "interventions": "RICORDO-DTx; Home-based unstructured cognitive stimulation", "sponsor": "IRCCS Centro San Giovanni di Dio Fatebenefratelli", "address": "", "url": "https://clinicaltrials.gov/study/NCT06657274", "diseases": ["Parkinson Disease"]}, {"lat": 40.58526, "lng": -105.08442, "nct": "NCT06447207", "color": "#6462f3", "title": "Occupational Therapy Led Social Prescription for People With Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Occupational Therapy Led Social Prescription", "sponsor": "Colorado State University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06447207", "diseases": ["Parkinson Disease"]}, {"lat": 50.87959, "lng": 4.70093, "nct": "NCT06798844", "color": "#8ff43f", "title": "Spinal Cord Stimulation for Freezing of Gait in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Spinal Cord Stimulation; Spinal electrophysiological recordings", "sponsor": "Universitaire Ziekenhuizen KU Leuven", "address": "", "url": "https://clinicaltrials.gov/study/NCT06798844", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT05910008", "color": "#85f98c", "title": "O-ARM Stereotactic Imaging in Deep Brain Stimulation for Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "O-Arm Stereotactic imaging; Standard Stereotactic imaging", "sponsor": "University Hospital, Toulouse", "address": "", "url": "https://clinicaltrials.gov/study/NCT05910008", "diseases": ["Parkinson Disease"]}, {"lat": 46.20222, "lng": 6.14569, "nct": "NCT05220449", "color": "#f03e43", "title": "Re-Orchestration of Interregional Oscillatory Activity to Promote Visual Recovery", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Cross-frequency dual-site tACS", "sponsor": "Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne", "address": "", "url": "https://clinicaltrials.gov/study/NCT05220449", "diseases": ["Parkinson Disease"]}, {"lat": 26.06287, "lng": -80.2331, "nct": "NCT05266417", "color": "#a17c6a", "title": "Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "INS-GSH; Matched Placebos", "sponsor": "Gateway Institute for Brain Research", "address": "", "url": "https://clinicaltrials.gov/study/NCT05266417", "diseases": ["Parkinson Disease"]}, {"lat": 25.8576, "lng": -80.27811, "nct": "NCT05266417", "color": "#a17c6a", "title": "Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "INS-GSH; Matched Placebos", "sponsor": "Gateway Institute for Brain Research", "address": "", "url": "https://clinicaltrials.gov/study/NCT05266417", "diseases": ["Parkinson Disease"]}, {"lat": 44.64269, "lng": -63.57688, "nct": "NCT06572150", "color": "#5e9687", "title": "Minimal Electrophysiology and Imaging Enhanced Deep Brain Stimulation", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation - Minimal Electrophysiology; Deep Brain Stimulation - Standard", "sponsor": "Nova Scotia Health Authority", "address": "", "url": "https://clinicaltrials.gov/study/NCT06572150", "diseases": ["Parkinson Disease"]}, {"lat": 46.516, "lng": 6.63282, "nct": "NCT06791902", "color": "#a53836", "title": "Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in Parkinson's Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "Adaptive DBS", "sponsor": "Jocelyne Bloch", "address": "", "url": "https://clinicaltrials.gov/study/NCT06791902", "diseases": ["Parkinson Disease"]}, {"lat": 40.73566, "lng": -74.17237, "nct": "NCT04804202", "color": "#02a210", "title": "Virtual Cycling Environments for Persons With Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Bicycling with and without virtual reality", "sponsor": "Rutgers, The State University of New Jersey", "address": "", "url": "https://clinicaltrials.gov/study/NCT04804202", "diseases": ["Parkinson Disease"]}, {"lat": 40.78871, "lng": -73.59957, "nct": "NCT04804202", "color": "#02a210", "title": "Virtual Cycling Environments for Persons With Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Bicycling with and without virtual reality", "sponsor": "Rutgers, The State University of New Jersey", "address": "", "url": "https://clinicaltrials.gov/study/NCT04804202", "diseases": ["Parkinson Disease"]}, {"lat": 39.91987, "lng": 32.85427, "nct": "NCT05900934", "color": "#fc12cd", "title": "The Effects Of Myofascial Release In Combined With Task-Oriented Circuit Training On Balance And Gait In People With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Myofascial Releasing Group; Sham Myofascial Releasing Group", "sponsor": "Hacettepe University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05900934", "diseases": ["Parkinson Disease"]}, {"lat": 32.06167, "lng": 118.77778, "nct": "NCT05850598", "color": "#cfd1d7", "title": "Effect of rTMS of the Cerebellum on Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "sham rTMS; active rTMS", "sponsor": "Jiangsu Province Nanjing Brain Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT05850598", "diseases": ["Parkinson Disease"]}, {"lat": 40.42587, "lng": -86.90807, "nct": "NCT06638944", "color": "#ebc7d5", "title": "Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "In-person sEMG-biofeedback; Remote sEMG-biofeedback; Standard-of-care treatment", "sponsor": "Purdue University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06638944", "diseases": ["Parkinson Disease"]}, {"lat": 34.27834, "lng": -119.29317, "nct": "NCT06538298", "color": "#b6e079", "title": "Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "Multimodal Exercise Program with Gamification", "sponsor": "California State University, Northridge", "address": "", "url": "https://clinicaltrials.gov/study/NCT06538298", "diseases": ["Parkinson Disease"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT07095400", "color": "#fa5046", "title": "Evaluation of Functional and Biochemical Effectiveness of a Strength Training Protocol in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "strength training", "sponsor": "Universidad Villanueva", "address": "", "url": "https://clinicaltrials.gov/study/NCT07095400", "diseases": ["Parkinson Disease"]}, {"lat": 31.30408, "lng": 120.59538, "nct": "NCT06129942", "color": "#a3c4bc", "title": "Light Therapy in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Bright light box; Dim Light box", "sponsor": "Second Affiliated Hospital of Soochow University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06129942", "diseases": ["Parkinson Disease"]}, {"lat": 32.71571, "lng": -117.16472, "nct": "NCT04735627", "color": "#baaf5c", "title": "Real-Time Levodopa Level Monitoring in Parkinson Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Levodopameter", "sponsor": "University of California, San Diego", "address": "", "url": "https://clinicaltrials.gov/study/NCT04735627", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06991335", "color": "#fd2400", "title": "VC/VS for Apathy in PD", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Deep Brain Stimulation", "sponsor": "Nora Vanegas", "address": "", "url": "https://clinicaltrials.gov/study/NCT06991335", "diseases": ["Parkinson Disease"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT07138560", "color": "#1f6daa", "title": "BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "CREXONT ER", "sponsor": "The Cleveland Clinic", "address": "", "url": "https://clinicaltrials.gov/study/NCT07138560", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT05182892", "color": "#39bf26", "title": "REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis", "status": "RECRUITING", "phases": ["NA"], "interventions": "Change of stimulation amplitudes in dopaminergic OFF drug state", "sponsor": "Insel Gruppe AG, University Hospital Bern", "address": "", "url": "https://clinicaltrials.gov/study/NCT05182892", "diseases": ["Parkinson Disease"]}, {"lat": 46.94809, "lng": 7.44744, "nct": "NCT05182892", "color": "#39bf26", "title": "REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis", "status": "RECRUITING", "phases": ["NA"], "interventions": "Change of stimulation amplitudes in dopaminergic OFF drug state", "sponsor": "Insel Gruppe AG, University Hospital Bern", "address": "", "url": "https://clinicaltrials.gov/study/NCT05182892", "diseases": ["Parkinson Disease"]}, {"lat": 29.42412, "lng": -98.49363, "nct": "NCT06133283", "color": "#6f7002", "title": "Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "High intensity endurance exercise; Stretching exercise; Virtual reality (VR)-based gaming", "sponsor": "The University of Texas Health Science Center at San Antonio", "address": "", "url": "https://clinicaltrials.gov/study/NCT06133283", "diseases": ["Parkinson Disease"]}, {"lat": 34.27834, "lng": -119.29317, "nct": "NCT06647277", "color": "#e74c2d", "title": "Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["PHASE1"], "interventions": "Fecal Microbiota Transplant", "sponsor": "ProgenaBiome", "address": "", "url": "https://clinicaltrials.gov/study/NCT06647277", "diseases": ["Parkinson Disease"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT07001072", "color": "#bd20ab", "title": "Smartshoes for Freezing of Gait in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Smartshoes with haptic vibration feedback", "sponsor": "Stanford University", "address": "", "url": "https://clinicaltrials.gov/study/NCT07001072", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT06909045", "color": "#f2cf63", "title": "Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Adaptive DBS; Continue DBS", "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06909045", "diseases": ["Parkinson Disease"]}, {"lat": 50.84833, "lng": 5.68889, "nct": "NCT06909045", "color": "#f2cf63", "title": "Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Adaptive DBS; Continue DBS", "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06909045", "diseases": ["Parkinson Disease"]}, {"lat": 52.07667, "lng": 4.29861, "nct": "NCT06909045", "color": "#f2cf63", "title": "Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Adaptive DBS; Continue DBS", "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06909045", "diseases": ["Parkinson Disease"]}, {"lat": 50.08804, "lng": 14.42076, "nct": "NCT06942533", "color": "#2cbfa6", "title": "Effect of Visual Feedback From the SpiroGym Mobile Application", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "EMST with SpiroGym app; EMST without SpiroGym app", "sponsor": "General University Hospital, Prague", "address": "", "url": "https://clinicaltrials.gov/study/NCT06942533", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT07022522", "color": "#0b01c2", "title": "Impact of Frequency-specific Subthalamic Nucleus Subregion Stimulation on Inhibitory Control in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "5Hz stimulation on the STN motor subregion; 5Hz stimulation on the STN associative subregion; 130Hz stimulation on the STN motor subregion; 130Hz stimulation on the STN associative subregion; No stimulation", "sponsor": "Beijing Tiantan Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT07022522", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT06090292", "color": "#5b763e", "title": "Effects of Peripheral Electrical Stimulation With Focused Ultrasound on Motor Symptoms in Parkinson's Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "Real TUS; Real FES; Sham TUS; Sham FES", "sponsor": "University Health Network, Toronto", "address": "", "url": "https://clinicaltrials.gov/study/NCT06090292", "diseases": ["Parkinson Disease"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT06167681", "color": "#ef1a4b", "title": "The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Human Dopaminergic Progenitor Cells", "sponsor": "iRegene Therapeutics Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06167681", "diseases": ["Parkinson Disease"]}, {"lat": 30.58333, "lng": 114.26667, "nct": "NCT06167681", "color": "#ef1a4b", "title": "The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Human Dopaminergic Progenitor Cells", "sponsor": "iRegene Therapeutics Co., Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06167681", "diseases": ["Parkinson Disease"]}, {"lat": 39.47391, "lng": -0.37966, "nct": "NCT04788693", "color": "#559ede", "title": "Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Physical rehabilitation of gait with motor imagery; Physical rehabilitation of gait without motor imagery", "sponsor": "University of Valencia", "address": "", "url": "https://clinicaltrials.gov/study/NCT04788693", "diseases": ["Parkinson Disease"]}, {"lat": 41.01384, "lng": 28.94966, "nct": "NCT06490809", "color": "#5de9d7", "title": "Minimal Clinically Important Difference of the Box and Block Test in Parkinson", "status": "RECRUITING", "phases": ["NA"], "interventions": "Physiotherapy", "sponsor": "Emre \u015eenocak", "address": "", "url": "https://clinicaltrials.gov/study/NCT06490809", "diseases": ["Parkinson Disease"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT07151378", "color": "#5a416d", "title": "Intestinal Levodopa + Entacapone Therapy (Lecigon\u00ae) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["PHASE3"], "interventions": "LECIG (levodopa, carbidopa, entacapone intestinal gel); Best oral medication", "sponsor": "University Hospital Tuebingen", "address": "", "url": "https://clinicaltrials.gov/study/NCT07151378", "diseases": ["Parkinson Disease"]}, {"lat": 60.45148, "lng": 22.26869, "nct": "NCT06659562", "color": "#ce8af5", "title": "Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "HER-096; Placebo", "sponsor": "Herantis Pharma Plc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06659562", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 28.62778, "lng": -81.36312, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 29.1872, "lng": -82.14009, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 28.53834, "lng": -81.37924, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 26.97617, "lng": -82.09064, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 29.13832, "lng": -80.99561, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 37.98869, "lng": -84.47772, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 40.38927, "lng": -74.76183, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 40.84288, "lng": -73.29289, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 35.7721, "lng": -78.63861, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 39.12711, "lng": -84.51439, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 36.15398, "lng": -95.99277, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 35.14953, "lng": -90.04898, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 29.96911, "lng": -95.69717, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 30.63269, "lng": -97.67723, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 38.84622, "lng": -77.30637, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 38.88233, "lng": -77.17109, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 37.55376, "lng": -77.46026, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 43.0389, "lng": -87.90647, "nct": "NCT06553027", "color": "#020e9d", "title": "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "CVN424 75 mg; CVN424 150 mg; Placebo", "sponsor": "Cerevance", "address": "", "url": "https://clinicaltrials.gov/study/NCT06553027", "diseases": ["Parkinson Disease"]}, {"lat": 31.86389, "lng": 117.28083, "nct": "NCT06607653", "color": "#52c269", "title": "The Efficacy of Olfactory Training Intervention on Olfactory and Other Non-motor Symptoms in PD", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Olfactory training", "sponsor": "Anhui Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06607653", "diseases": ["Parkinson Disease"]}, {"lat": 34.25833, "lng": 108.92861, "nct": "NCT06390761", "color": "#4f73a7", "title": "Efficacy of Acupuncture for the Treatment of Parkinson's Disease Related Constipation", "status": "RECRUITING", "phases": ["NA"], "interventions": "Acupuncture", "sponsor": "Xi'an No.3 Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06390761", "diseases": ["Parkinson Disease"]}, {"lat": 49.9, "lng": 2.3, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 45.17869, "lng": 5.71479, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 45.74846, "lng": 4.84671, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 43.29695, "lng": 5.38107, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 48.68439, "lng": 6.18496, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 43.70313, "lng": 7.26608, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 49.44313, "lng": 1.09932, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 48.58392, "lng": 7.74553, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT04884412", "color": "#bf1ebd", "title": "Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure", "status": "ACTIVE_NOT_RECRUITING", "phases": ["NA"], "interventions": "Surgery under general anesthesia with experimental targeting; Usual Surgery", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04884412", "diseases": ["Parkinson Disease"]}, {"lat": 43.70643, "lng": -79.39864, "nct": "NCT05402163", "color": "#2e4792", "title": "CANadian Adaptive DBS TriAl", "status": "RECRUITING", "phases": ["NA"], "interventions": "Adaptive DBS; Continuous DBS", "sponsor": "University of Toronto", "address": "", "url": "https://clinicaltrials.gov/study/NCT05402163", "diseases": ["Parkinson Disease"]}, {"lat": 37.566, "lng": 126.9784, "nct": "NCT06324448", "color": "#c963f2", "title": "Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD", "status": "RECRUITING", "phases": ["NA"], "interventions": "Transcranial direct current stimulation", "sponsor": "Seoul National University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06324448", "diseases": ["Parkinson Disease"]}, {"lat": 55.13333, "lng": -6.66667, "nct": "NCT06697626", "color": "#2ba79e", "title": "Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Inulin, B-vitamins and vitamin D; Placebo group", "sponsor": "University of Ulster", "address": "", "url": "https://clinicaltrials.gov/study/NCT06697626", "diseases": ["Parkinson Disease"]}, {"lat": 22.27832, "lng": 114.17469, "nct": "NCT05524961", "color": "#14134f", "title": "Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Bright light therapy; Inactivated negative ion generator", "sponsor": "Chinese University of Hong Kong", "address": "", "url": "https://clinicaltrials.gov/study/NCT05524961", "diseases": ["Parkinson Disease"]}, {"lat": 41.80843, "lng": -72.24952, "nct": "NCT07115563", "color": "#b651a1", "title": "Daily Amino Acid Supplementation for People With Parkinson's Disease", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Targeted Amino Acid Supplement; Control (placebo)", "sponsor": "Cristina Colon-Semenza", "address": "", "url": "https://clinicaltrials.gov/study/NCT07115563", "diseases": ["Parkinson Disease"]}, {"lat": 32.22174, "lng": -110.92648, "nct": "NCT06263010", "color": "#12bb14", "title": "Allopregnanolone As a Regenerative Treatment for Parkinson's Disease", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "Allopregnanolone", "sponsor": "Roberta Brinton", "address": "", "url": "https://clinicaltrials.gov/study/NCT06263010", "diseases": ["Parkinson Disease"]}, {"lat": 39.91987, "lng": 32.85427, "nct": "NCT06017336", "color": "#57adb3", "title": "Effects of Inspiratory Muscle Training in Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Inspiratory Muscle Training Group; Control Group (breathing exercises)", "sponsor": "Gazi University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06017336", "diseases": ["Parkinson Disease"]}, {"lat": 24.9896, "lng": 121.3187, "nct": "NCT06367101", "color": "#e07d5e", "title": "AR Stimulation Effects on Gait, Anxiety, and Brain Connectivity in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "AR training with gait and HRV feedback", "sponsor": "Chang Gung University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06367101", "diseases": ["Parkinson Disease"]}, {"lat": 40.78871, "lng": -73.59957, "nct": "NCT05884944", "color": "#8c60ad", "title": "Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients", "status": "RECRUITING", "phases": ["NA"], "interventions": "Sham- Light touch, not reaching restrictive barrier; Experimental: Interventional Group- OMM- Muscle energy", "sponsor": "New York Institute of Technology", "address": "", "url": "https://clinicaltrials.gov/study/NCT05884944", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT06618157", "color": "#7a30f1", "title": "Connectomic Guided DBS for Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Cerebellothalamic optimized deep brain stimulation; Pallidothalamic optimized deep brain stimulation; No deep brain stimulation; Usual care deep brain stimulation", "sponsor": "Duke University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06618157", "diseases": ["Parkinson Disease"]}, {"lat": 33.52066, "lng": -86.80249, "nct": "NCT06289582", "color": "#d4de56", "title": "Longitudinal TSPO PET Imaging with [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "[F-18]DPA714 administration IV", "sponsor": "University of Alabama at Birmingham", "address": "", "url": "https://clinicaltrials.gov/study/NCT06289582", "diseases": ["Parkinson Disease"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT06008704", "color": "#fad364", "title": "Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Clinical assessment; Pain characteristics assessment; MRI; Thermotest; UPDRS-III Scale; [18F]-MPPF PET scan", "sponsor": "University Hospital, Toulouse", "address": "", "url": "https://clinicaltrials.gov/study/NCT06008704", "diseases": ["Parkinson Disease"]}, {"lat": 33.66946, "lng": -117.82311, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 34.04835, "lng": -117.26115, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 38.89511, "lng": -77.03637, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 26.97617, "lng": -82.09064, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 42.73698, "lng": -84.48387, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 36.17497, "lng": -115.13722, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 35.9132, "lng": -79.05584, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 43.07305, "lng": -89.40123, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 52.52437, "lng": 13.41053, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 50.80904, "lng": 8.77069, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 49.79391, "lng": 9.95121, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 54.35227, "lng": 18.64912, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 50.25841, "lng": 19.02754, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 52.22977, "lng": 21.01178, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 51.45523, "lng": -2.59665, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 51.48, "lng": -3.18, "nct": "NCT06285643", "color": "#838eb8", "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "AAV2-GDNF Gene therapy; Control Surgery", "sponsor": "AskBio Inc", "address": "", "url": "https://clinicaltrials.gov/study/NCT06285643", "diseases": ["Parkinson Disease"]}, {"lat": 37.566, "lng": 126.9784, "nct": "NCT02018406", "color": "#ffb55e", "title": "Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "Combination injection of EPO and G-CSF; Injection of normal saline", "sponsor": "Yonsei University", "address": "", "url": "https://clinicaltrials.gov/study/NCT02018406", "diseases": ["Parkinson Disease"]}, {"lat": 25.06199, "lng": 121.45703, "nct": "NCT07143006", "color": "#f44a41", "title": "Application of Smart Electric Vehicles in Analyzing Gait Abnormalities in Patients With Neurodegenerative Diseases", "status": "RECRUITING", "phases": ["NA"], "interventions": "BestShape Go Intelligent Generation Transformable Electric Vehicle", "sponsor": "Taipei Medical University Shuang Ho Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT07143006", "diseases": ["Parkinson Disease"]}, {"lat": 33.70918, "lng": -117.95367, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 37.33939, "lng": -121.89496, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 34.19731, "lng": -118.64398, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 25.95648, "lng": -80.13921, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 25.72149, "lng": -80.26838, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 26.27119, "lng": -80.2706, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 25.5783, "lng": -80.3377, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 29.21081, "lng": -81.02283, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 25.81954, "lng": -80.35533, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 30.33218, "lng": -81.65565, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 28.62778, "lng": -81.36312, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 28.6, "lng": -81.33924, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 43.57814, "lng": -70.32172, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 40.12067, "lng": -75.11795, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 35.14953, "lng": -90.04898, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 29.96911, "lng": -95.69717, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 30.50826, "lng": -97.6789, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT06822517", "color": "#905d0c", "title": "A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "VENT-02; Placebo", "sponsor": "Ventus Therapeutics U.S., Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06822517", "diseases": ["Parkinson Disease"]}, {"lat": 48.11198, "lng": -1.67429, "nct": "NCT05822258", "color": "#d05fb4", "title": "DetectFoG : Detection of Gait Freezing Episodes in Parkinsonian Patients Using Inertial Measurement Units", "status": "RECRUITING", "phases": ["NA"], "interventions": "Walk under 3 conditions (normal, physical tasks, verbal tasks)", "sponsor": "Rennes University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT05822258", "diseases": ["Parkinson Disease"]}, {"lat": 45.82058, "lng": 8.82511, "nct": "NCT06705517", "color": "#c3d1a8", "title": "Mediterranean Diet Effects on Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Mediterranean Diet", "sponsor": "Universit\u00e0 degli Studi dell'Insubria", "address": "", "url": "https://clinicaltrials.gov/study/NCT06705517", "diseases": ["Parkinson Disease"]}, {"lat": 48.11198, "lng": -1.67429, "nct": "NCT05808504", "color": "#977325", "title": "Investigation of the Benefits of Electrical Non-invasive Stimulation on Cognitive Symptoms in Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Neuropsychological assessment; Neurological assessment; Cognitive task; EEG; tACS (real or sham)", "sponsor": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", "address": "", "url": "https://clinicaltrials.gov/study/NCT05808504", "diseases": ["Parkinson Disease"]}, {"lat": 25.07777, "lng": 121.39348, "nct": "NCT06248073", "color": "#3f8f3b", "title": "Effectiveness of Online Program and Task-related Training for Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "on-line self-management training; onsite task-related training", "sponsor": "Chang Gung University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06248073", "diseases": ["Parkinson Disease"]}, {"lat": 51.8425, "lng": 5.85278, "nct": "NCT04848077", "color": "#b355a8", "title": "STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Step count increase with the use of a motivational smartphone application", "sponsor": "Radboud University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT04848077", "diseases": ["Parkinson Disease"]}, {"lat": 32.06167, "lng": 118.77778, "nct": "NCT06409338", "color": "#73180d", "title": "Research on the Brain Mechanism of taVNS in Regulating PD Motor Symptoms", "status": "RECRUITING", "phases": ["NA"], "interventions": "Transcutaneous auricular vagus nerve stimulation (active\uff09; Transcutaneous auricular vagus nerve stimulation (sham\uff09", "sponsor": "The First Affiliated Hospital with Nanjing Medical University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06409338", "diseases": ["Parkinson Disease"]}, {"lat": -32.88946, "lng": -68.84582, "nct": "NCT06629389", "color": "#e71032", "title": "Clinical Trial with Cannabidiol (Kanbis\u00ae) for Parkinson Disease Symptoms", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Cannabidiol 100 mg/ml; cannabidiol 300 mg/ml; Cannabidiol 400 mg/ml; Placebo", "sponsor": "Laboratorio Elea Phoenix S.A.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06629389", "diseases": ["Parkinson Disease"]}, {"lat": 45.52345, "lng": -122.67621, "nct": "NCT05680597", "color": "#835ca7", "title": "Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "Balance Tele-Rehabilitation Agility Boot Camp (ABC)", "sponsor": "Oregon Health and Science University", "address": "", "url": "https://clinicaltrials.gov/study/NCT05680597", "diseases": ["Parkinson Disease"]}, {"lat": 30.43826, "lng": -84.28073, "nct": "NCT06593860", "color": "#a1a3ab", "title": "Dysarthria Management for Minor Groups", "status": "RECRUITING", "phases": ["NA"], "interventions": "Remote speech rehabilitation", "sponsor": "Florida State University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06593860", "diseases": ["Parkinson Disease"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT05065151", "color": "#f782e5", "title": "Understanding Motivation in Parkinson's Patients Through Neurophysiology", "status": "RECRUITING", "phases": ["NA"], "interventions": "Stimulation on; Stimulation off; Decision Making Task", "sponsor": "University of California, San Francisco", "address": "", "url": "https://clinicaltrials.gov/study/NCT05065151", "diseases": ["Parkinson Disease"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT04681534", "color": "#53f2b7", "title": "Safety and Efficacy of Adaptive Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "AlphaDBS System", "sponsor": "Newronika", "address": "", "url": "https://clinicaltrials.gov/study/NCT04681534", "diseases": ["Parkinson Disease"]}, {"lat": 45.40797, "lng": 11.88586, "nct": "NCT04681534", "color": "#53f2b7", "title": "Safety and Efficacy of Adaptive Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "AlphaDBS System", "sponsor": "Newronika", "address": "", "url": "https://clinicaltrials.gov/study/NCT04681534", "diseases": ["Parkinson Disease"]}, {"lat": 41.89193, "lng": 12.51133, "nct": "NCT04681534", "color": "#53f2b7", "title": "Safety and Efficacy of Adaptive Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "AlphaDBS System", "sponsor": "Newronika", "address": "", "url": "https://clinicaltrials.gov/study/NCT04681534", "diseases": ["Parkinson Disease"]}, {"lat": 45.07049, "lng": 7.68682, "nct": "NCT04681534", "color": "#53f2b7", "title": "Safety and Efficacy of Adaptive Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "AlphaDBS System", "sponsor": "Newronika", "address": "", "url": "https://clinicaltrials.gov/study/NCT04681534", "diseases": ["Parkinson Disease"]}, {"lat": 50.84833, "lng": 5.68889, "nct": "NCT04681534", "color": "#53f2b7", "title": "Safety and Efficacy of Adaptive Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "AlphaDBS System", "sponsor": "Newronika", "address": "", "url": "https://clinicaltrials.gov/study/NCT04681534", "diseases": ["Parkinson Disease"]}, {"lat": 54.35227, "lng": 18.64912, "nct": "NCT04681534", "color": "#53f2b7", "title": "Safety and Efficacy of Adaptive Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "AlphaDBS System", "sponsor": "Newronika", "address": "", "url": "https://clinicaltrials.gov/study/NCT04681534", "diseases": ["Parkinson Disease"]}, {"lat": 52.22977, "lng": 21.01178, "nct": "NCT04681534", "color": "#53f2b7", "title": "Safety and Efficacy of Adaptive Deep Brain Stimulation", "status": "RECRUITING", "phases": ["NA"], "interventions": "AlphaDBS System", "sponsor": "Newronika", "address": "", "url": "https://clinicaltrials.gov/study/NCT04681534", "diseases": ["Parkinson Disease"]}, {"lat": 52.37403, "lng": 4.88969, "nct": "NCT06223399", "color": "#095914", "title": "DBS Imaging-based vs. Threshold Assessment-based Programming", "status": "RECRUITING", "phases": ["NA"], "interventions": "Imaging-based programming; Threshold assessment-based programming", "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", "address": "", "url": "https://clinicaltrials.gov/study/NCT06223399", "diseases": ["Parkinson Disease"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT06236230", "color": "#1a6805", "title": "Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "levodopa/carbidopa/entacapone", "sponsor": "Second Affiliated Hospital of Soochow University", "address": "", "url": "https://clinicaltrials.gov/study/NCT06236230", "diseases": ["Parkinson Disease"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT05357612", "color": "#ea528a", "title": "Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases", "status": "RECRUITING", "phases": ["PHASE4"], "interventions": "Pimavanserin", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT05357612", "diseases": ["Parkinson Disease"]}, {"lat": 40.67545, "lng": 14.79328, "nct": "NCT06821256", "color": "#12707e", "title": "Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant", "status": "RECRUITING", "phases": ["NA"], "interventions": "Anodal transcranial direct current stimulation (a-tDCS); Sham stimulation", "sponsor": "University of Salerno", "address": "", "url": "https://clinicaltrials.gov/study/NCT06821256", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT03042988", "color": "#f0ded7", "title": "Overnight Trials with Heat Stress in Autonomic Failure Patients with Supine Hypertension", "status": "RECRUITING", "phases": ["NA"], "interventions": "Heating pad; Sham control", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT03042988", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.98869, "lng": -84.47772, "nct": "NCT06683365", "color": "#6542b0", "title": "Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Sural Nerve Graft to the Substantia Nigra; Sham surgery", "sponsor": "Craig van Horne, MD, PhD", "address": "", "url": "https://clinicaltrials.gov/study/NCT06683365", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.26266, "lng": 11.39454, "nct": "NCT06072105", "color": "#849a48", "title": "Medical Decision Making in Multiple System Atrophy", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telemedicine visits; Multidisciplinary, personalized symptomatic treatment", "sponsor": "Medical University Innsbruck", "address": "", "url": "https://clinicaltrials.gov/study/NCT06072105", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.70918, "lng": -117.95367, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.30815, "lng": -72.92816, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 30.33218, "lng": -81.65565, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 25.77427, "lng": -80.19366, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.27756, "lng": -83.74088, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.25626, "lng": -95.94043, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.12711, "lng": -84.51439, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.28592, "lng": -76.65025, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.55376, "lng": -77.46026, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.68149, "lng": -122.20874, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.60621, "lng": -122.33207, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.038, "lng": 136.99931, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.26667, "lng": 140.86667, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 34.78244, "lng": 135.46932, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.67452, "lng": 139.48216, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.02107, "lng": 135.75385, "nct": "NCT05923866", "color": "#192075", "title": "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "ONO-2808; Placebo", "sponsor": "Ono Pharmaceutical Co. Ltd", "address": "", "url": "https://clinicaltrials.gov/study/NCT05923866", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT02726711", "color": "#5fe124", "title": "Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "Trimethaphan; Placebo", "sponsor": "Vanderbilt University", "address": "", "url": "https://clinicaltrials.gov/study/NCT02726711", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT06174948", "color": "#f43c26", "title": "The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders", "status": "RECRUITING", "phases": ["NA"], "interventions": "CUE1 non-invasive device; CUE1+ device active vs sham CUE1+ device", "sponsor": "Queen Mary University of London", "address": "", "url": "https://clinicaltrials.gov/study/NCT06174948", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.75222, "lng": -1.25596, "nct": "NCT05197816", "color": "#b7e49f", "title": "MotIoN aDaptive Deep Brain Stimulation for MSA", "status": "RECRUITING", "phases": ["NA"], "interventions": "Deep brain stimulation", "sponsor": "University of Oxford", "address": "", "url": "https://clinicaltrials.gov/study/NCT05197816", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 34.74648, "lng": -92.28959, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.39093, "lng": -72.85954, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.76838, "lng": -86.15804, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.25626, "lng": -95.94043, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.4995, "lng": -81.69541, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.44062, "lng": -79.99589, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": -33.91938, "lng": 150.92588, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": -33.80383, "lng": 150.98768, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": -27.96724, "lng": 153.39796, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": -37.814, "lng": 144.96332, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.63297, "lng": 3.05858, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.61093, "lng": 3.87635, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 52.25965, "lng": 12.92662, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 49.59099, "lng": 11.00783, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.16196, "lng": 12.17942, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.52266, "lng": 9.05222, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.49381, "lng": 11.33875, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.70853, "lng": 10.4036, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.67545, "lng": 14.79328, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.42291, "lng": 136.76039, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.06667, "lng": 141.35, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.26667, "lng": 140.86667, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.92259, "lng": 139.04125, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.6895, "lng": 139.69171, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.566, "lng": 126.9784, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.47391, "lng": -0.37966, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 53.48771, "lng": -2.29042, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 55.86515, "lng": -4.25763, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 54.97328, "lng": -1.61396, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT06706622", "color": "#c7de68", "title": "A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)", "status": "RECRUITING", "phases": ["PHASE3"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT06706622", "diseases": ["Multiple System Atrophy"]}, {"lat": 46.516, "lng": 6.63282, "nct": "NCT06920134", "color": "#d93152", "title": "Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease", "status": "RECRUITING", "phases": ["NA"], "interventions": "ARC-IM Investigational System", "sponsor": "Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne", "address": "", "url": "https://clinicaltrials.gov/study/NCT06920134", "diseases": ["Multiple System Atrophy"]}, {"lat": 59.36004, "lng": 18.00086, "nct": "NCT06891703", "color": "#bfc0a7", "title": "[18F]ACI-15916 PET in \u03b1-synucleinopathies", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "[18F]ACI-15916", "sponsor": "AC Immune SA", "address": "", "url": "https://clinicaltrials.gov/study/NCT06891703", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT05167721", "color": "#2c0648", "title": "Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Autologous Mesenchymal Stem Cells; Placebo", "sponsor": "Mayo Clinic", "address": "", "url": "https://clinicaltrials.gov/study/NCT05167721", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.70918, "lng": -117.95367, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.84727, "lng": -117.2742, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.77493, "lng": -122.41942, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.64777, "lng": -104.98776, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 29.65163, "lng": -82.32483, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.06975, "lng": -87.78784, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.25626, "lng": -95.94043, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.28592, "lng": -76.65025, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.95238, "lng": -75.16362, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.44062, "lng": -79.99589, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.038, "lng": 136.99931, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.42291, "lng": 136.76039, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.26667, "lng": 140.86667, "nct": "NCT05104476", "color": "#41c2c7", "title": "A Study of Lu AF82422 in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE2"], "interventions": "Lu AF82422; Placebo", "sponsor": "H. Lundbeck A/S", "address": "", "url": "https://clinicaltrials.gov/study/NCT05104476", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT03482297", "color": "#730f78", "title": "Automated Abdominal Binder for Orthostatic Hypotension", "status": "RECRUITING", "phases": ["PHASE1", "PHASE2"], "interventions": "automated abdominal binder; Sham binder; Placebo; Midodrine", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT03482297", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.84727, "lng": -117.2742, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.89511, "lng": -77.03637, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.99403, "lng": -78.89862, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.28592, "lng": -76.65025, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.44062, "lng": -79.99589, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.80484, "lng": -77.04692, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.65966, "lng": -117.42908, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.29695, "lng": 5.38107, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.83732, "lng": 2.35823, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 52.25965, "lng": 12.92662, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.05089, "lng": 13.73832, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.22172, "lng": 6.77616, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.31667, "lng": 9.5, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.33962, "lng": 12.37129, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.80904, "lng": 8.77069, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.60698, "lng": 13.31243, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.96236, "lng": 7.62571, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.39841, "lng": 9.99155, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.81303, "lng": 34.99928, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.08088, "lng": 34.78057, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.49381, "lng": 11.33875, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.49223, "lng": 15.07041, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.78235, "lng": 12.59836, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 45.40797, "lng": 11.88586, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.99364, "lng": 11.10642, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.67545, "lng": 14.79328, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.67452, "lng": 139.48216, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.42291, "lng": 136.76039, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.92259, "lng": 139.04125, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.56707, "lng": 139.24167, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.26667, "lng": 140.86667, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.38879, "lng": 2.15899, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.81687, "lng": -1.64323, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.38283, "lng": -5.97317, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.47391, "lng": -0.37966, "nct": "NCT06568237", "color": "#7c3043", "title": "A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "TEV-56286; Placebo", "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06568237", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.66946, "lng": -117.82311, "nct": "NCT04680065", "color": "#b65bd2", "title": "GDNF Gene Therapy for Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "AAV2-GDNF gene therapy; Sham (Placebo) Surgery", "sponsor": "Brain Neurotherapy Bio, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04680065", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT04680065", "color": "#b65bd2", "title": "GDNF Gene Therapy for Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "AAV2-GDNF gene therapy; Sham (Placebo) Surgery", "sponsor": "Brain Neurotherapy Bio, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04680065", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT04680065", "color": "#b65bd2", "title": "GDNF Gene Therapy for Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "AAV2-GDNF gene therapy; Sham (Placebo) Surgery", "sponsor": "Brain Neurotherapy Bio, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04680065", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT04680065", "color": "#b65bd2", "title": "GDNF Gene Therapy for Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "AAV2-GDNF gene therapy; Sham (Placebo) Surgery", "sponsor": "Brain Neurotherapy Bio, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04680065", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT04680065", "color": "#b65bd2", "title": "GDNF Gene Therapy for Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "AAV2-GDNF gene therapy; Sham (Placebo) Surgery", "sponsor": "Brain Neurotherapy Bio, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04680065", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.96118, "lng": -82.99879, "nct": "NCT04680065", "color": "#b65bd2", "title": "GDNF Gene Therapy for Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "AAV2-GDNF gene therapy; Sham (Placebo) Surgery", "sponsor": "Brain Neurotherapy Bio, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04680065", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT04680065", "color": "#b65bd2", "title": "GDNF Gene Therapy for Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "AAV2-GDNF gene therapy; Sham (Placebo) Surgery", "sponsor": "Brain Neurotherapy Bio, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04680065", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.50921, "lng": -111.89903, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.70918, "lng": -117.95367, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.84727, "lng": -117.2742, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.44188, "lng": -122.14302, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.89511, "lng": -77.03637, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.35869, "lng": -80.0831, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.14234, "lng": -81.79596, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 26.97617, "lng": -82.09064, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 27.94752, "lng": -82.45843, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 33.749, "lng": -84.38798, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 21.30694, "lng": -157.85833, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.85003, "lng": -87.65005, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.06975, "lng": -87.78784, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.11417, "lng": -94.62746, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.26259, "lng": -71.80229, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.48531, "lng": -83.37716, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.12711, "lng": -84.51439, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.78306, "lng": -96.80667, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.76078, "lng": -111.89105, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -32.88946, "lng": -68.84582, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -37.91667, "lng": 145.11667, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -37.814, "lng": 144.96332, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -37.78333, "lng": 144.95, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.26266, "lng": 11.39454, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.32829, "lng": 16.05858, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -25.42778, "lng": -49.27306, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -19.92083, "lng": -43.93778, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -30.03283, "lng": -51.23019, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.05011, "lng": -114.08529, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 55.67594, "lng": 12.56553, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 59.43696, "lng": 24.75353, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 58.38062, "lng": 26.72509, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.83665, "lng": 4.35788, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.88029, "lng": 12.08187, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 52.52437, "lng": 13.41053, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.49835, "lng": 19.04045, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.08088, "lng": 34.78057, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.49381, "lng": 11.33875, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.78235, "lng": 12.59836, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.89193, "lng": 12.51133, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.67545, "lng": 14.79328, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.56335, "lng": 12.64329, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 46.06787, "lng": 11.12108, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.93018, "lng": 18.35421, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -36.86029, "lng": 174.76566, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": -43.53333, "lng": 172.63333, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 54.35227, "lng": 18.64912, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.25841, "lng": 19.02754, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.06143, "lng": 19.93658, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.03437, "lng": 19.21037, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.09109, "lng": -9.2586, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.80401, "lng": 20.46513, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.56667, "lng": 2.01667, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.29639, "lng": -2.98813, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.4165, "lng": -3.70256, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 25.05306, "lng": 121.52639, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 52.48142, "lng": -1.89983, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 53.48771, "lng": -2.29042, "nct": "NCT05696717", "color": "#0ab456", "title": "Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE3"], "interventions": "Ampreloxetine; Placebo", "sponsor": "Theravance Biopharma", "address": "", "url": "https://clinicaltrials.gov/study/NCT05696717", "diseases": ["Multiple System Atrophy"]}, {"lat": 32.08088, "lng": 34.78057, "nct": "NCT05698017", "color": "#977e8d", "title": "Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)", "status": "ACTIVE_NOT_RECRUITING", "phases": ["PHASE1"], "interventions": "hOMSC300", "sponsor": "Cytora Ltd.", "address": "", "url": "https://clinicaltrials.gov/study/NCT05698017", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.84044, "lng": -0.5805, "nct": "NCT04250493", "color": "#cc7f36", "title": "Insulin Resistance in Multiple System Atrophy", "status": "RECRUITING", "phases": ["NA"], "interventions": "Homeostasis Model Assessment of insulin resistance (HOMA); MOntreal Cognitive Assessment (MoCA); Clinical characteristics of AMS patients; Brain Magnetic Resonance Imaging (MRI); Blood sampling", "sponsor": "University Hospital, Bordeaux", "address": "", "url": "https://clinicaltrials.gov/study/NCT04250493", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT04782830", "color": "#c469f9", "title": "Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms", "status": "RECRUITING", "phases": ["NA"], "interventions": "Accelerometer; placebo pill; Midodrine or atomoxetine pill", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT04782830", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT02429557", "color": "#b9cbf8", "title": "Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Abdominal compression; Sham abdominal compression; Placebo pill; midodrine", "sponsor": "Vanderbilt University Medical Center", "address": "", "url": "https://clinicaltrials.gov/study/NCT02429557", "diseases": ["Multiple System Atrophy"]}, {"lat": 49.24966, "lng": -123.11934, "nct": "NCT06838637", "color": "#7bd798", "title": "Transcutaneous Spinal Cord Stimulation Home Study", "status": "RECRUITING", "phases": ["NA"], "interventions": "Spinal COrd NEuromodulation (\"SCONE\") Device", "sponsor": "Michael Berger", "address": "", "url": "https://clinicaltrials.gov/study/NCT06838637", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.37787, "lng": -71.062, "nct": "NCT06098612", "color": "#e9e57c", "title": "PET Imaging Evaluation of [11C]SY08", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "C11-SY08", "sponsor": "Massachusetts General Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06098612", "diseases": ["Multiple System Atrophy"]}, {"lat": 37.566, "lng": 126.9784, "nct": "NCT04782284", "color": "#e7b7b0", "title": "Comprehensive Swallowing Rehabilitation in Patients With MSA", "status": "RECRUITING", "phases": ["NA"], "interventions": "Comprehensive swallowing rehabilitation; Swallowing education", "sponsor": "Seoul National University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT04782284", "diseases": ["Multiple System Atrophy"]}, {"lat": 34.05223, "lng": -118.24368, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 44.02163, "lng": -92.4699, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 40.71427, "lng": -74.00597, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 36.16589, "lng": -86.78444, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 29.76328, "lng": -95.36327, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 35.6895, "lng": 139.69171, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 25.05306, "lng": 121.52639, "nct": "NCT06848231", "color": "#bed2ec", "title": "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "YA-101; Placebo", "sponsor": "Yoda Therapeutics Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT06848231", "diseases": ["Multiple System Atrophy"]}, {"lat": 39.9075, "lng": 116.39723, "nct": "NCT06765733", "color": "#47c5bb", "title": "The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy", "status": "RECRUITING", "phases": ["EARLY_PHASE1"], "interventions": "Aleeto", "sponsor": "Beijing Tiantan Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06765733", "diseases": ["Multiple System Atrophy"]}, {"lat": 42.35843, "lng": -71.05977, "nct": "NCT06868628", "color": "#3e036e", "title": "A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)", "status": "NOT_YET_RECRUITING", "phases": ["PHASE2"], "interventions": "Foralumab Nasal", "sponsor": "Brigham and Women's Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06868628", "diseases": ["Multiple System Atrophy"]}, {"lat": 47.26266, "lng": 11.39454, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 45.74846, "lng": 4.84671, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.85341, "lng": 2.3488, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 48.39841, "lng": 9.99155, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.22172, "lng": 6.77616, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 52.37052, "lng": 9.73322, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.80904, "lng": 8.77069, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.60698, "lng": 13.31243, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.83091, "lng": -9.16845, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.50853, "lng": -0.12574, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 51.75222, "lng": -1.25596, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 53.48771, "lng": -2.29042, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 50.90395, "lng": -1.40428, "nct": "NCT04165486", "color": "#7deb26", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "ION464; Placebo", "sponsor": "Ionis Pharmaceuticals, Inc.", "address": "", "url": "https://clinicaltrials.gov/study/NCT04165486", "diseases": ["Multiple System Atrophy"]}, {"lat": 59.91273, "lng": 10.74609, "nct": "NCT06162013", "color": "#0bd023", "title": "The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06162013", "diseases": ["Multiple System Atrophy"]}, {"lat": 60.39299, "lng": 5.32415, "nct": "NCT06162013", "color": "#0bd023", "title": "The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06162013", "diseases": ["Multiple System Atrophy"]}, {"lat": 59.74389, "lng": 10.20449, "nct": "NCT06162013", "color": "#0bd023", "title": "The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism", "status": "RECRUITING", "phases": ["PHASE2"], "interventions": "Nicotinamide Riboside; Placebo", "sponsor": "Haukeland University Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT06162013", "diseases": ["Multiple System Atrophy"]}, {"lat": 34.75778, "lng": 113.64861, "nct": "NCT06671236", "color": "#80a43a", "title": "Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases", "status": "RECRUITING", "phases": ["PHASE1"], "interventions": "Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)", "sponsor": "Novabio Therapeutics", "address": "", "url": "https://clinicaltrials.gov/study/NCT06671236", "diseases": ["Multiple System Atrophy"]}, {"lat": 43.60426, "lng": 1.44367, "nct": "NCT05819957", "color": "#ef5a81", "title": "Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers", "status": "RECRUITING", "phases": ["NA"], "interventions": "Therapeutic Education Program (TEP)", "sponsor": "University Hospital, Toulouse", "address": "", "url": "https://clinicaltrials.gov/study/NCT05819957", "diseases": ["Multiple System Atrophy"]}, {"lat": 38.19394, "lng": 15.55256, "nct": "NCT05792332", "color": "#b8000a", "title": "Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telemonitoring; Standard-of-care", "sponsor": "Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta", "address": "", "url": "https://clinicaltrials.gov/study/NCT05792332", "diseases": ["Multiple System Atrophy"]}, {"lat": 45.46427, "lng": 9.18951, "nct": "NCT05792332", "color": "#b8000a", "title": "Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telemonitoring; Standard-of-care", "sponsor": "Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta", "address": "", "url": "https://clinicaltrials.gov/study/NCT05792332", "diseases": ["Multiple System Atrophy"]}, {"lat": 45.19205, "lng": 9.15917, "nct": "NCT05792332", "color": "#b8000a", "title": "Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telemonitoring; Standard-of-care", "sponsor": "Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta", "address": "", "url": "https://clinicaltrials.gov/study/NCT05792332", "diseases": ["Multiple System Atrophy"]}, {"lat": 41.51142, "lng": 14.06252, "nct": "NCT05792332", "color": "#b8000a", "title": "Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)", "status": "RECRUITING", "phases": ["NA"], "interventions": "Telemonitoring; Standard-of-care", "sponsor": "Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta", "address": "", "url": "https://clinicaltrials.gov/study/NCT05792332", "diseases": ["Multiple System Atrophy"]}, {"lat": 31.22222, "lng": 121.45806, "nct": "NCT07036939", "color": "#cecbdf", "title": "Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy", "status": "NOT_YET_RECRUITING", "phases": ["NA"], "interventions": "Immediate LVA; Delayed LVA", "sponsor": "Ruijin Hospital", "address": "", "url": "https://clinicaltrials.gov/study/NCT07036939", "diseases": ["Multiple System Atrophy"]}];  // array of points with all needed meta

      function initWhenReady(tries){
        var map = window[MAP_NAME];
        if (!map || !map.getContainer) {
          if ((tries||0) < 200) return setTimeout(function(){initWhenReady((tries||0)+1)}, 50);
          return;
        }

        // Panel into map
        var panel = document.getElementById('nct-panel');
        var mapContainer = map.getContainer();
        if (panel.parentNode !== mapContainer) mapContainer.appendChild(panel);

        // Build cluster group & markers (in JS, so we fully control them)
        var clusterGroup = L.markerClusterGroup();
        map.addLayer(clusterGroup);

        // Build marker registry
        var MARKERS = []; // each: { marker, nct, lat, lng, diseases }
        DATA.forEach(function(p){
          var m = L.circleMarker([p.lat, p.lng], {
            radius: 6, color: p.color, fillColor: p.color, fillOpacity: 0.85
          });
          var phases = (p.phases || []).join(', ');
          var html = '<b>' + (p.title||'') + '</b><br>'
                   + 'NCT: <a href="' + (p.url||'#') + '" target="_blank">' + p.nct + '</a><br>'
                   + 'Status: ' + (p.status||'') + ' | Phase: ' + (phases||'') + '<br>'
                   + 'Interventions: ' + (p.interventions||'n/a') + '<br>'
                   + 'Sponsor: ' + (p.sponsor||'—') + '<br>'
                   + (p.address||'');
          m.bindPopup(html, {maxWidth:350});
          MARKERS.push({ marker:m, nct:p.nct, lat:p.lat, lng:p.lng, diseases:(p.diseases||[]), color:p.color });
        });

        // Add all markers initially
        MARKERS.forEach(function(r){ clusterGroup.addLayer(r.marker); });

        // ==== Disease selection UI ====
        // Universe of diseases
        var ALL_DISEASES = [];
        (function(){
          var seen = new Set();
          DATA.forEach(function(p){
            (p.diseases||[]).forEach(function(d){ if(!seen.has(d)){seen.add(d); ALL_DISEASES.push(d);} });
          });
          ALL_DISEASES.sort();
        })();
        var sel = new Set(ALL_DISEASES);

        // Checkboxes
        var df = document.getElementById('disease-filters');
        df.innerHTML = '';
        ALL_DISEASES.forEach(function(d){
          var id = 'dchk_' + d.replace(/\W+/g,'_');
          var label = document.createElement('label');
          label.innerHTML = '<input type="checkbox" id="'+id+'" '+(sel.has(d)?'checked':'')+'> ' + d;
          df.appendChild(label);
          label.querySelector('input').addEventListener('change', function(e){
            if (e.target.checked) sel.add(d); else sel.delete(d);
            applyMarkerFilter();
            rerender(currentBounds());
          });
        });

        // Presets
        function setSelectionTo(listOrAll){
          sel.clear();
          if (listOrAll === "ALL") ALL_DISEASES.forEach(function(d){ sel.add(d); });
          else (listOrAll||[]).forEach(function(d){ sel.add(d); });
          // sync UI
          ALL_DISEASES.forEach(function(d){
            var id = 'dchk_' + d.replace(/\W+/g,'_');
            var el = document.getElementById(id);
            if (el) el.checked = sel.has(d);
          });
          applyMarkerFilter();
          rerender(currentBounds());
        }
        document.querySelectorAll('#nct-presets .preset').forEach(function(btn){
          btn.addEventListener('click', function(){
            var val = btn.getAttribute('data-diseases');
            if (val === 'ALL') return setSelectionTo('ALL');
            try { setSelectionTo(JSON.parse(val)); } catch(e) {}
          });
        });

        // ==== Filtering + chart logic ====
        function markerIncluded(rec){
          if (!ALL_DISEASES.length) return true; // single-disease mode
          var ds = rec.diseases || [];
          for (var i=0;i<ds.length;i++) if (sel.has(ds[i])) return true;
          return false;
        }
        function applyMarkerFilter(){
          MARKERS.forEach(function(rec){
            var has = clusterGroup.hasLayer(rec.marker);
            var should = markerIncluded(rec);
            if (should && !has) clusterGroup.addLayer(rec.marker);
            else if (!should && has) clusterGroup.removeLayer(rec.marker);
          });
        }

        function withinBounds(lat, lng, bounds) {
          return bounds.contains(L.latLng(lat, lng));
        }
        function currentBounds(){
          return map.getBounds ? map.getBounds() : L.latLngBounds([[-90,-180],[90,180]]);
        }

        function localCounts(bounds){
          var counts = {};
          MARKERS.forEach(function(r){
            if (!markerIncluded(r)) return;
            if (!bounds || withinBounds(r.lat, r.lng, bounds)) {
              counts[r.nct] = (counts[r.nct]||0) + 1;
            }
          });
          return counts;
        }
        function globalCountsSelected(){
          var counts = {};
          MARKERS.forEach(function(r){
            if (!markerIncluded(r)) return;
            counts[r.nct] = (counts[r.nct]||0) + 1;
          });
          return counts;
        }

        function renderBars(local){
          var cont = document.getElementById('nct-rows');
          cont.innerHTML = '';
          var globalSel = globalCountsSelected();

          var keys = Object.keys(local);
          if (!keys.length) {
            cont.innerHTML = '<div style="color:#666;font-size:12px;">No sites in selection for chosen diseases.</div>';
            return;
          }

          keys.sort(function(a,b){
            if (local[b] !== local[a]) return local[b] - local[a];
            return (globalSel[b]||0) - (globalSel[a]||0);
          });

          var maxG = 1;
          keys.forEach(function(k){ maxG = Math.max(maxG, globalSel[k]||0); });
          keys.forEach(function(nct){
            var g = globalSel[nct] || 0;
            var l = local[nct] || 0;
            var color = (MARKERS.find(function(r){return r.nct===nct;})||{}).color || '#888';
            var gPct = Math.max(4, Math.round(100 * g / (maxG||1)));
            var lPct = Math.min(gPct, Math.round(gPct * (l / (g||1))));

            var row = document.createElement('div'); row.className = 'bar-row';

            var label = document.createElement('div'); label.className = 'bar-label';
            label.textContent = nct;
            // Use any marker’s popup title as tooltip by scanning DATA quickly
            var any = DATA.find(function(p){return p.nct===nct;});
            label.title = (any && any.interventions) ? any.interventions : 'Intervention: n/a';

            var track = document.createElement('div'); track.className = 'bar-track';
            track.title = label.title;

            var gdiv = document.createElement('div'); gdiv.className='bar-global';
            gdiv.style.width = gPct + '%'; gdiv.style.background = color;
            var ldiv = document.createElement('div'); ldiv.className='bar-local';
            ldiv.style.width = lPct + '%'; ldiv.style.background = color;

            var cnt = document.createElement('div'); cnt.className='bar-count';
            cnt.textContent = l + ' / ' + g;

            track.appendChild(gdiv); track.appendChild(ldiv);
            row.appendChild(label); row.appendChild(track); row.appendChild(cnt);
            cont.appendChild(row);
          });
        }

        function rerender(bounds){ renderBars(localCounts(bounds)); }

        // Initial sync
        applyMarkerFilter();
        rerender(L.latLngBounds([[-90,-180],[90,180]]));

        // Cluster click → render for that area
        clusterGroup.on('clusterclick', function(e){
          rerender(e.layer.getBounds());
        });
      }
      initWhenReady(0);
    })();
    </script>
    
    
            <div class="folium-map" id="map_27dca3867907e8cc88ae649e97195903" ></div>
        
</body>
<script>
    
    
            var map_27dca3867907e8cc88ae649e97195903 = L.map(
                "map_27dca3867907e8cc88ae649e97195903",
                {
                    center: [20.0, 0.0],
                    crs: L.CRS.EPSG3857,
                    ...{
  "zoom": 2,
  "zoomControl": true,
  "preferCanvas": false,
}

                }
            );

            

        
    
            var tile_layer_1ba80199fa4136f13a82d4b6f5100583 = L.tileLayer(
                "https://tile.openstreetmap.org/{z}/{x}/{y}.png",
                {
  "minZoom": 0,
  "maxZoom": 19,
  "maxNativeZoom": 19,
  "noWrap": false,
  "attribution": "\u0026copy; \u003ca href=\"https://www.openstreetmap.org/copyright\"\u003eOpenStreetMap\u003c/a\u003e contributors",
  "subdomains": "abc",
  "detectRetina": false,
  "tms": false,
  "opacity": 1,
}

            );
        
    
            tile_layer_1ba80199fa4136f13a82d4b6f5100583.addTo(map_27dca3867907e8cc88ae649e97195903);
        
    
            var marker_cluster_0e87d6d5d9623e4fae462e6afd106d75 = L.markerClusterGroup(
                {
}
            );
        
    
            marker_cluster_0e87d6d5d9623e4fae462e6afd106d75.addTo(map_27dca3867907e8cc88ae649e97195903);
        
</script>
</html>